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Abstract
Transformation of fibroblasts with the v-fos oncogene produces a highly invasive 
phenotype. Accordingly, genes up- and down- regulated by v-Fos are of crucial 
importance in mediating a multigenic invasion programme.
Differential expression studies revealed that components of histone deacetylase 
(HDAC) transcriptional co-repressor complexes are up-regulated in FBR-v-Fos- 
transformed (FBR) cells. Since HDACs facilitate gene silencing, we investigated the 
consequences of inhibiting their activity in terms of gene re-expression and 
phenotypic changes.
We treated FBR cells with the HDAC inhibitors, trichostatin A (TSA) and valproic acid 
(VPA), at a range of sub-growth-inhibitory concentrations. At higher concentrations 
within this range, actin stress-fibres reform, transformed morphology reverts, cells are 
less motile and invasion is inhibited. Significantly, however, at lower concentrations 
within this range we inhibit invasion and actin stress-fibres reform but morphology, 
motility and chemotaxis are unaffected. This demonstrates the involvement of different 
groups of genes in different aspects of the transformed phenotype.
In a limited study, we found several genes, down-regulated in FBR cells, which are 
then re-expressed as a consequence of HDAC inhibition. Ectopic re-expression 
(stable and transient) of three of these genes (RYBP, PCDHGC3 and STAT6 ) 
individually, in FBR cells, inhibits invasion without affecting morphology, motility or 
chemotaxis; nor do actin stress-fibres reform. These results demonstrate that the 
down-regulation of genes by Fos can be mediated by histone deacetylases and that 
many of these down-regulated genes, when normally expressed in fibroblasts, 
function to maintain the non-invasive state, in that their expression is incompatible 
with the invasive phenotype.
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Chapter 1: Introduction
1.1 General introduction
The work detailed in this thesis considers the role of the transforming oncoprotein v- 
Fos in the invasive cell phenotype. Following a comparative study of genes expressed 
by normal fibroblasts with those expressed by v-Fos-transformed fibroblasts (Johnston 
et al. 2 00 0 ), we sought to provide evidence to support the proposal that the invasive 
phenotype of these v-Fos transformed cells is not mediated solely by a very small 
number of up-regulated invasion-specific genes and down-regulated invasion 
suppressors, but as a consequence of the interplay between the majority (if not all) of 
those proteins expressed in the transformed cells and importantly, the specific levels 
at which they are expressed in relation to one another. Thus the status of a cell, for 
example, non-transformed, transformed, invasive, differentiated, could be considered 
as a steady-state in terms of gene expression, with each steady-state governed by its 
own specific multigene programme of expression. This work then, explores the 
hypothesis that the v-fos oncogene regulates a multigenic invasion programme.
Our differential expression results (Johnston et al. 2000), in combination with other 
published studies (Bakin and Curran 1999), led us to consider the consequences of v- 
Fos-mediated increased histone deacetylase (HDAC) expression, and consequently, 
increased histone deacetylation, as a means of achieving wide-scale gene expression 
changes and adjustments, culminating in the establishment of a new steady-state of 
protein expression: the invasive state.
Firstly, we sought to investigate the consequences of altering the level of 
deacetylation in the transformed cells by several mechanisms, but with emphasis on 
pharmacological HDAC inhibition, and secondly we considered individual genes, 
down-regulated in the transformed cells as a consequence of increased HDAC 
expression, with respect to the phenotypic consequences of their re-expression.
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In providing a background to these experiments, this introduction begins with a 
description of Fos and its known functions, with relevance to our study, and therefore, 
to invasion and cancer in general. It goes on to explain the current understanding of 
the role of HDACs in transcriptional control against a background of interrelated 
control mechanisms such as méthylation of DMA. There follows an explanation of the 
strategies we employed to both increase and decrease HDAC activity in our cell 
system. In addition to studies with HDAC inhibitors, these include over-expressing 
HDAC4, expressing deacetylase-inactive HDAC4, and altering the level of HDAC4 
localised to the nucleus. Finally the introduction is completed with a description of 
those proteins, down-regulated in response to increased HDAC expression, which we 
chose to re-express in Fos-transformed cells; these being: Ring 1 and ying yang 1 
(YY1) binding protein (RYBP); Qrotoca^erin % subfraction C^3 (PCDHGC3); and, 
signal transducer and activator of transcription 6 (STAT6 ).
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1.2 Fos
1.2.1 c-Fos and AP-1
C-fos is a nuclear protein. It is a component of the Activator Protein 1 (AP-1) 
transcription factor, which is the nuclear effector of several signal transduction 
pathways. Thus, AP-1 activation regulates gene expression in response to a wide 
range of extracellular stimuli. Its viral counterpart, v-fos, is constitutively active and 
therefore becomes part of a constitutively active AP-1, directly regulating gene 
expression. It transforms rodent cells, replacing the requirement for the activation of 
endogenous AP-1 via the signal transduction pathways.
The c-fos gene encodes a protein of 381 amino acids which is highly conserved (van 
Straaten et al. 1983); moreover, the mouse and human genes have a similar 
intron/exon structure, with the mRNA encoding a 2.2 Kb transcript comprised of four 
exons from the 3.5 Kb transcription unit (van Straaten et al. 1983). This strong 
conservation of c-Fos suggests an important role for the protein in normal cellular 
physiology.
c-Fos is the founding member of a family of transcription factors which also includes, 
Fos-related antigen 1 (Fra1), Fra2, FosB and FosB2 (also called AFosB). As part of 
AP-1 these proteins heterodimerise with members of the Jun family of transcription 
factors, which is comprised of c-Jun, JunD, JunB and also includes the retroviral 
oncoprotein v-Jun. The DMA binding site of AP-1 is the TPA responsive element 
(TRE). TPA (12-0-tetradecanoylphorbol-13-acetate) is a phorbol ester; a tumour 
promoter, which was found to mediate gene induction through AP-1 (Lamph et al. 
1988). In addition to Jun family members, Fos can form heterodimers with several 
other protein families (Table 1.1), for example, activating transcription factors (ATFs) 
and musculoaponeurotic fibrosarcoma proteins (MAFs), generally recognising similar.
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but distinct DNA binding sites. Fos family members cannot form homodimers, 
whereas, Jun family members can.
c-Fos can form dimers with preferred binding site alternative binding site
c-Jun TRE ORE
JunB TRE ORE
JunD TRE ORE
ATFa does not bind DNA -
ATF2 ORE TRE
ATF4 ORE -
C-MAF MARE I/Ill -
MAFA MARE I/Ill -
MAFB MARE I/Ill -
MAFF/G/K MARE I/Ill -
NRL TRE-like -
NRF2 ARE -
NFIL6 TRE -
Table 1.1
The binding partners of c-Fos and their preferred DNA binding sites. Adapted from Eferl and 
Wagner 2003.
AP-1 has been shown to play a major role in diverse cellular processes such as, 
embryogenesis, bone formation and organogenesis, cell cycle and proliferation, 
differentiation, apoptosis, angiogenesis, and T-cell activation. Given that the 
processes of differentiation, cell cycle, proliferation, angiogenesis and apoptosis, are 
those which are frequently deregulated in cancer, it is not surprising that AP-1 has 
been shown to play a central role in the disease.
1.2.2 The v-fos^®'  ^oncogene
The v-fos oncogene was initially identified in 1966, when two viral isolates were 
recovered, one from a spontaneously occurring murine osteosarcoma and one from a 
®°Sr-induced osteosarcoma. The first of these isolates to be studied yielded the Finkel- 
Biskis-Jinkins Murine Sarcoma Virus (FBJ-MuSV; Finkel et al. 1966), and the second
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yielded the Finkel-Biskis-Reilly Murine Sarcoma Virus (FBR-MuSV; Finkel et al. 1973), 
which is the more transforming of the two and is the subject of this study.
The FBR-MuSV proviral sequence has a 1662 base pair ORF, encoding a 75KDa 
protein termed, p75' '^^°  ^ which is a fusion of gag, fos and fox sequences (Figure 1.1) 
(Van Beveren et al. 1984). The first 310 amino acids of p75^^* are part of a viral Gag 
sequence, which is fused to 236 amino acids of Fos sequence at asp25 of c-Fos, thus 
there is a 24 amino acid, N-terminal, deletion of the cellular sequence and, in addition, 
a 98 amino acid truncation of the C-terminus of c-Fos, which is replaced by 8 amino 
acids of Fox sequence, originating from the murine or rat genome. Within the v-Fos 
sequence there are also two small internal deletions of 13 and 9 amino acids, and 5 
single amino acid substitutions, resulting from 9 point mutations in the nucleotide 
sequence (Van Beveren et al. 1984). In total, approximately 60% of the c-fos 
nucleotide sequence is retained in v-fos^^^.
The inoculation of newborn mice with FBR-MuSV induced locally invasive tumours 
(Finkel et al. 1973). V-Fos has been shown to morphologically transform a variety of 
cell types including fibroblasts, fibroblast-like cells of mesenchymal origin, human 
kératinocytes and T lymphocytes (Bradbury and Edwards 1988; Appleby et al. 1989; 
Valge-Archer et al. 1990; Lee et al. 1993). As well as transformation of primary rodent 
cells in tissue culture, FBR-MuSV is also able to immortalise them (Jenuwein et al. 
1985). No other retroviral oncogene is able to induce both these changes.
It was the discovery of v-fos which led to the identification of the normal cellular c-fos 
gene (van Straaten et al. 1983), hence the origin of the name Fos: FBJ-derived 
osteosarcoma.
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Comparison of fos genes and proteins
A
c-Fos
TATA
box
Poly(A)
signal
24aa \ 98aa-
FBR v-fos
\%s % s
310aa 236aa
of c-Fos-derived 
sequence
\  ’^Qaa deletion 
13aa deletion 
— ►
B
208F FBR
c-Fos
v-Fos^^^
actin
c-Fos: Mr. 50-65KDa 
pi 4.4-4.7
tubulins
actin
v-Fos^BR: Mr. 75KDa 
pi 5.0-6.3
Figure 1.1
A. Comparison of the c-fos and v-fos^^^ genes, s = postion of amino acid substitution.
B. Comparison of Immunoprecipitated, ^^S-met/cys-labelled c-Fos and v-Fos proteins, separated by 2- 
dimensional polyacrylamide gel electrophoresis. Cells were serum starved then induced with 10% FCS 
1 hour prior to harvest. Actins and tubulins are expected artifacts in these experiments.
1.2.3 Control of Fos activity
1.2.3.1 Introduction
Control of the cellular activity of Fos is complex and occurs at several levels. Firstly, 
there is the rate of transcription of the fos gene itself, and the stability of the fos 
mRNA. Secondly, there is the activity of the Fos protein, its DNA binding affinity, 
stability, and its efficiency of transactivation. In addition there may be control over the 
composition of AP-1. Although this is generally agreed to depend largely on the 
relative amounts of AP-1 component proteins present in the nucleus, phosphorylation 
of c-Jun at a cluster of sites near its DNA binding domain (Figure 1.2), inhibits 
homodimer binding, favouring Fos-Jun heterodimer binding. The enzymes primarily 
responsible for mediating control at all levels are mitogen-activated protein kinases 
(MAPKs).
1.2.3.2 Signal transduction and MAP kinase pathways
MAP kinases are serine/threonine kinases which mediate signals from a vast array of 
cell membrane receptors, activated by binding of their specific stimuli, such as: growth 
factors; cytokines; and proteins involved in cell-cell or cell-matrix interactions. Four 
main MAP kinase pathways have been characterised (Figure 1.3): The extracellular 
signal-regulated protein kinase (ERK) pathway; the c-Jun NH2-terminal kinase/stress- 
activated protein kinase (JNK/SAPK) pathway; the p38 pathway; and lastly, the 
ERK5/BMK pathway. The ERK pathway signals through Ras, Raf, Mos, MEK1 and 2, 
to the MAP kinases, ERK1 and 2. It is stimulated by a large variety of growth factors 
and cytokines and is central to the up-regulation of transcription from the c-fos gene 
(Figure 1.4) and for the activity of AP-1 (Figure 1.2). JNK/SAPK pathway signalling is 
via: MEK kinases (MEKKs); to JNK kinases (JNKKs) and SAP kinases (SAPKKs); to
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Control of AP-1 activity
c-Fos c-Jun
RAS
PKA, P9QRSK
COOH
aa 267-381 
deleted in 
v-Fos^ '^^
^ T91 
p T93
COOH
BASIC
aa 1 -24 deleted 
in v-Fos^BR
JNK
R T 2 3 5 ^ G s k -3 (3
T G A 0  T C A S253 ERK,Gsk-3p,Ckll
Gsk-3p,Ckll,DNA-PK
Figure 1.2
Schematic diagram of AP-1 DNA binding, showing the kinases which phosphorylate AP-1 proteins at 
indicated sites.
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JNK and SAPK. This pathway is stimulated by UV and other environmental stress, as 
well as pro-inflammatory cytokines, however JNK can also be stimulated through Ras, 
to MEKK1 which phosphorylates JNKK. p38 is closely related to SAPK and JNK, and 
is activated by similar stimuli, though it is activated by different MEKKs and, unlike 
JNK, does not phosphorylate c-Jun. Finally, c-Fos can be phosphorylated by ERK5 
(Terasawa et al. 2003) in response to stimuli such as peroxide and osmotic shock, 
which initiate signalling through the ERK5/BMK pathway (Lee et al. 1995; Zhou et al. 
1995).
1.2.3.3 Activation of the c-fos gene and the c-Fos protein
Although signal transduction is often discussed in terms of linear pathways, there is a 
high degree of cross-talk between them, such that they are in fact, highly complex 
signalling networks, reflecting the complexity of the transcriptional response to each 
individual extracellular signal; consequently, the signal transduced from any stimulus 
can be shown to terminate in increased AP-1 expression, however, this is primarily 
achieved through Ras activation via Raf and MEK to ERKs, which phosphorylate 
ternary complex factors (TCFs), in this case Elk-1 (Figure 1.4). The TCF binds the 
serum response factor (SRF) dimer, creating, as the name suggests, a three 
component (ternary) complex, bound to the serum response element (SRE) in the c- 
fos promoter, activating transcription. TCFs can also be phosphorylated by p38 and by 
JNK, thus providing a means by which a wide variety of stimuli can activate fos. As 
well as activation via the SRE, transcription from fos can also be stimulated via the 
cyclic AMP response element (ORE) and the sis-inducible enhancer (SIE) (Figure 
1.4). Activation at the ORE is in response to signals such as polypeptide hormones 
and neurotransmitters which use Ca^^ or cyclic adenosine monophosphate (cAMP) as 
second messengers; signalling to Ca^Vcalmodulin-dependent kinase (CamK) or
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protein kinase A (PKA) respectively. Signal transduction via both these pathways 
results in the phosphorylation and activation of CRE binding protein (CREB). CREB 
mediates transactivation of fos, at least in part, by recruitment of a histone acetyl 
transferase (HAT) activity: CREB binding protein (CBP). Finally fos can be 
transactivated by interleukins and interferon as well as growth factors and cytokines, 
via the JAK/STAT pathway where a STAT homodimer is phosphorylated and 
transactivates from the SIE (Figure 1.4).
The activity of AP-1 is modulated through phosphorylation of its Fos and Jun family 
components (Figure 1.2). Many enzymes can phosphorylate AP-1, including, ERK, 
JNK, p38, ribosomal S6 kinase (pQO^ *^^ ), casein kinase II (CKII), glycogen synthase 
kinase 3p (GSK-3P), and DNA-dependent protein kinase (DNA-PK) (reviewed in Eferl 
and Wagner 2003). There are several phosphorylation sites on the c-Fos protein; 
phosphorylation at any of the four C-terminal sites of c-Fos, results in a protein with a 
longer half-life as well as increased transactivational activity (Chen et al. 1996; 
reviewed in Piechaczyk and Blanchard 1994). These sites are deleted in v-Fos^®^, 
therefore, the protein escapes regulation by kinases at these sites. In addition, 
phosphorylation by FRK, at threonine 232 (though Ras signalling), increases the 
transactivation capacity of the protein.
1.2.4 Fos and invasion
In 1992, it was shown that mammary epithelial cells over-expressing an introduced c- 
fos gene become invasive (Reichmann et al. 1992). Now, there is a growing body of 
evidence that implicates AP-1 in the control of invasion. In this laboratory it was shown 
that normal rat fibroblasts (208F cells; section 1.2.5) can be induced to invade when 
treated with epidermal growth factor (EGF) or glatelet derived growth factor (PDGF) 
(Hennigan et al. 1994), stimuli of signal transduction pathways which culminate in the
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induction of c-fos (Section 1.2.3). These fibroblasts also become invasive in in vitro 
assay when transformed by v-Fos*"®  ^(FBR cells; section 1.2.5; Hennigan et al. 1994), 
and various Fos target genes implicated in their invasive phenotype have been 
identified, for example: CD44 (Lamb et al. 1997a); cathepsin L; metastasis-1 (Mts-1; 
Hennigan et al. 1994); and kelch-related grotein (Krpi; Spence et al. 2000); and, ezrin 
(Jooss and Muller 1995; Lamb et al. 1997b). When expression of CD44, Krp-1 or ezrin 
was negated the cells were no longer able to invade (Lamb et al. 1997a; Lamb et al. 
1997b; Spence et al. 2000). Fos has also been shown to up-regulate tropomyosin 3 
and 5b (Jooss and Muller 1995) which are associated with invasion. Recently, in this 
laboratory, v-Fos^ ®*^ ^^ - and Ha-Ras-transformed human fibroblasts were shown to be 
invasive and in both of these cell lines, genes relevant to invasion were found to be 
differentially expressed (Scott et al. 2004).
When a dominant negative form of c-Jun, termed Tam67, is introduced into the FBR 
cells they lose their ability to invade (Lamb et al. 1997a), and a dominant negative 
form of c-Fos, called aFos, has a similar effect in HT1080 fibrosarcoma cells (Bahassi 
et al. 2004). Also in this laboratory, Tam67 was shown to inhibit invasion in human 
squamous cell carcinoma (A431) cells (Malliri et al. 1998). A431 cells over-express the 
EGF receptor, and it was also shown that this over-expression, in squamous cell 
carcinoma-derived cell lines, correlates with invasive ability (Malliri et al. 1998), again 
demonstrating the link between the induction of fos, via growth factor signalling, and 
invasion. Finally, normal mouse kératinocytes can be induced to invade by TPA (Dong 
et al. 1997), a phorbol ester which is the initial stimulus in another /bs-inducing signal 
transduction pathway (Figure 1.4). Inhibition of Jun activity by Tam67, inhibits this TPA 
induced invasion (Dong et al. 1997).
The /bs-family member, Fra-1 is also implicated in promoting invasion. Fra-1 can be a 
component of AP-1 (Section 1.2.1) and its expression is induced by c-Fos. Mammary
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adenocarcinoma-derived cell lines over-expressing Fra-1 have been shown to be 
more invasive in in vitro invasion assays (Kustikova et al. 1998). More recently, it was 
shown that the invasion of colon carcinoma-derived cell lines, which have activated Ki- 
Ras, was inhibited when the levels of Fra-1 protein was reduced using siRNA (Vial 
and Marshall 2003). Fra-1 containing AP-1 has also been shown to preferentially 
induce expression of those extracellular matrix proteinases of the urokinase 
plasminogen activator system (Kustikova et al. 1998).
The invasive potential of a tumour is, to a large extent, determined by the balance 
between expression of matrix metallogroteinases (MMPs), which degrade the 
extracellular matrix (ECM), and tissue inhibitors of MMPs (TIMPs), secreted by tumour 
cells. MMPs, then, play a central role in the mechanism of invasion and they can be 
induced by AP-1. The majority of these genes have at least one conserved AP-1 
consensus sequence up-stream of the transcription start site (between -189 and -50) 
which is required for the induction of MMP expression by growth factors (Kerr et al. 
1988; Schonthal et al. 1988; Brenner et al. 1989; Sato et al. 1993; reviewed in 
Westermarck and Kahari 1999). In c-Fos deficient fibroblasts the induction of MMP-1 
and MMP-3 by EGF and PDGF is abrogated (Hu et al. 1994), showing the link 
between AP-1 and MMPs. In c-Fos deficient cells there was shown to be decreased 
expression of MMP-1 and MMP-3 (stromelysin) (Hu et al. 1994), and skin tumour 
progression, in these mice, to invasive squamous cell carcinoma (in the presence of a 
v-Ha-ras transgene) was impaired (Saez et al. 1995). Increased levels of MMPs have 
been detected in invasive tumours, for example: MMP-1 (collagenase 1) activity was 
shown to be necessary for keratinocyte migration on a collagen matrix (Pilcher et al. 
1997); AP-1 DNA-binding and transcriptional activation of the MMP-9 (gelatinase) 
promoter were increased when mouse kératinocytes progressed to invasive spindle 
cells (Papathoma et al. 2001); and, in human urothelial carcinoma, levels of MMP-9
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correlated strongly with tumour invasiveness (Papathoma et al. 2000). Conversely, 
inhibition of MMPs inhibits invasion or metastasis (Albini et al. 1991; Wang et al. 1997; 
Valante et al. 1998; Baker et al. 1999).
1.2.5 Transformation of rat fibroblasts with the v-Fos^ ®*^  oncogene
In this study we use rat fibroblasts (208F cells) which have previously been infected 
with the FBR-MuSV and thus stably express the v-/bs™  oncogene (FBR cells) 
(Jenuwein et al. 1985). Western analysis revealed that the constitutive expression of 
v-Fos^®^ in these cells results in the up-regulation of other Fos and Jun family 
members (Figure 1.5A). In addition, we also see up-regulation of these proteins in 
208F cells transformed by the v-ras oncogene; though it is perhaps surprising that we 
see an up-regulation of FosB and FosB2, since this is in contrast to a previous study
208F FBR
Expression of AP-1 components + +++
Transformed morphology - +++
Stress fibres +++ -
Motility + +++
In vitro invasion +++
Focal adhesions +++ -
Focus formation - +++
Growth in soft agar - +++
Tumourigenicity - +++
Growth in 0.5% FCS - -
Table 1.2
Phenotypic differences observed between 208F cells and FBR cells.
of AP-1 compostion in Ras-transformed NIH3T3 cells (Mechta et al. 1997). The Fos- 
transformed cells differ from the parental, 208F cell line in several important aspects of 
their phenotype, as a consequence of increased AP-1 activity (Table 1.2). FBR cells
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Genotypic and phenotypic differences between normal, transformed 
and EGF-treated cells
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Figure 1.5
A. Western blots showing the up-regulation of Fos and Jun family members in Fos and Ras 
transformation
(FBR and RAS respectively) and in response to EGF stimulation (100 ngmM for 24 hrs). An example 
PCNA loading control is shown.
B. Photographs of phase microscope images showing the difference in morphology between 208F and 
FBR cells.
C. Confocal microscope images of FITC-phalloidin-stained cells, showing the difference in actin structure 
between 208F and FBR cells.
D. Windrose diagrams showing the difference in motility between 208F and FBR cells. The tracks of 30 
cells are included in each diagram.
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have a transformed, bipolar, spindle-cell morphology, with extending pseudopods and 
a highly light retractile cell body, compared to 208F cells which are flat and polygonal 
(Figure 1.5B). This shape change is accompanied by a rearrangement of actin stress- 
fibres such that only cortical F-actin is detectable in FBR cells, in comparison to 208F 
cells which have a highly defined network of actin stress- fibres (Figure 1.5C). FBR 
cells are more motile (Figure 1.5D) and can invade in an in vitro invasion assay, in 
growth factor-depleted conditions, unlike 208F cells. In addition FBR cells have 
considerably less focal adhesions than 208F cells (Neil Carragher, BICR, personal 
communication). FBR cells also differ in that they form foci on plastic, are anchorage 
independent for growth, as determined by soft agar assay (Hennigan et al. 1994), and 
can form locally invasive tumours in nude mice (Finkel et al. 1973). Both cell lines, 
however, are growth factor dependent for proliferation (Hennigan et al. 1994), showing 
that Fos, in contrast to Ras, is not sufficient to facilitate cell cycle progression.
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1.3 Control of transcription
1.3.1 DNA méthylation and histone deacetylation in v-Fos transformation
1.3.1.1 Introduction
Two pieces of work initiated this present study. One was a study from our own 
laboratory, which identified proteins associated with histone deacetylation, as being 
up-regulated in v-Fos transformation (Johnston et al., 2000), and the other was a 
publication by Bakin and Curran (Bakin and Curran 1999), which demonstrated a role 
for DNA méthylation and histone deacetylation, in mediating transformation by v-Fos.
1.3.1.2 Changes in gene expression as a consequence ofv-Fos expression
In our laboratory, DNA suppressive subtractive hybridisation (SSH) studies identified 
sequences differentially expressed between immortalised rat fibroblasts (208F cells; 
section 1.2.5) and their v-Fos^^^-transformed derivative cell line (FBR cells; section 
1.2.5) (Johnston et al., 2000). The technique of SSH (Diatchenko et al. 1996), is a 
PCR-based approach which selectively amplifies restriction enzyme fragments of 
cDNAs derived from differentially expressed genes. The technique also suppresses 
amplification of commonly expressed genes. Two cDNA libraries were created, one 
comprised of cDNA fragments from genes that are up-regulated in FBR cells, and the 
other comprised of down-regulated sequences. Random clones were selected from 
each library and sequenced. Database searches provided names and functions for 55 
genes that are up-regulated in FBR cells and 63 genes that are down-regulated. Their 
differential expression was confirmed by northern analysis. Of the 55 up-regulated 
genes, 22 had been reported as being associated with tumours or oncogenic 
transformation and 27 had functions consistent with a role in some aspect of invasion. 
Twelve of these genes are common to both groups. The remaining 18 genes include 7
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associated with protein synthesis, 4 with vesicle transport, and 4 with metabolism. Of 
the 63 down-regulated genes, 25 had been reported as being associated with tumours 
or oncogenic transformation and 19 had functions consistent with a role in some 
aspect of invasion. Fourteen genes are common to both groups. The remaining 33 
genes are associated with functions which include, adhesion, vesicle transport, and 
some are cytoskeletal components or proteases. All of which could be considered 
consistent with the invasive phenotype.
Two of the up-regulated sequences matched to genes encoding Sin3-associated 
protein 18KDa (SAP 18) and retinoblastoma-associated protein 46KDa (RbAp46). 
These proteins are known to exist as components of large multiprotein complexes 
(Section 1.3.4) which are thought to be recruited to methylated DNA or to transcription 
factors and facilitate gene silencing by deacetylating the lysine residues of the N- 
terminal “tail” of histone H4 or H3 (Section 1.3.2.1). RbAp46 is thought to tether the 
complex to the histone (Parthun 1996, Verreault 1996) and SAP 18 is thought to direct 
complex formation (Zhang et al. 1997). Northern analysis confirmed their up-regulation 
at the RNA level (Figure 1.6) and western analysis of RbAp46/48 expression levels 
also demonstrated increased protein expression in Fos-transformation (Figure 3.1 B).
1.3.1.3 DNA méthylation and histone deacetylation in Fos transformation 
In 1999 Bakin and Curran first presented evidence that 5-methylcytosine transferase 
and histone deacetylases have a role in Fos-transformation. They used 
representational difference analysis to compare mRNA populations present in normal 
fibroblasts with those present in fibroblasts transformed with inducible c-fos, or v- 
fos^ '^^^^  (MWler et al. 1985) genes. One of nine up-regulated genes identified was, DNA 
(cytosine 5) methyltransferase 1 (dnmtl) which catalyses the transfer of a methyl
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SAP 18 and RbAp46/48 are up-regulated in FBR cells
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Figure 1.6
Northern blots demonstrating increased expression of SAP 18 and RbAp46/48 mRNA in FBR, RAS, and 
EGF-treated (100 ngmM for 24 hrs) 208F cells. This experiment was performed by Dr. Joseph Winnie.
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group from S-adenosyl methionine to the C-5 position of the cytosine residues of DNA. 
Dnmtl is up-regulated 2 to 3-fold in both their c- and v- Fos-transformants. Moreover, 
high pressure liquid chromatography (HPLC) analyses of nucleosides derived from the 
DNA present in these cells revealed that the Fos-transformants have 20% more 5- 
methylcytosine. They went on to show that when recombinant dnmtl is expressed in 
normal fibroblasts these cells became morphologically transformed and that when 
they inhibited the activity of Dnmtl in c- and v-Fos transformed cells, with 5-aza- 
deoxycytosine, their morphology reverted to that of normal fibroblasts. Finally they 
showed that the transformed morphology is also reverted when histone deacetylases 
are inhibited by trichostatin A (TSA). The conclusion can then be drawn that Fos- 
transformation is mediated by increased expression of Dnmtl which represses gene 
expression probably by the increased recruitment of histone deacetylases to 
methylated DNA. Later it was shown that Dnmtl is directly associated with a 
deacetylase activity (Fuks et al. 2000).
1.3.2 Méthylation and deacetylation
1.3.2.1 Chromatin
The packaging of DNA into chromatin restricts the accessibility of DNA to factors 
involved in fundamental processes such as DNA replication and transcription. The 
repeating organising unit of chromatin is the nucleosome (van Holde 1988). Each 
nucleosome consists of a core built of two copies of histones H2A, H2B, H3, and H4, 
around which the DNA is tightly wrapped and bound by electrostatic interactions 
(Luger et al. 1997). Consistent with the repressive effects of chromatin on gene 
expression, gene activation is often accompanied by nucleosomal rearrangements 
(Workman and Kingston 1998). Such local or extended structural changes in 
chromatin are achieved by ATP-driven chromatin remodelling complexes (Wu 1997)
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and by méthylation, phosphorylation, ubiquitination, and of key importance to our 
study, acétylation, of histones (Jones and Kadonaga 2000; Wolffe and Guschin 2000).
1.3.2.2 DNA méthylation
The correlation between DNA méthylation and lack of gene transcription has been well 
documented since it was initially reported over twenty years ago (Razin and Riggs 
1980), however, it was not known whether méthylation mediates transcriptional 
silencing or is as a consequence of transcriptional silencing. It is only in the last five 
years that an understanding of the link between méthylation and deacetylation of 
histones has emerged, as a means by which the down-regulatory effects of 
méthylation are mediated.
DNA can be methylated at carbon 5 on those cytosine nucleotides which appear in 
CpG dinucleotides. In mammalian gene coding sequences, CpG dinucleotides appear 
at a frequency much lower than one would expect by chance, and these CpGs are 
generally methylated. In promoter regions CpGs appear at approximately the 
expected random frequency, however, these CpGs are not methylated in actively 
transcribed genes. These promoter regions of non-methylated CpGs are termed CpG 
islands (Antequera and Bird 1993a; Antequera and Bird 1993b). CpG island chromatin 
contains highly acetylated histones H3 and H4.
Dnmtl was the first DNA methyltransferase to be cloned (Bestor et al. 1988). This 
enzyme preferentially methylates hemimethylated CpGs, and is thought to be 
responsible for the maintenance of méthylation patterns post-replication; methylating 
the daughter strand CpG after replication of a symmetrically methylated locus. It does 
this without any apparent sequence specificity, other than the CpG itself, suggesting 
that a hemimethylated CpG sequence is sufficient to guide méthylation (Yoder et al. 
1997). It is noteworthy, that Dnmtl is found to be capable of de novo méthylation in
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vitro, since presumably it is this ability which facilitates the increase in the total amount 
of genomic méthylation found in human cancer in correlation with up-regulated dnmtl. 
Methvl-CpG-bindinq protein 2 (MeCP2) was the first methylated-DNA binding protein 
which binds to a single methyl-CpG pair, to be identified (Lewis et al. 1992; Meehan et 
al. 1992). It carries an N-terminal methylated DNA binding domain (MBD) and a C- 
terminal transcriptional repression domain (TRD). The presence of an MBD domain 
now defines a family of proteins which, along with MeCP2, is comprised of MBD1 to 
MBD4. Members of this family have been shown to bind large transcriptional co­
repressor complexes which have HDAC activity (Section 1.3.4), thereby recruiting 
HDAC activity to methylated DNA (Jones et al. 1998; Nan et al. 1998). MeCP2 can 
become part of the switch independent 3 (Sin3) complex, whilst MBD2 and MBD3 can 
be included in the nucleosome remodelling and deacetylase activities (NuRD/Mi-2) 
complex.
1.3.2.3 Acétylation and deacetylation of histones
The most widely studied post-translational modification of chromatin is the reversible 
acétylation of lysine residues in the amino terminal tails of the four core histones. 
Transcriptionally silenced regions, such as heterochromatin and the inactivated 
mammalian X chromosome, are associated with hypoacetylated histones (Grunstein 
1997). In contrast, transcriptionally active domains in euchromatin are often 
associated with histone hyperacetylation (Wolffe 1998). Localised changes in histone 
acétylation levels near the transcriptional start site of certain genes are linked to gene 
activation or repression (Rundlett et al. 1998). The causal link between histone 
acétylation and transcriptional regulation is illustrated clearly by the identification and 
characterisation of transcriptional regulators containing HAT (Cheung et al. 2000) or 
HDAC activities (Ng and Bird 2000).
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1.3.3 Histone deacetylases
1.3.3.1 Introduction
Mammalian HDACs were identified by their homology to yeast histone deacetylases. 
Yeast cells have at least two distinguishable histone deacetylase activities residing in 
two multiprotein complexes, termed the histone deacetylase A (Carmen et al. 1996), 
and histone deacetylase B (Rundlett et al. 1996), complexes, which have molecular 
weights of 350kD and 600kD respectively. The catalytic subunit of the histone 
deacetylase A complex is HDA1 and the active component of the histone deacetylase 
B complex is the reduced potassium dependency 3 (Rpd3) catalytic subunit, or the 
Rpd3 related proteins HDA one similar (HOS) 1, 2 or 3 (Rundlett et al. 1996). 
Mammalian HDACs form two homology groups: class I HDACs are more closely 
related to Rpd3 and class II HDACs are more closely related to HDA1. All HDACs 
share an approximately 390 amino acid region of homology, termed the deacetylase 
core (Figure 1.7), which defines the gene superfamily.
1.3.3.2 Class I histone deacetylases
Human HDAC1 was first isolated, along with an associated protein RbAp48, by its 
binding to an analogue of the HD AC inhibitor, trapoxin, in affinity chromatography 
(Taunton et al. 1996). Sequence analysis revealed 60% homology to Rpd3, a yeast 
transcriptional regulator (Section 1.3.3.1; Vidal and Gaber 1991), at the protein level. 
This then linked transcriptional control and histone deacetylation for the first time. In 
the same year Yang and colleagues (Yang et al. 1996) identified HDAC2 in yeast two- 
hybrid studies, as a protein binding to the transcription factor YY1. Human HDAC1 
and 2 are 75% identical in DNA sequence and share 85% homology at the protein 
level. The sequences of HDAC1 and 2 were then used by a number of groups to
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The catalytic core of histone deacetylases
Figure 1.7
The structure of the catalytic core of HDACs, shown complexed to the inhibitor, TSA, as determined by 
X-ray crystallographic studies. The active catalytic site was shown to be formed by a tubular pocket, a 
zinc binding site, and two asparagine-histidine charge-relay systems.
Reproduced from Finnin et al., 1999.
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identify database sequence homologies and consequently HDACS was cloned (Yang 
et al. 1997; Dangond et al. 1998; Emiliani et al. 1998; Mahlknecht et al. 1999). Finally, 
two remaining class I HDACs were isolated; HDAC8 (Buggy et al. 2000; Hu et al. 
2000; Van den Wyngaert et al. 2000) and HDAC11, which has least homology to other 
class I HDACs and shows tissue specific expression (Gao et al. 2002).
1.3.3.3 Class II histone deacetylases
Database searches by at least four groups (Fischle et al. 1999; Grozinger et al. 1999; 
Miska et al. 1999; Wang et al. 1999), for sequence similarity to yeast H DAI produced 
several homologies in humans. Collectively these proteins were termed class II 
histone deacetylases, and, initially this group was comprised of HDAC4, HDACS and 
HDAC6. Following this, HDAC7 (Kao et al. 2000; Fischle et al. 2001), HDAC9 (Zhou et 
al. 2001b), HDAC10 (Guardiola and Yao 2001; Kao et al. 2001) and HDAC11 (Gao et 
al. 2002) were identified. Unlike class I, these class II histone deacetylases show a 
tissue specific pattern of expression. HDAC4 and 5 are reported to be expressed in 
brain, heart and skeletal muscle. HDAC6 can be detected in heart, liver, kidney and 
pancreas, and HDAC7 is present in heart, lung and skeletal muscle (Grozinger et al. 
1999; Verdel and Khochbin 1999; Kao et al. 2000).
1.3.3.4 The Sir family of histone deacetylases
The silent information regulator (Sir) family of HDACs are now generally considered as 
the third class of histone deacetylases. In humans, 7 sequences with homology to the 
yeast Sir2 protein have been identified which, like all Sir HDACs, have NAD*- 
dependent activities (Afshar and Murnane 1999; Frye 1999). Class III HDACs appear 
to have a unique catalytic reaction and are insensitive to inhibition by TSA (Guarente 
2000). Interestingly, Sir2 can interact with, and deacetylate p53, reducing its
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transcriptional activity (Luo et ai. 2001; Vaziri et al. 2001). This is an example of direct 
deacetylation of a transcription factor to suppress transcription and is probably 
demonstrates one of multiple mechanisms of repression, which are beginning to 
emerge for HDACs.
1.3.4 Protein complexes with histone deacetylase activity
1.3.4.1 Sin3 complex
In 1997 two groups published in the same issue of Cell (Laherty et al. 1997; Zhang et 
al. 1997) providing the first evidence that HDACs exist in the mammalian cell as part 
of multiprotein complexes. Studies in yeast had previously made the functional link 
between the SinS protein and the yeast Class I HDAC homologue, RpdS, since they 
function in the same pathway. This gave rise to these studies, which both showed 
mSinSA associates with HDAC1 and HDAC2 in vivo. In addition, the study by Zhang 
and co-workers identified other mSinS associated proteins, two of which were novel. 
They called these, SAP 18 and SAP30. They also identified, RbAp46 and RbAp48 as 
being part of the complex. Previous evidence suggests these proteins act as a 
molecular bridge between the complex and the histone (Parthun et al. 1996; Verreault 
et al. 1996). The study by Laherty and co-workers also demonstrated that these 
mSin3-associated HDACs mediate transcriptional repression by the DNA-binding 
protein. Mad. Previously, it had been shown that the Mad-Max heterodimer represses 
genes which are activated by Myc-Max (Ayer et al. 1993) and that this repression is 
dependent on binding of Mad to mSin3 (Ayer et al. 1995). This provided the first 
evidence that the Sin3 complex can be recruited to promoter sites through interaction 
with transcription factors. Mad interacts with mSin3 at the second of its four paired 
amphipathic helix (PAH) domains (Ayer et al. 1995). These protein-protein interaction
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domains can mediate associations with other complex components as well as with 
several transcription factors and transcriptional repressors (Table 1.3).
In 1998, Nan and co-workers demonstrated the link between méthylation and the 
HDAC-containing, Sin3 complex. They found that the methylated-DNA binding protein, 
MeCP2, was able to bind HDAC1 and 2 and mSin3A, and that its transcriptional 
repression was relieved by the HDAC inhibitor TSA. Thus methylated DNA binding 
proteins are part of the Sin3 complex.
Protein Example of cellular role Reference
NGoR / SMRT transcriptional repressor complex components Heinzel et al. 1997
RAR (via N-CoR/SMRT) retinoic acid receptor / transcription factor Chen et al. 1995
TR thyroid hormone receptor / transcription factor Chen et al. 1995
ETC transcriptional repressor Wang et al. 1998
MeCP2 methylated DNA binding protein Nan et al. 1998
Mad / Mxi transcriptional repressors Ayer et al. 1995
c-Ski / Sno transcriptional co-repressor Nomura et al. 1999
REST transcriptional repressor Grimes et al. 2000
p53 transcription factor Murphy et al. 1999
Ikaros / Aiolos transcriptional repressors Koipally et al. 1999
Table 1.3
Examples of proteins which interact with components of the SinS complex.
1.3.4.2 NuRD/Mi-2 complex
Like the Sin3 complex, the NuRD/Mi-2 complex (Tong et al. 1998; Xue et al. 1998; 
Zhang et al. 1998) is also capable of connecting methylated DNA and HDAC activity, 
however, it differs in that it also has nucleosome remodelling activity. The core NuRD 
complex contains Mi-2, HDAC1 and 2, and, RbAp46 and RbAp48, but also in the 
complex are metastasis associated protein 2 (MTA2), which modulates the HDAC 
enzymatic activity, MBD3 which, unlike its close relative MBD2, doesn't bind 
methylated DNA directly but appears to mediate association of MTA2 with the core 
complex (Zhang et al. 1999).
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1.3.4.3 N-CoR and SMRT
Although cloned on the basis of their interaction with unliganded retinoic acid receptor 
(RAR) and thyroid hormone receptor (TR), nuclear receptor co-repressor (N-CoR) and 
silencing mediator of retinoic acid and thyroid hormone receptors (SMRT) appear to 
confer transcriptional repression on many transcription factors. The current majority of 
these are members of the nuclear receptor superfamily, however, they are also co­
repressors for a variety of other transcription factors which regulate diverse cellular 
processes (Table 1.4). AP-1 can bind to the co-repressor at a C-terminal region which 
overlaps the binding site for nuclear receptors. Several binding sites 
overlap on the N-CoR/SMRT protein, suggesting a possible control mechanism 
whereby transcription factors compete to recruit the co-repressor complex to DNA.
Protein Examples of cellular roles Reference
AP-1 regulates many diverse cellular processes Lee et al. 2000
SRF activates c-Fos, growth, differentiation, neuronal 
transmission, muscle development and function
Lee et al. 2000
STATS induced by cytokine signalling Nakajima et al. 2001
Myo-D mediates muscle differentiation Bailey et al. 1999
NFkB immune and inflammatory response, cell survival Lee et al. 2000
BCL-6 apoptosis Dhordain et al. 1998
Oct-1 development Kakizawa et al. 2001
Pit-1 development Xu et al. 1998
PBX homeobox factor Saieh et al. 2000
HERPs stress-responsive endoplasmic reticulum protein Iso et al. 2001
Su(H)/RBP-J/CBF1 transcriptional repressor Zhou and Hayward 2001a
Table 1.4
Examples of transcription factors known to bind N-CoR/SMRT.
The HDACs 3, 4, 5 and 7 have been shown to bind N-CoR and SMRT directly. 
HDACs 4, 5 and 7 share a common binding site within the region required for 
repression, whereas HDAC3 has two separate binding sites only one of which 
overlaps a repressor domain. The fact that class I and class II HDACs have separate
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binding sites may suggest differential control by these two classes of enzymes. SMRT 
and N-CoR can also bind the Sin3 complex proteins, therefore HDAC1 and 2 are also 
found in association with SMRT and N-CoR.
One study has shown that the SMRT/N-CoR complex has nucleosome remodelling 
activity: it was found that an N-CoR-SMRT-HDAC3 complex can also contain Krab- 
associated protein 1 (KAP-1), a TSA-sensitive co-repressor that interacts with 
members of the heterochromatin 1 (HP-1) family, which has homology to the switch/ 
sucrose non-fermenting (Swi/Snf), ATP-dependent chromatin remodelling complex 
proteins found in NuRD/Mi-2 (Underhill et al. 2000).
1.3.4.4 CoREST
Studies purifying HDAC1- and HDAC2-associated proteins, identified a novel protein 
found to be a co-repressor of the RE1 silencing transcription factor/neural restrictive 
silencing factor (REST) protein (Andres et al. 1999), and so was called Co-REST (You 
et al. 2001). REST has been shown to have two repression domains: the N-terminal 
domain recruits the Sin3 complex and the C-terminal domain recruits Co-REST. The 
Co-REST complex, which recruits HDAC activity, was found to be distinct from Sin3 in 
composition (You et al. 2001), for example, it lacks RbAp46/48 present in both the 
Sin3 and NuRD/Mi-2 core complex, and includes a IIOKDa protein not found in the 
other complexes. Thus REST has the potential to mediate transcriptional repression 
via two distinct HDAC complexes. Although CoREST was identified as a REST 
associated protein it has emerged that CoREST interacts with other transcription 
factors, for example, zinc finger protein 217 (ZNF217), which is a transcription factor 
and candidate oncogene, by virtue of its up-regulation in several human cancers (Bar- 
Shira et al. 2002; Peiro et al. 2002; Freier et al. 2003; Weiss et al. 2003).
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1.3.5 Deacetylase independent transcriptional repression by HDACs
MeCP2 has been found to repress transcription by a histone deacetylase-independent 
pathway (Yu et al. 2000). In colorectal carcinoma and in leukaemic cell lines, 
hypermethylated, transcriptionally silent genes can be reactivated by simultaneous 
treatment with the HDAC inhibitor, TSA, and the demethylating agent, 5-Aza-dC but 
not by TSA alone (Cameron et al. 1999). These findings suggest either that DNA 
méthylation has additional repressive effects that are independent of histone 
deacetylation, or that unknown TSA-insensitive HDACs are also involved. 
Interestingly, Dnmtl associates with Dnmtl-associated protein 1 (DMAP1), which is a 
putative HDAC-independent transcriptional repressor (Rountree et al. 2000).
Several of the class II histone deacetylases have a second transcriptional repression 
domain. HDAC4 and 5 posses two independent repression domains, the first of which 
is able to repress transcription independently of deacetylase activity (Wang et al.
1999). HDAC6 has two active deacetylase domains, however, in HDAC10, which is 
closely related, the second domain is catalytically inactive. Both HDAC6 and 10 are 
resistant to trapoxin B and butyrate and this resistance is reported to be dependent on 
the presence of the second putative deacetylase domain (Guardiola and Yao 2001). 
HDAC9 (Zhou et al. 2001b) was found to have several alternatively spliced isoforms 
(as has HDAC10; Kao et al. 2001) including the previously discovered HDAC-related 
protein/myocyte enhancer factor 2-interacting transcriptional repressor (HDRP/MITR; 
Sparrow et al. 1999; Zhou et al. 2000) which has 50% homology to the N-terminus of 
HDAC4 which includes the deacetylase-independent repression domain and can 
repress transcription by a deacetylation independent mechanism. Although 
HDRP/MITR was not found to possess intrinsic HDAC activity it does form complexes 
with both HDAC1 and HDACS and is therefore able to recruit deacetylase activity. 
HDAC7 has just one catalytic domain, however, it is found to be inactive with its
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activity dependent on HDAC7 binding to HDACS in the nucleus (Kao et al. 2000; 
Fischle et al. 2001).
1.3.6 Subcellular localisation of class II HDACs regulates their activity
Although most class II HDACs can be detected in both the nucleus and the cytoplasm 
they differ in their relative distribution. HDACs 4, 5 and 6 are predominantly 
cytoplasmic (Miska et al. 1999; Grozinger and Schreiber 2000; McKinsey et al. 2000b; 
Verdel et al. 2000; Wang et al. 2000), HDAC7 and HDAC11 localise predominantly to 
the nucleus (Dressel et al. 2001; Fischle et al. 2001; Gao et al. 2002) though they can 
be detected in the cytoplasm, and HDAC10 can be found in equal nuclear/cytoplasmic 
amounts (Guardiola and Yao 2001; Kao et al. 2001). This differential distribution 
coupled with the tissue specific pattern of expression of class II HDACs strongly 
suggests different molecular roles for each protein.
The active transport of class II HDACs from the nucleus is a major mechanism 
controlling their activity. Nucleocytoplasmic shuttling has been demonstrated or 
implied for all class II HDACs. Surprisingly, the class I histone deacetylase, HDACS, 
has also been found to carry a nuclear export signal and associates with chromosomal 
maintenance region 1 protein (CRM1), a nuclear export factor, in co-transfections 
(Yang et al. 2002). Endogenous HDACS has been detected in both the cytoplasm and 
nucleus of DT40 cells (Takami and Nakayama 2000; Yang et al. 2002) though other 
studies maintain that HDACS is an exclusively nuclear protein (Emiliani et al. 1998; 
Grozinger and Schreiber 2000).
A large part of the research on this subject has been concentrated on HDACs 4 and 5. 
These deacetylases are seen to localise exclusively to either the cytoplasm or the 
nucleus within the same cell culture (Miska et al. 1999; Grozinger and Schreiber 
2000), a phenomenon which we have observed in both 208F and FBR cells stably
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transfected with GFP-tagged HDAC4 (Figure 5.4), where the larger proportion of cells 
have HDAC4 in the cytoplasm, though it can also be observed exclusively in the 
nucleus. This nuclear localisation is dynamic and translocation can occur under 
normal conditions of cell growth (Grozinger and Schreiber 2000). Immunoprécipitation 
and yeast two-hybrid experiments identified 14-3-3 proteins as HDAC 4 and 5 
interacting factors (Grozinger and Schreiber 2000; McKinsey et al. 2000b; Wang et al.
2000) and later this was also shown for HDAC7 (Dequiedt et al. 2003) and implied for 
HDAC9 based on homologies. The 14-3-3 family of proteins function as signal- 
dependent intracellular chaperones, which bind proteins, allowing them to be 
transported across the nuclear membrane by the nuclear export receptor, 
CRMI/exportinI (Adachi and Yanagida 1989; Stade et al. 1997), in a trimeric 
complex, and sequester them in the cytoplasm (Fu et al. 2000) preventing them from 
performing their nuclear function. They are known to bind specifically to conserved 
phosphoserine-containing motifs which act as docking sites. Deletion analyses 
indicated that S246, S467, and S632 of HDAC4 mediate this interaction [S259 and 
S498 in HDAC5 (McKinsey et al. 2000a), and S I55, S318 and S448 in HDAC7 
(Dequiedt et al. 2003)], and alanine substitutions of these serine residues abrogated 
14-3-3 binding, with very minimal effects on the deacetylase activity of HDAC4 
(Grozinger and Schreiber 2000; Wang et al. 2000). In transient transfections this triple 
mutant HDAC4 (TMHDAC4) showed increased nuclear localisation compared to 
transiently expressed wild type HDAC4 (Wang et al. 2000) and when wild type HDAC4 
is co-expressed transiently with 14-3-3 it showed increased cytoplasmic localization 
(Grozinger and Schreiber 2000). The association of 14-3-3 with HDAC4, 5 and 7 then, 
results in the sequestration of these proteins in the cytoplasm and loss of this 
interaction allows HDAC4 and HDAC5 to translocate to the nucleus.
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In muscle myogenesis, calcium/calmodulin-dependent protein kinase IV (CamKIV) has 
been demonstrated to phosphorylate those serines in HDAC4 and 5, which 
subsequently serve as docking sites for 14-3-3 (McKinsey et al. 2000a; McKinsey et 
al. 2000b).
Since class II HDACs can be found in the cytoplasm, the possibility of their having a 
cytoplasmic role cannot be ruled out. Indeed HDAC6 has a known cytoplasmic role. It 
has been shown to reverse the post-translational acétylation of tubulin, which is 
reported to destabilise the microtubules and enhance microtubule dependent cell 
motility (Hubbert et al. 2002; Matsuyama et al. 2002). Very recently it has also been 
shown that HDAC6 is involved in the removal of cytotoxic aggregates of misfolded 
proteins, via the microtubule network, to a processing organelle called the aggresome 
(Kawaguchi et al. 2003). In this role HDAC6 is considered to be a linker protein.
1.3.7 Histone deacetylases and cancer
A wealth of evidence is now appearing in the literature implicating histone 
deacetylases in cancers, particularly of the blood and lymphoid systems. The current 
evidence points mainly to the aberrant recruitment of histone deacetylases by mutated 
transcription factors or to the recruitment of deacetylases by transcription factors 
which are ectopically expressed, rather than to deregulated or ectopic expression of 
the HDACs themselves.
Several transcription factors implicated in leukaemias repress expression of specific 
genes because of aberrant recruitment of HDACs. In acute promyelocytic leukaemia 
(APL) the transforming proteins are fusions of the promyelocytic leukaemia (PML) or 
the promyelocytic leukaemia zinc-finger (PLZF) proteins with the retinoic acid 
receptor-a (RAR-a). The ability of the RAR-a protein to block haematopoietic 
differentiation depends on its DNA binding domain which is retained by the fusion
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protein; however, the retinoic acid binding ability of the RAR is also retained which 
provides the opportunity for therapy with retinoic acid.
In cell lines derived from patients with APL, the oncoprotein encoded by the 
translocation-generated fusion gene (PML-RAR-a) represses transcription by 
recruitment of HDAC1 (Grignani et al. 1998; He et al. 1998; Lin et al. 1998). APL 
patients can be treated with retinoic acid but often become resistant. In one patient 
this resistance was overcome by co-treatment with an inhibitor of histone 
deacetylases (Warrell et al. 1998), though no other studies, to date, have shown this. 
HDAC-dependent aberrant transcriptional repression is implicated as the main 
oncogenic mechanism in specific types of myeloid leukaemia and lymphomas. In non- 
Hodgkin's lymphoma, the transcriptional repressor, B-cell lymphoma gene 6 (BCL6) 
[also called lymphoma-associated zinc finger protein 3 (LAZ3)] is inappropriately 
expressed within the lymphoid compartment, resulting in aberrant transcriptional 
repression (Kerckaert et al. 1993). BCL6 has been found to co-immunoprecipitate with 
SMRT, mSin3 and an HDAC activity (Dhordain et al. 1998). In addition HDAC 
inhibitors significantly reduce BCL6-mediated repression. It is therefore concluded that 
oncogenic transcriptional repression by BCL6 is mediated, largely, by an associated 
histone deacetylase activity.
In acute myeloid leukaemia (AML), 12-15% of cases have a t(8;21) chromosomal 
translocation. This is the second most common genetic lesion in AMLs where the N- 
terminus of the AML1 gene is fused to the C-terminus of the eight twenty one (ETC) 
gene (Erickson et al. 1992). In the normal cell, the AML-1 protein is a transcriptional 
activator of a number of genes involved in haematopoiesis, however, fused to ETC, is 
becomes a potent dominant transcriptional repressor. Experiments showed that ETC 
is able to co-immunoprecipitate N-CoR (Section 1.3.4.3) mSin3 and HDAC1. The 
binding to N-CoR was found to be direct and hence it was concluded that ETO recruits
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the N-CoR/Sin3/histone deacetylase complex by binding to N-CoR, resulting in a 
fusion protein which is a transcriptional repressor by virtue of its associated 
deacetylase activity (Wang et al. 1998). Significantly, the AML1 ETO fusion protein 
represses transcription of the p14^^^ tumour suppressor (Linggi et al. 2002) and does 
so by binding co-repressors and HDACs (Hiebert et al. 2003).
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1.4 Histone deacetylase inhibitors
1.4.1 Introduction
In our study we used chemical inhibitors to HDACs to investigate the consequences of 
reducing HDAC activity in our Fos-transformed cells (FBR), remembering that HDACs 
are up-regulated in these cells, compared to levels in their non-transformed parental 
cell line (208F). We chose the inhibitors, TSA and valproic acid (VPA), on the basis 
that since they come from structurally distinct inhibitor families their inhibition is 
mechanistically different and, because they are both currently prime candidate drugs 
in anticancer therapy.
1.4.2 Classes of histone deacetylase inhibitors
1.4.2.1 Introduction
There are four main classes of known histone deactetylase inhibitors. These are: 
hydroxamic acid-related hybrid compounds (HRCs); short chain fatty acids; 
benzamidines; and cyclic tetrapeptides. TSA is a member of the family of hydroxamic 
acid-related HRCs whilst VRA is a short chain fatty acid.
1.4.2.2 TSA: a hydroxamic acid-related hybrid polar compound
TSA is an HRC (Tsuji et al. 1976; Yoshida et al. 1990). The essential characteristics of 
HRCs are: a polar site, the hydroxamic group, a six-carbon hydrophobic methylene 
spacer, a second polar site and a terminal hydrophobic group (Figure 1.8). Another 
HRC which is currently in clinical trials is suberoylanilide hydroxamic acid (SAHA) 
(Richon et al. 1998).
TSA was originally isolated (along with its glucopyranosyl derivative, trichostatin 0) in 
1976 as an antibiotic against trichophytons and some fungi (Tsuji et al. 1976). It was
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not until about 10 years later it was found that these trichostatins were able to strongly 
induce the differentiation in two types of murine erythroleukaemia (MEL) cells such 
that they became haemoglobin-positive after 5 days in 15nM TSA and to inhibit 
proliferation in mammalian cells (Yoshida et al. 1987).
TSA was initially found to cause an accumulation of acetylated histones, and pulse- 
chase experiments subsequently revealed that histone hyperacetylation induced by 
TSA is due, not to increased acétylation but to decreased deacetylation of histones 
(Yoshida et al. 1990). In vitro experiments using partially purified histone deacetylase 
from mouse mammary tumour cells have shown that TSA is a potent inhibitor with a Ki 
value of 3.4nM. A TSA resistant cell line derived from these tumour cells was found to 
have a markedly increased Ki value of 31 nM, indicating that the enzyme itself had 
become resistant to TSA. This confirmed that histone deacetylase is the primary 
intracellular target of TSA. Figure 1.6 shows the catalytic core of an HDAC complexed 
to TSA. The hydroxamic acid moiety of TSA bind to the zinc at the bottom of the 
tubular pocket and the benzene-ring group projects out of the pocket on the surface of 
the protein.
hydrophobic 
I  moiety
N polar site
r hyclrox3mic scidII hydrophobic 
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Figure 1.8
The structure of TSA, showing the essential characteristics of ail hydroxamic acid-related hybrid polar 
compounds.
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1.4.2.3 VPA: a short chain fatty acid.
Until recently butyrate and phenylbutyrate (Newmark et al. 1994; Carducci et al. 1996) 
were the only class of HDAC inhibitors approved for use in the treatment of cancer, 
with mixed results. They have, however, the limitation that they must be used at very 
high concentrations to inhibit HDAC activity, particularly in vivo since they are 
degraded rapidly after intravenous administration (Warrell et al. 1998), furthermore 
they are not specific for HDACs as they also inhibit phosphorylation and méthylation of 
proteins as well as DNA méthylation (Newmark and Young 1995).
OH
O
Figure 1.9
The simple structure of VPA: 2-propylpentanoic acid.
VPA is one of the more recent short chain fatty acid, anti-cancer drugs to be studied. 
In the clinic it has several names, for example; depakene, depakote and divalproex 
sodium. It has the simple chemical structure: 2-propylpentanoic acid (Figure 1.9). VPA 
was used, historically, as a treatment for epilepsy and is without major side effects, 
though during early pregnancy it has been seen to cause serious birth defects such as 
non-closure of the neural tube (Nau et al. 1991). Interestingly its antiepileptic function 
and its teratogenic function are mechanistically distinct since modification of the 
molecule has been shown to generate compounds which may be antiepileptic or 
teratogenic but not both (Nau et al. 1991; Vorhees et al. 1991). The ability of VPA to 
inhibit HDACs was discovered almost 20 years ago (Horie and Suga 1985), but only
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recently has it been demonstrated to be a potent HDAC inhibitor which relieves 
HDAC-dependent transcriptional repression and causes hyperacetylation of histones 
both in cultured cells and in vivo (Gottlicher et al. 2001). VPA has been shown to 
induce differentiation in carcinoma cells (Werling et al. 2001), transformed 
haematopoietic progenitor cells and leukaemic blasts from acute myeloid leukaemia 
patients (Gottlicher et al. 2001). Most interestingly, tumour growth and metastasis 
formation are significantly reduced in animal experiments (Gottlicher et al. 2001).
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1.5 Re-expressed genes
1.5.1 Introduction
We show in this study that the following three proteins (with others) are down- 
regulated in v-Fos'^^^-transformed cells and that their expression can be restored by 
treatment with HDAC inhibitors. We go on to re-express these genes ectopically in 
FBR cells, and show that their expression inhibits invasion.
1.5.2 STAT6
Signal transducer and activator of transcription (STAT) 6, is a transcription factor. It is 
activated at the cell membrane by phosphorylation at Tyr-641 (Mikita et al. 1996; 
Mikita et al. 1998). This happens when, for example, the activating cytokine, IL 
(interleukin) -4 or IL-13 binds to its cell surface receptor, leading to receptor clustering 
and transphosphorylation of receptor-associated Janus kinases (Jaks), which then 
mediate phosphorylation of STAT6 (Shimoda et al. 1996; Takeda et al. 1996). This 
tyrosine phosphorylation is essential for dimérisation of STAT6 preceding 
translocation of the dimer to the nucleus. STATs, however, can also undergo serine 
phosphorylation (Decker and Kovarik 2000 ) and are therefore potential substrates for 
MAP kinases. This would provide a mechanism for cross-talk between the JAK-STAT 
and MAP kinase signal transduction pathways.
Generally, the deregulation of STAT signalling pathways is considered to contribute to 
cellular transformation in vivo particularly leukaemogenesis (Benekli et al. 2003), but 
this is associated with increased STAT activity particularly STAT3 and STAT5. In vitro, 
STAT3 is constitutively active in Src-transformed NIH3T3 cells. It is thought that 
STATs exert their transforming activity through the induction of an anti-apoptotic
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pathway (Barton et al. 2004), however, there is also evidence of the opposite effect. 
STAT1-deficient mice develop spontaneous tumours and STAT1-deficient cells are 
more resistant to agents which induce apoptosis (Stephanou and Latchman 2003). In 
addition STAT1-deficient cells have increased MDM2 (a p53 inhibitor) and decreased 
p53 expression (Townsend et al. 2004).
Interestingly, in addition to a role in activating transcription of tissue inhibitor of matrix 
metalloQroteinase (TIMP) genes (Gatsios et al. 1996; Bugno et al. 1995), STAT6 has 
recently been shown to have a role in activating extracellular matrix genes. It has been 
demonstrated by two groups that IL-4 can up-regulate type I collagen and that this up- 
regulation is mediated through STAT6 (McGaha et al. 2003; Buttner et al. 2004).
1.5.3 RYBP
Ringl and YY1 binding protein (RYBP), a zinc finger protein, was first identified, by 
virtue of its binding, in a yeast two-hybrid screen (Garcia et al. 1999), to Ringl A, a 
member of the mammalian polycomb complex. The same study also showed that 
RYBP binds Ringl B and M33, the mammalian homologue of the Drosophila Polycomb 
(PC) protein, and also to the transcription factor YY1. It was found initially to have 
homology to YY1 associated factor 1 (YAF1) and later acquired the alternative name 
of YY1 and E4TF1/hGABP associated factor 1 (YEAF1), which reflects this homology 
(Sawa et al. 2002) and its binding to both adenovirus early 4 transcription factor 1 / 
human GA binding protein (E4TF1/hGABP) and YY1. RYBP was also later recognised 
by yeast two-hybrid screen as interacting with the E2 promoter binding factor 2 (E2F2) 
and E2F3 proteins (Schlisio et al. 2002) and with E2F6 (Trimarchi et al. 2001).
From all of these studies, comes the idea that RYBP functions as a molecular bridge. 
Interactions between transcription factors to which it binds, occur only in the presence 
of RYBP. Thus, it is thought to mediate interactions between transcription factors
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which bind to a promoter at neighbouring response elements; such that the 
transcription factors act synergistically, in activating (or repressing) transcription. This 
is also thought to provide a basis for specificity within the E2F protein family (Schlisio 
et al. 2002), where E2F binding in combination with YY1, and their interaction, is 
required to control promoter activity correctly.
RYBP was initially considered to be a transcriptional co-repressor, by virtue of its 
associations with polycomb group proteins, which maintain the repressed state of 
genes, particularly during development, and also by its binding to the repressor 
domain of E2F6, which is also a component of the Bmi-containing polycomb complex 
(Trimarchi et al. 2001). It now seems though, that RYBP can act as either repressor or 
activator (Schlisio et al. 2002) depending on the combination of transcription factors to 
which it binds.
1.5.4 PCDHGC3
Protocadherin % subfraction Ç3 (PCDHGC3) first appears in the literature as pc43, 
which was originally identified along with pc42 as founding members of the 
protocadherin subfamily of the cadherin super family (Sano et al. 1993; Suzuki 2000) 
characterised by their extracellular cadherin repeat motif. More than 70 protocadherins 
have now been identified in mammals, and they are also present in a wide range of 
species, including invertebrates. Cadherins, however, are not found in lower order 
species and for this reason protocadherins are thought to have preceded cadherins in 
evolution. They are integral membrane proteins. Their extracellular domains consist of 
five or more cadherin repeats and their cytoplasmic domains have no homology to 
cadherins, nor any other databased protein sequences. Little homology exists 
between these domains in protocadherins themselves, though some sequence 
homology has been demonstrated between the cytoplasmic domain of PCDHGG3 and
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two other protocadherin-like molecules (Obata et al. 1998). PCDHGC3 (which has 
also been called PCDH2) has six extracellular cadherin repeats and participates in 
calcium-dependent hemophilic cell-cell adhesions, as do all cadherins. It is known to 
be highly expressed in the central nervous system, where levels are developmentally 
regulated, and it is thought to be involved in the formation of neuronal circuits (Sano et 
al. 1993; Suzuki 2000; Kallenbach et al. 2003). Its expression is also high in adult 
brain, however, where it is thought to be involved in the formation of synaptic contacts 
and in transmission of signals across the synapse (Sano et al. 1993; Suzuki 2000). Its 
expression has also been demonstrated in fibroblasts and kératinocytes (Matsuyoshi 
and Imamura 1997) and we show here that the mRNA is relatively abundant in 208F 
cells. The hemophilic interaction of protocadherin molecules is weak in comparison to 
that between classical cadherins (Obata et al. 1995). This is thought to be a function 
of the intracellular domain. Classical cadherins are known to be linked intracellularly to 
the actin cytoskeleton through binding to p, y, (directly) and a  (indirectly) catenins 
(Ozawa et al. 1989; Ozawa et al. 1990; Ozawa and Kemler 1992), however, 
PGDHGC3 does not bind catenins (Obata et al. 1995). When the interacellular domain 
of PGDHGG3 is replaced with that of E-cadherin, PGDHGG3 becomes capable of 
strong homophilic interaction, and co-immunoprecipitates with a and p catenins 
(Obata et al. 1995).
The developmental role PGDHGG3 in the central nervous and the capability of 
protocadherins for only weak interaction has led to the suggestion that they may be 
more concerned with cell-cell recognition rather that cell-cell adhesion (Dunne et al. 
1995). It is also thought possible that these proteins may be capable of heterophilic 
interaction since localisation studies have shown that, at cell-cell contacts, PGDHGG3 
can be present only in one cell membrane (Obata et al. 1995).
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1.6 Summary of experiments
Initially here, we demonstrate HDACs to be up-regulated in FBR cells. The following 
three chapters examine the role of HDACs in the Fos-transformed phenotype. Firstly, 
we use pharmacological inhibition of HDACs in FBR cells to determine the contribution 
of these enzymes to specific phenotypic aspects. Secondly, we identify genes which 
are down-regulated as a consequence of v-Fos expression but which are re­
expressed on inhibition of HDACs; the implication being, that HDAC activity mediates 
their down-regulation. We re-express three of these proteins, from cDNAs, and 
examine the consequence to the transformed phenotype. Thirdly, we employ several 
stategies to modulate the activity of, specifically, HDAC4, in our cell system. 
Theoretically we anticipated that increasing HDAC4 activity in 208F cells may confer 
some aspect of transformation on them, and that decreasing HDAC activity in FBR 
cells may revert some aspect of their transformed phenotype. With the intention of 
increasing HDAC4 activity, we ectopically express wild type HDAC4 or a mutant of 
HDAC4 which cannot be exported from the nucleus. With the intention of decreasing 
HDAC4 activity we ectopically express a deacetylase-inactive HDAC4 mutant, or 
those proteins involved in the nuclear export of HDAC4: 14-3-3(3 and/or constitutively 
active CamKIV.
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2.1 Materials
Materials are listed by “technique” in, essentially, chronological order. The same order 
is used in the “Methods” and “Results” sections.
2.1.1 Cells
2.1.1.1 Cell lines
208F cells are a subclone of the Rat-1 fibroblast cell line and were obtained from Dr. 
Kristine Quade, Cancer Research UK., London Research Institute, London, UK.
FBR cells are 208F cells infected with FBR-MuSV (Sections 1.2.2 and 1.2.5). 208F 
cells are non-producer cells and FBR-MuSV is replication defective. FBR cells were 
obtained from Prof. Tom Curran, St. Jude Children's Research Hospital, Memphis, 
Tennessee, USA.
Cos-7 cells were supplied by Dr. Joseph Winnie, BICR.
2.1.1.2 Tissue culture
Sterile glass pipettes and plastic Gilson tips and sterile solutions: PE, PBS, MilliQ H2O 
were prepared by central services personnel, BICR.
•Cell culture plastic dishes (all sizes)
•Cell scraper (plastic)
•DMEM
•DMSO
Becton-Dickinson Labware, Cowley, 
Oxfordshire, UK.
Corning UK Ltd., High Wycombe, 
Buckinghamshire, UK.
Invitrogen, Paisley, UK.
Fisher Scientific (UK) Ltd., Loughborough, 
Leicestershire, UK.
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•FCS
•Freezing “Nunc” vials
•G418 (Geneticin) 
•HEPES 
•L-glutamine 
•Liquid Nitrogen 
•Sodium bicarbonate 
•Sodium pyruvate 
•Sodium valproate 
•Trichostatin A 
•Trypsin (2.5%)
Sigma, Gillingham, Dorset, UK. 
Nalge Nunc International, Roskilde, 
Denmark.
Invitrogen, Paisley, UK.
Invitrogen, Paisley, UK.
Invitrogen, Paisley, UK.
Cryoservice Ltd., Worcester, UK. 
Sigma, Gillingham, Dorset, UK. 
Sigma, Gillingham, Dorset, UK. 
Sigma, Gillingham, Dorset, UK. 
Sigma, Gillingham, Dorset, UK. 
Sigma, Gillingham, Dorset, UK.
2.1.2 Northern analysis
•EcoscintA
•Expresshyb
•Formaldehyde
•Formamide
•Hybond N+ nylon membrane 
•MOPS
•Oligolabelling Kit
National Diagnostics, Atlanta, Georgia, USA. 
Clontech Laboratories, Basingstoke, 
Hampshire, UK.
Fisher Scientific, Loughborough, 
Leicestershire, UK.
Fluka Chemika-Biochemika AG, Buchs, 
Switzerland.
Amersham Pharmacia, Little Chalfont, 
Buckinghamshire, UK.
Roche Diagnostics, Lewes, East Sussex, UK. 
Amersham Pharmacia Biotech UK Ltd.,
Chapter 2: Materials and Methods 49
•RNAzol B
•Sephacryl S-400 HR Microspin 
columns 
•Sodium acetate
•Sodium citrate
•Super RX medical X-ray film 
•7S ribosomal RNA, cDNA probe
.[a^^P]-dCTP 3000 CimmoM
Little Chalfont, Buckinghamshire, UK. 
Tel-Test Inc., Friendswood, Texas, USA. 
Amersham Pharmacia Biotech UK Ltd., 
Little Chalfont, Buckinghamshire, UK. 
Fisons Scientific (UK) Ltd., Loughborough, 
Leicestershire, UK.
Fisher Scientific (UK) Ltd., Loughborough, 
Leicestershire, UK.
Fuji Photofilm Co. Ltd.,Tokyo, Japan.
Dr. Fiona McGregor, BICR.
Amersham Pharmacia Biotech UK Ltd., 
Little Chalfont, Buckinghamshire, UK.
2.1.3 Western analysis
2.1.3.1 Protein extraction
•Ap rotin in
•Leupeptin
•Nonidet P-40 (NP-40) 
•PMSF
•Sodium fluoride 
•96 well assay plate
Sigma, Gillingham, Dorset, UK. 
Sigma, Gillingham, Dorset, UK. 
Sigma, Gillingham, Dorset, UK. 
Sigma, Gillingham, Dorset, UK. 
Sigma, Gillingham, Dorset, UK. 
Corning UK Ltd., High Wycombe, 
Buckinghamshire, UK.
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2.1.3.2 SDS-PAGE
•Benchmark prestained protein ladder Invitrogen, Paisley, UK. 
(PAGE molecular weight markers)
•Precast 10% Tris-glycine gels,
10 well, 1.0 mm
Invitrogen, Paisley, UK.
2.1.3.3 Blotting and detection 
•ECl Western Blotting Detection Kit
•Immobilon-P
•Marvel dried milk powder
•Saranwrap
•Super RX medical X-ray film 
•3MM filter paper
Amersham Pharmacia, Little Chalfont, 
Buckinghamshire, UK.
Millipore (UK) Ltd., Watford, Hertfordshire, 
UK.
Premier Brands UK Ltd., Spalding, 
Lincolnshire, UK.
Dow Chemical Company, USA.
Fuji Photofilm Co. Ltd., Tokyo, Japan. 
Whatmann International Ltd., Maidstone, 
Kent, UK.
2.1.3.4 Antibodies
•anti-(human)HDAC4 rabbit polyclonal antibody was a gift from Dr. Eric Miska, 
Wellcome/ Cancer Research UK Institute, University of Cambridge, Cambridge, UK. 
This antibody could be used in western analysis to visualise wtHDAC4, HDAC4- 
H803A, HDAC4-D840N and TMHDAC4, though was not suitable for use in 
immunocytochemistry.
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•anti-14-3-3 p and Ç, rabbit 
polyclonal antibody, 06-351 
•anti-(human)CamKIV, mouse 
monoclonal antibody, C28420 
•anti-flag M2 mouse monoclonal 
antibody
•Living colours A.v. (JL-8), anti- EGFP 
mouse monoclonal antibody 
•HRP- conjugated anti-mouse IgG, 
F(ab’)2 fragment (from sheep) 
•HRP-conjugated anti-rabbit IgG, 
whole molecule (from donkey)
Upstate Biotechnology, Lake Placid, 
New York, USA.
Transduction Laboratories, Lexington, 
Kentucky, USA.
Sigma, Gillingham, Dorset, UK.
Clontech Laboratories, Basingstoke, 
Hampshire, UK.
Amersham Pharmacia Biotech UK Ltd., 
Little Chalfont,Buckinghamshire, UK. 
Amersham Pharmacia Biotech UK Ltd., 
Little Chalfont, Buckinghamshire, UK.
2.1.4 Invasion assays 
•Calcein, AM
TM►Complete Matrigel
►Epidermal growth factor 
►Propidium Iodide 
►Reduced growth factor matrigel
►6.5mm Transwell™, 8.0pm pore size
Molecular Probes, Leiden, The Netherlands. 
Becton-Dickinson Labware, Cowley, 
Oxfordshire, UK.
Sigma, Gillingham, Dorset, UK.
Sigma, Gillingham, Dorset, UK. 
Becton-Dickinson Labware, Cowley, 
Oxfordshire, UK.
Corning UK Ltd., High Wycombe, 
Buckinghamshire, UK.
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2.1.5 Genetic manipulation
2.1.5.1 cDNAs
RYBP full-length cDNA (Garcia et al. 1999) was a kind gift from Dr. Miguel Vidal, 
Centro De Investigaciones Biologicas, Madrid, Spain.
STAT6 full-length cDNA (Quelle et al. 1995) was a kind gift from Prof. James Ihle, St. 
Jude Children’s Research Hospital. Memphis, USA.
Protocadherin 43 (PCDHGC3) (Sano et al. 1993) full-length cDNA was a kind gift from 
Dr. Shintaro T. Suzuki, Kwanseigakuin University, Hyogo, Japan.
The human HDAC4 wild type gene, Genbank accession number API 32607 was 
provided by Dr. Eric Miska, Wellcome/Cancer Research UK Institute, University of 
Cambridge, Cambridge, UK. I have referred to this as wtHDAC4.
Mutant human HDAC4, which has three serine residues (S246, S467, and S632) 
mutated to alanines was a gift from Dr. Xiang-Jiao Yang. I have referred to this as 
TMHDAC4.
Two mutant human HDAC4 genes: HDAC4-H803A, which has histidine 803 mutated 
to alanine; and HDAC4-D840N which has aspartic acid 840 mutated to asparagine; 
were supplied by Dr. Eric Miska, Wellcome/Cancer Research UK Institute, University 
of Cambridge, Cambridge, UK, in pcDNA3.1.
CamKIVi_3i3, a constitutively active mouse CamKIV gene, Genbank accession 
number NM_009793 (full length sequence), in an RSV vector was made by Dr. 
Peiqing Sun, Oregon Health Sciences University, Oregon, USA.
The human 14-3-3p wild type gene, Genbank accession number X57346, was 
provided in the pcDNA3 vector, by Prof. Walter Kolch, BICR, Glasgow, UK., in 
collaboration with Dr. John Sedivy, Yale University, Connecticut, USA.
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2.1.5.2 Vectors 
•pCR-Script
•pEGFP-N1
•pLPCX2
Stratagene Europe, Amsterdam Zuidoost,
The Netherlands.
Clontech Laboratories (UK) Ltd., Basingstoke, 
Hampshire, UK.
Clontech Laboratories (UK) Ltd., Basingstoke, 
Hampshire, UK.
2.1.5.3 PCR
•BIOTAQ™ DNA polymerase 
•dNTPs
•Glycerol
•Magnesium chloride 
(supplied with BIOTAQ) 
•NH4 reaction buffer 
(supplied with BIOTAQ)
•pfu reaction buffer 
(supplied with pfu) 
•PTC-100 Programmable 
Thermal Controller 
•Turbo pfu DNA polymerase
Bioline UK Ltd., London, UK.
Promega Corporation, Madison, Wisconsin, 
USA.
Fisher Scientific (UK) Ltd., Loughborough, 
Leicestershire, UK.
Bioline UK Ltd., London, UK
Bioline UK Ltd., London, UK.
Stratagene Europe, Amsterdam Zuidoost, 
The Netherlands.
M.J. Research Inc., Watertown, 
Massachusetts, USA.
Stratagene Europe, Amsterdam, Zuidoost, 
The Netherlands.
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2.1.5.4 Kits
•PCR-Script Cloning Kit
•Qiafilter Plasmid Maxi Kit 
•Qiagen Mini Plasmid Kit 
•QIAquick Gel Extraction Kit 
•Rapid DNA Ligation Kit
Stratagene Europe, Amsterdam Zuidoost, 
The Netherlands.
Qiagen Ltd., Crawley, West Sussex, UK. 
Qiagen Ltd., Crawley, West Sussex, UK. 
Qiagen Ltd., Crawley, West Sussex, UK. 
Roche Diagnostics, Lewes, East Sussex, UK.
2.1.5.5 Agarose gel electrophoresis 
•Bioline Hyperladder I 
•Boric acid
•Ficoll
Bioline UK Ltd., London, UK.
Fisher Scientific (UK) Ltd., Loughborough, 
Leicestershire, UK.
Sigma, Gillingham, Dorset, UK.
2.1.5.6 Manipulations in bacteria
•Ampicillin
•Kanamycin
•Chloramphenicol
•X-gal
•IPTG
•BactoAgar
•DH5a competent cells
Sigma, Gillingham, Dorset, UK.
Sigma, Gillingham, Dorset, UK.
Sigma, Gillingham, Dorset, UK.
Melford Laboratories Ltd., Ipswich, Suffolk, 
UK.
Melford Laboratories Ltd., Ipswich, Suffolk, 
UK.
Becton-Dickinson, Cowley, Oxfordshire, UK. 
Anachem, Luton, Bedfordshire, UK. 
Invitrogen, Paisley, UK.
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2.1.5.7 Restriction digestion 
•Restriction enzymes (except Sacll) 
•React buffers 
(supplied with restriction enzymes) 
•Sacll
Invitrogen, Paisley, UK.
Invitrogen, Paisley, UK.
Promega Corporation, Madison, Wisconsin, 
USA.
Promega Corporation, Madison, Wisconsin, 
USA.
•Acetylated BSA (supplied with Sacll) Promega Corporation, Madison, Wisconsin,
USA.
•Alkaline phosphatase (calf intestinal) Transgenomic, Crewe, Cheshire, UK.
•Reaction buffer C 
(supplied with Sacll)
2.1.5.8 DNA Sequencing 
•Dextran blue 
•“DyeDeoxy” reaction mix
Sigma, Gillingham, Dorset, UK.
Perkin Elmer, Roche Molecular Systems Inc., 
Branchburg, New Jersey, USA.
2.1.6 Transfection / nucleofection 
•FuGeneG
•Nucleofection cuvettes 
•Nucleofection solution R, plus 
supplement 
•Nucleofector 
•RPMI medium
Roche Diagnostics, Lewes, East Sussex, UK. 
Amaxa, Nattermannallee, Germany.
Amaxa, Nattermannallee, Germany.
Amaxa, Nattermannallee, Germany. 
Invitrogen, Paisley, UK.
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2.1.7 Immunohistochemistry I actin staining
Confocal microscope images were taken using a BioRad MRC 600 confocal 
illumination unit attached to a Nikon Diaphot inverted microscope at stated 
magnifications.
2.1.7.1 Antibodies and stains 
•FITC-conjugated phalloidin 
•TRITC-conjugated phalloidin 
•anti-myc 9E10 mouse monoclonal 
antibody
•anti-flag M2 mouse monoclonal 
antibody.
•Vectashield containing DAP I stain
•FITC-conjugated anti-mouse antibody 
(F(ab’)2 fragment, from sheep) 
•TRITC-conjugated anti-mouse 
antibody (Fab specific, from goat)
Sigma, Gillingham, Dorset, UK.
Sigma, Gillingham, Dorset, UK. 
Invitrogen, Paisley, UK.
Sigma, Gillingham, Dorset, UK.
Vector Laboratories Ltd., Peterborough, 
Cambridgeshire, UK.
Sigma, Gilligham, Dorset, UK.
Sigma, Gilligham, Dorset, UK.
2.1.7.2 Preparation of coverslips 
•Paraformaldehyde 
•Bovine albumin fraction V 
•Coverslips (glass)
•Vectashield
Sigma, Gilligham, Dorset, UK.
Sigma, Gilligham, Dorset, UK.
BDH Chemicals Ltd., Poole, Dorset, UK. 
Vector Laboratories Ltd., Peterborough, 
Cambridgeshire, UK.
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2.1.8 General
2.1.8.1 Water
MilliRO H2O, which is purified by reverse osmosis, was obtained from a MilliRO 10, 
Water Purification System from Millipore UK Ltd., Watford, Hertfordshire, UK.
MilliQ H2O, which is MilliRO H2O further purified by fine filtration, was obtained from a 
Millipore MilliQplus Ultrapure Water System from Millipore UK Ltd., Watford, 
Hertfordshire, UK.
2.1.8.2 Chemicals and Reagents
Solutions and buffers were prepared using MilliRO H2O.
•Agarose
•Bicinchoninic acid solution 
•P-mercaptoethanol 
•Bromophenol blue 
•Copper II sulphate 
•Dithiothreitol (DTT)
•EDTA
•Ethanol
•Ethidium bromide
•Glycine
•Methanol
•Nonidet-P40
Invitrogen, Paisley, UK.
Sigma, Gillingham, Dorset, UK.
Sigma, Gillingham, Dorset, UK.
Sigma, Gillingham, Dorset, UK.
Sigma, Gillingham, Dorset, UK.
Millipore UK Ltd.,Watford, Hertfordshire, UK. 
Fisher Scientific UK., Loughborough, 
Leicestershire, UK.
James Burrough Ltd., Witham, Essex, UK. 
Sigma, Gillingham, Dorset, UK.
BDH Chemicals Ltd., Poole, Dorset, UK. 
Fisher Scientific, Loughborough, 
Leicestershire, UK.
BDH Laboratory Supplies, Poole, Dorset, UK.
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•Parafilm ‘M’ 
•Paraformaldehyde 
•PBS tablets
•Propan-2-ol (isopropanol)
•Sodium Chloride
•Sodium dodecyl sulphate
•Sodium hydroxide
•Sodium orthovanadate 
•Sucrose
•Tris
•Triton X-100 
•Tween 20
American National Can, Chicago, llanois, 
USA.
Sigma,
r
Gillingham, Dorset, UK.
Oxoid Ltd., Basingstoke, Hampshire, UK 
Fisher Scientific (UK) Ltd.,Loughborough, 
Leicestershire, UK.
Fisher Scientific (UK) Ltd., Loughborough, 
Leicestershire, UK.
Fisher Scientific (UK) Ltd., Loughborough, 
Leicestershire, UK.
Fisher Scientific (UK) Ltd.,Loughborough, 
Leicestershire, UK.
BDH Chemicals Ltd., Poole, Dorset, UK. 
Fisher Scientific (UK) Ltd., Loughborough, 
Leicestershire, UK.
Melford Laboratories Ltd.,Ipswich, Suffolk. 
Sigma, Gillingham, Dorset, UK.
Sigma, Gillingham, Dorset, UK.
2.1.8.3 Plasticware 
•Bijou bottles (sterile)
•Falcon tubes 15ml and 50ml
Bibby Sterilin, Stone, Staffordshire, UK. 
Becton-Dickinson Labware, Cowley, 
Oxfordshire, UK.
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►Filter pipette tips
►Glass microscope slides 
►Microfuge tubes 1.5ml
►Pipette tips
►Universal bottles (sterile)
Greiner Labortechnik Ltd., Gloucestershire, 
UK.
BDH Laboratory Supplies, Poole, Dorset, UK. 
Eppendorf-Netheler-Hinz GmbH.,
Cambridge, Cambridgeshire, UK.
Elkay Laboratory Products UK Ltd., 
Basingstoke, Hampshire, UK.
Bibby Sterilin, Stone, Staffordshire, UK.
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2.2 Methods
Methods are listed in the order in which they appear in the results sections, i.e., 
essentially, in chronological order.
2.2.1 Tissue culture
2.2.1.1 Maintenance of cell lines
Cells were maintained in DMEM supplemented with 0.3% sodium bicarbonate, 1 mM 
sodium pyruvate, 2 mM glutamine, 10 mM HEPES and, 10% PCS. G418 (Geneticin), 
to a final concentration of 700 pgmM, was also added to DMEM used to maintain 
those cell lines carrying stably transfected genes. Cells were passaged every 3 to 4 
days with a 1:10 split ratio. For all cell lines, other than FBR, the DMEM was removed 
and the cells rinsed once in 0.25% trypsin. After a short incubation in the residual 
trypsin (approximately 2 mins depending on the cell line) 10ml of DMEM with 10% 
FCS (and other supplements discussed above) was sprayed onto the plate from a 10 
ml glass pipette and the cells resuspended. 1 ml of this suspension was added to 
each new 10 cm plate and the volume of DMEM made up to 10 ml. Cells were then 
incubated at 37°C in a humidified atmosphere also containing 5% CO2. Passage of 
FBR cells differed only in that cells were not incubated in trypsin prior to being 
sprayed from the plate.
2.2.1.2 Storage o f cells
Long-term storage of cells was in liquid nitrogen. Cells were trypsinised or sprayed 
from a subconfluent 10 cm plate (as described above) and centrifuged at 1000 rpm in 
a Beckman GP bench top centrifuge for 5 mins. The resulting pellet was then 
resuspended in 1 ml DMEM plus supplements (as described above) but, in this
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instance, containing 50% FCS and 10% DMSO. This 1 ml was then transferred to a 
“nunc” vial, which was then wrapped in cotton wool transferred to a small plastic box 
and placed at -70°C for at least 4 hours to allow the cells to freeze slowly. After this 
time vials were transferred to liquid nitrogen.
Vials were defrosted quickly by transfer from liquid nitrogen immediately into water at 
37°C. Their contents were then transferred to a plastic universal containing 20 ml of 
DMEM and centrifuged as described above. The resultant pellet was resuspended in 
10 ml DMEM (plus supplements) and transferred to a 10 cm dish.
2.2.2 Northern analysis
2.2.2.1 Isolation of total cellular RNA
The method of total cellular RNA isolation was that supplied with RNAzol B. Cells 
were grown to sub-confluence in 10cm tissue culture dishes. Growth medium was 
aspirated and 1 ml of RNAzol B added to each dish. The cell lysate was scraped into 
the RNAzol using a cell scraper and pipetted 3 times into a 1 ml Gilson tip, before 
being transferred into a 1 ml Eppendorf. For convenience the lysates were then stored 
at -70°C until required. On defrosting 100 pi of chloroform was added to each lysate 
which was then shaken vigorously and left on ice for 5 mins to allow the phase 
separation to establish. Samples were then centrifuged at 12,000 x g for 10 mins in a 
refrigerated centrifuge at 4°C. The upper, aqueous phase was then removed into a 
new Eppendorf and an equal volume (approximately 500 pi) of propan-2-ol added. 
The tubes were shaken vigorously and left on ice for 15 mins, followed by 
centrifugation at 12,000 x g for 15 mins at 4°C. The liquid was then removed leaving 
an RNA pellet which was washed once in 75% ethanol. The pellet was then dried for 
15 mins by centrifugation under vacuum and resuspended in 50 pi DEPC treated
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water. 5 pi of the RNA preparation was then diluted 1:100 in dH20 and quantified by 
UV-spectrophotometry at 260 nm.
2.22.2 Denaturing gel electrophoresis and electroblotting o f RNA 
Total cellular RNA samples were separated on both small (50 ml) and large (300 ml) 
agarose gels. 10 pg and 30 pg of total cellular RNA was loaded respectively, both 
having been aliquoted then dried down by centrifugation under vacuum for 
approximately 1 hour and resuspended in 12 pi RNA sample loading buffer (50% 
formamide; 33.3% formaldehyde, from a 37% solution; 0.5X MOPS buffer (see 
below); 5 pgml'^ ethidium bromide; and, 13.3% RNA loading dye, which comprises, 
50% glycerol, 1 mM EDTA, 0.4% bromophenol blue. Prior to loading, samples were 
heated in a heating block to 68°C for 5 mins then placed immediately on ice. To make 
a small agarose gel, 0.5 g of agarose was dissolved in 31.1 ml sterile dH20 by 
microwaving. 10 ml of 5X MOPS buffer (0.1 M MOPS; 50 mM sodium acetate; 5 mM 
EDTA; pH to 7.0 with NaOH pellets) was then added and the solution allowed to cool 
to approximately 60°C before the addition of 8.9 ml of formaldehyde (from a 37% 
stock solution), immediately prior to pouring. After loading, samples were run at 100 V 
for approximately 3.5 hours, under IX  MOPS running buffer. The RNA was then 
visualised by UV transillumination and the gel photographed. The RNA was then 
transferred to Hybond N+ nylon membrane overnight by upward capillary blotting by 
the method of Maniatis (Sambrook et al. 1989), using IX  SSC (150 mM NaCI, 15 mM 
sodium citrate, pH 7.0) as transfer buffer. The blot was then allowed to dry before UV- 
crosslinking of the nucleic acid to the membrane using a UV Stratalinker™ 1800 
(Stratagene).
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2 2 2 .3  Random priming and hybridisation
DNA probes were radiolabelled by random priming using an oligolabelling kit. 
Approximately 50 ng of DNA in a total volume of 34 pi was denatured by heating to 
100°C in a heating block and transferred immediately to ice. 10 pi of reagent mix (a 
buffered solution containing dATP, dGTP, dTTP and random hexadeoxyribo- 
nucleotides) was added, then 1.85 MBq (5 pi) of [a-^^P] dCTP and 1 pi Klenow 
fragment. This solution was incubated at 37°C for 1 hour. Unincorporated nucleotides 
were then removed by passing the reaction mix through a Sephacryl S-400 HR 
microspin column (previously centrifuged at 3 K for 2 mins) by centrifugation at 3,000 
rpm in an Eppendorf 5415c microfuge for 2 mins. The eluted probe was then heated 
to 100°C in a heating block for 5 mins and immediately transferred to ice for 2 mins. 1 
pi was removed into a scintillation vial containing 10 ml of scintillation fluid (Ecoscint 
A). The counts per minute (cpm) were then determined by counting in a Beckman 
LS5000CE scintillation counter and those samples with values greater than 10  ^
considered acceptable for hybridisation. The labelled probe was then transferred to a 
plastic universal containing the Hybond N+ nylon membrane which had immediately 
previously been incubated at 68°C for 30-60 mins with 5 ml of Expresshyb. Care was 
taken to add the probe directly into the Expresshyb at 68°G and to disperse it 
immediately. The membrane and probe were then incubated at 68°C for at least 1 
hour, rotating slowly. The membrane was then removed into wash buffer 1 (IX  SSC, 
0.1% SDS) which had been preheated to 50°C. After a few seconds the membrane 
was transferred to fresh wash buffer 1 at 50°C and the container allowed to shake 
gently in a 50°C water bath for 30 mins. A Geiger-Muller tube was then used to 
monitor the cpm present on the membrane. If these were low then the membrane was 
removed for autoradiography. If they were still high the membrane was transferred to 
wash buffer 2 (0.1X SSC, 0.1% SDS) and incubated at 50°C with gentle agitation for
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SOmins. If counts were still high this wash was repeated with fresh wash buffer and 
finally the temperature of the wash could be raised to 6 8 °C if necessary. The 
membrane was then wrapped in Saranwrap, placed in a medical X-ray cassette with 
two intensifying screens, and overlayed with Fuji Super RX medical X-ray film. 
Exposure, at -70°C, was initially overnight. The autoradiograph was developed using a 
Kodak X-Omat 480 RA, X-ray processor. To control for loading, membranes were 
later stripped of hybridised probe and reprobed for 7S RNA following the protocol 
described above. To strip the membrane a 0.1% SDS solution was heated to boiling 
in a microwave oven. The membrane was immediately immersed and rocked gently in 
the solution which was allowed to cool to room temperature before the membrane 
was removed and rinsed in 2X SSC.
2.2.3 Western analysis
2.2.3.1 Protein extraction
Cells were grown to approximately 70% confluence in 10 cm dishes. They were 
washed 3 times in ice cold PBS then drained well before the addition of 300 pi of EBC 
(50 mM Tris-HCI pH 8.0, 120 mM NaCI, 0.5% Nonidet P-40, 1 mM EDTA) 
supplemented with the protease inhibitors, aprotinin (10  pgmM), leupeptin (10  pgml'^), 
and PMSF (1 mM), and the phosphatase inhibitors Nas(V0)4 (50 pM), and NaF (50 
mM). Cells were scraped into the buffer and transferred to a 1.5 ml microfuge tube. 
They were kept on ice for 30 mins then centrifuged at 12,000 x g for 5 mins at 4°C. 
The supernate was then decanted into a fresh microfuge tube and the protein 
concentration determined.
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22.3.2 Nuclear protein extraction
Cells were grown to approximately 70% confluence in 10 cm dishes. They were 
washed 3 times in ice cold PBS then drained well before being scraped into 1.5 ml ice 
cold PBS and centrifuged at 1,500 x g for 2 mins. The cell pellet was resuspended in 
400pl ice cold nuclear extract buffer A (10 mM HEPES, 10 mM KCI, 0.1 mM EDTA) 
supplemented with 1 mM DTT and 0.5 mM PMSF immediately before use. Samples 
were then incubated on ice for 15 mins, following which, 25 pi of 10% NP-40 was 
added and the samples vortexed for 30 secs. They were then centrifuged at 12,000 x 
g for 30 secs. The nuclear pellet is resuspended in 50 pi ice cold nuclear extract 
buffer C (20 mM HEPES pH 7.9, 0.4 M NaCI, 1 mM EDTA, 25% glycerol) 
supplemented with 1 mM DTT and 0.5 mM PMSF immediately before use, and the 
samples are rocked vigorously for 15 mins at 4°C. Samples are then centrifuged at 
12,000 X g for 5 mins at 4°C and the resulting supernate of nuclear proteins 
transferred to a fresh Eppendorf tube.
2.23.3 Determination o f protein concentration
The protein concentration of the whole cell and nuclear extracts was determined by a 
bicinchoninic acid colourimetric assay based on the method by Lowry (Lowry et al. 
1951). The extracts were incubated at 37°C for 30 mins in a 50:1 solution of 
bicinchoninic acid: copper II sulphate solution, in 96 well assay plate and the resulting 
optical density at 580 nm was measured using a Dynatech MR7000 
spectrophotometer. The standard curve was drawn from six BSA standards at 80, 
100, 200, 400, 1000 and 2000 pgmM in the same buffer as the protein samples being 
measured.
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2.2.3 A  Polyacrylamide gel electrophoresis of proteins
Proteins were resolved by polyacrylamide gel electrophoresis through a precast 10% 
polyacrylamide gel measuring 8 cm x 6.5 cm x 0.1 cm, electrophoresed in SDS-PAGE 
running buffer (50 mM Tris-HCI; 1% glycine; 0.1% SDS) for 1 hour 45 mins at 125 
volts. 25 pg of protein extract in a volume adjusted to 20 pi with dHaO was combined 
with 5 pi of 5X sample loading buffer (final concentration: 60 mM Tris-HCI, pH 6 .8 ; 2% 
SDS; 0.1% bromophenol blue; 25% glycerol; 100 mM p-mercaptoethanol) and loaded 
per lane.
2.2.3.5 Blotting and hybridisation to antibody
After separation by polyacrylamide gel electrophoresis, proteins were then transferred 
to Immobilon-P (Millipore) by semi-dry blotting in buffer containing: 60 mM Tris-HCI, 
50 mM glycine, 1.6 mM SDS, 20% (v/v) methanol. Blots were incubated in blocking 
solution (PBS containing 5% Marvel and 0.1% Tween-20). Then in blocking solution 
containing the appropriate antibody at dilution as directed by the manufacturer for 
each individual antibody. Blots were washed three times in blocking solution then 
incubated in blocking solution containing anti-rabbit or anti-mouse immunoglobulin 
horseradish peroxidase-linked whole antibody, diluted as directed by the 
manufacturer. All incubations were for 1 hour at room temperature with gentle 
agitation. Blots were washed three times in PBS containing 0.1% Tween-20 and 
proteins visualised using ECL western blotting chemilluminescent detection reagent 
followed by autoradiography, where the membrane was then wrapped in Saranwrap, 
placed in a medical X-ray cassette, and overlayed with Fuji Super RX medical X-ray 
film. Exposure was initially for 30 secs to determine optimal exposure times. The 
autoradiograph was developed using a Kodak X-Omat 480 RA, X-ray processor.
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2.2.4 Growth curves
Cells were seeded in multiple wells of 3.6 cm diameter tissue culture (6 well) plates at 
2 X 10"^  or 4 X 10"^  per well, medium was changed every 2 days and cells from 3 wells 
per sample counted on indicated days using a Sharfe Casy1 TT cell counter.
2.2.5 F-actin staining
Cells were seeded at 5 x 10^ per well on sterile glass coverslips (19 mm) in 2.1 cm 
diameter tissue culture wells. At stated times and concentrations, VPA or TSA was 
added to the growth medium (and replaced every 48 hrs), so that cells were fixed at 
equivalent confluence on day 5, irrespective of length of treatment. To fix cells to 
coverslips, the medium (plus VPA or TSA if present) was removed and replaced with 
400 pi of fix solution (4% paraformaldehyde; 2% sucrose in PBS) for 15 mins. The 
paraformaldehyde was removed and the cells washed three times in PBS. They were 
then permeabilised with 400 pi of PBS containing 20 mM glycine and 0.05% Triton X- 
100, for 5 mins and again washed 3 times in PBS. Coverslips were then transferred to 
a light-tight container which was lined with parafilm to ease handling of coverslips with 
forceps. FITC-conjugated-phalloidin was diluted to 100 ngml"  ^ in blocking buffer (0.5% 
BSA, 10% FCS in PBS), and 100 pi was added to each coverslip. After 15 mins 
incubation in the dark (lid on), the coverslips were dipped sequentially in three 
beakers of dH2 0 , blotted onto a paper towel and placed face-down slowly onto a drop 
of Vectashield on a glass microscope slide. Excess Vectashield was aspirated and the 
edge of the coverslip was then sealed with clear nail varnish. Confocal microscope 
(Section 2.1.7) images were taken using a 63X or 40X objective for display purposes, 
and a 20X objective for quantitation purposes, to obtain a larger sample size per field. 
For quantitation, an average of 28 cells were counted per field and 12 fields were 
counted per treatment.
Chapter 2: Materials and Methods 68
2.2.6 Motility assays
2.2.6.1 Wounding assays
Cells were seeded at 7 x 10"^  in the 3.6 cm diameter wells of a 6 well tissue culture 
plate, approximately 3.5 days prior to wounding, in the absence or presence of VPA or 
TSA at the required concentration. For 1 day treatments inhibitor was added 14 hours 
before wounding. A single wound was made down the centre of each well with the 
200 pi tip of a Gilson pipetman. The growth medium, plus VPA or TSA if required, was 
then replaced. Phase contrast timelapse images were captured at 20 min intervals 
over a 24 hour period, on a Zeiss Axiovert 200m microscope with a Hamamatsu Orca 
camera. Images were captured from 6 wells per time point, by this method. During this 
time the plate was incubated in a Solent CO2 incubator designed around a LudI 
microscope stage. The timelapse stage manipulation and captured images were 
handled using "AQM" software by Kinetic Imaging. For each assay, we chose the time 
point immediately before the cells in the wound edge make contact with the other 
edge. This avoids cell-cell contact effects which may be differential between wounds, 
given that, although wound sizes are comparable, it is impossible to make them 
absolutely exact. At the chosen time point we measured the width of the wound in the 
centre of the field and compared it to the measurement taken at t=0. This determined 
the rate of movement of cells into the wound.
2.2.6 .2 Free motility assays
Early motility assays were carried out on cells grown to low density in 10 cm diameter 
tissue culture plates, having been seeded at 10"^  cells per plate 4 days prior to 
wounding. For 4 day TSA treatments, TSA was added four hours after seeding, for 2 
day treatments, DMEM (10% FCS) was replaced with DMEM (10% FCS) plus TSA, 2 
days prior to imaging, and for 1 day treatments, this was done 1 day prior to imaging.
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Images were captured with a Zeiss, Axiovert S 100 microscope using "Openlab" 
software by Improvision. Measurements of cell nucleus displacement were made by 
hand on still images from the timelapse sequence, and results expressed in 
comparative, not absolute values.
In later assays imaging and VPA treatment was carried out as described for wounding 
assays above (Section 2.2.6.1), except that cells were seeded at 10^ cells per well 
and grown to low density, and that images were captured at 10 min intervals over a 10 
hour period. Using "Tracker" software, by Kinetic Imaging, a track was drawn following 
the displacement of an individual cell nucleus over a 5 hour period within the 10 hours 
of timelapse sequence; this was to avoid periods of cell division. The co-ordinates of 
each of the 30 points per track were then exported to Microsoft Excel XP software, 
and tracks depicted in graph form, such that each had same origin, thus Wind rose 
diagrams were constructed, of 30 overlayed tracks.
2.2.7 Inverse Invasion assays
2.2.7.1 Inverse invasion assay
The method used was a modified version of that devised previously in our laboratory 
(Hennigan et al. 1994). An aliquot of Matrigel was thawed slowly on ice then diluted 
1:1 in ice cold PBS (containing 2X concentration TSA or VPA, if required). 100 pi of 
this was then pipetted carefully into each Transwell (inserted into a well of a 24 well 
tissue culture plate) and incubated for 2 hours at 37°C to allow it to set. During this 
time, cell suspensions of 2 x 10® cells per ml were prepared in DMEM containing 10% 
FCS. The Transwells were inverted and 100 pi of the cell suspension (2 x 10"^  cells) 
was pipetted onto the underside of the filter. If the cells are to be nucleofected prior to 
the invasion assay refer to section 2.2.10.4. The Transwells were covered carefully 
with the base of the 24 well tissue culture plate such that it contacts the droplet of cell
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suspension. The plate was incubated, inverted, for 2 hours to allow the cells to attach. 
It was then turned right-side-up and each Transwell removed and dipped sequentially 
into 2 X 1 ml serum free DMEM (containing TSA or VPA, if required) to wash, and 
finally placed into 1ml of serum free DMEM (containing TSA or VPA, if required). Then 
100 pi of DMEM plus 10% PBS (containing TSA or VPA or EGF, if required) was 
pipetted gently into the Transwell on top of the matrigel/PBS. The lid was replaced 
and the plate incubated at 37°C for 3 days.
2.2.7.2 Fixation and staining o f inverse invasion assays 
To fix and/or stain the assays, one of two methods was used.
Propidium iodine staining: 2 ml of methanol was pipetted into the wells of a 24 well 
plate and placed at -20°C for 1 hour. The Transwells were then placed in these wells 
for 20  mins after which they were transferred to wells containing 2 ml propidium iodide 
at 10 pgml'^ in PBS. Each Transwell was then washed 3 times by placing sequentially 
into wells containing 2 ml PBS for 5 mins per well. This method fixes the cells, stains 
only the nucleus (fluorescent red) and can be kept at 4°C for up to 5 days prior to 
confocal microscopy (Section 2.2.7.3).
Calcein staining: Transwells were transferred to wells containing 0.5 ml calcein AM 
(acetoxymethylester of calcein) diluted to 4 pM in serum free DMEM and 0.5 ml of the 
same calcein solution was pipetted into the Transwell. After 1 hour incubation at 37°C, 
assays were ready for confocal microscopy (Section 2.2.7.3). This method uses a 
living dye, stains the whole cell (fluorescent green) and should not be stored for more 
than 1 hour prior to confocal microscopy.
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2.2.7.3 Imaging and quantitation of inverse invasion assays
Stained nuclei or whole cells were visualised by confocal microscope (Section 2.1.7) 
using a 20X objective. Optical sections (Z-sections) were scanned at 3 pm intervals 
(Z-steps) moving up from the underside of the filter into the matrigel, producing a 
series of up to 10 grey-scale images (Figure 2.1). To quantify these Z-sections a 
computer programme, designed “in house” (by Mr. Peter McHardy and Dr. Robert 
Hennigan), was used. Essentially, this programme gives each on-screen pixel an 
intensity value from 0 (black) through to 255 (white). The background pixel value is 
then operator-defined as the point (pixel value) on the 0-255 scale at which only cells 
from that individual section are visible with no bleed-through from bordering sections. 
Only pixels with an intensity value greater than background are then counted by the 
computer and expressed as a percentage of the total pixels. For quantitation 
purposes, only cells in the 4th (9 pm) section or above were considered invasive. A 
compound image of these sections (Figure 2.2) was created using “Confocal 
Assistant” computer software (by Todd Clarke, Berlje), quantified as described, then 
normalised to the value obtained from the corresponding 0 pm section as a “loading” 
control. Overall results were determined from at least three separate assays with 
duplicate samples in each and a total of at least three Z-series were taken for each 
sample per assay.
2.2.8 Chemotaxis assay
Chemotaxis was measured using the results from the invasion assay. In this case the 
0 pm and 3 pm sections were used in quantitation as described for the inverse 
invasion assay (Section 2.2.7.3), with the exception that a higher background
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Example inverse invasion assay: serial sections
0 pm
(Base of filter) 
3pm
(Upper suface 
of filter)
6 pm
9pm
FBR + VPA
12pm
15pm
18pm
2 1 pm
25pm
27pm
Figure 2.1
Raw data from a 3 day, Calcein-stained, inverse invasion assay, showing 2 series of 10, Z-sections taken 
(by confocal microscope) through the Matrigel. The 0pm section corresponds to the underside of the filter 
where the cells were seeded and the 3pm section corresponds to the top of the filter; cells which are 
motile and respond to chemotaxis can reach this point, they do not require the ability to invade. Cells 
which have reached the next Z-section at 6 pm are invasive. For the purpose of quantitation of invasion, 
only cells in the 9pm section and above were counted, this reduces the error of including cells which have 
only reached the top of the filter but can still be seen (due to bleed-through) in the 6 pm section. At least 
three of these Z-series were taken for each sample per assay.
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Example inverse invasion assay: quantitation
FBR
Basal section » .
FBR + VPA (25ug/ml)
Compound 
image of 
sections 9pm to 
27pm
'y »  *  j t  * L  L
Figure 2.2
These are the images used to quantify the inverse invasion assay shown in Figure 2.1 ; The basal 0pm 
section shows those cells which have remained on the filter where they were seeded. The compound 
image of sections 9pm to 27pm, shows cells which have invaded 9pm or more into the Matrigel.The 
number of positive pixels per image is expressed as a percentage of the total number of pixels. The 
values calculated for the basal section are used to normalise the values for the compound image. Overall 
results were determined from at least three separate assays with duplicate samples in each and a total of 
at least three Z-series were taken for each sample per assay.
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subtraction threshold was set for the 3 |im section to minimise the interference from 
the bright basal section. The 3 \im section shows cells that have migrated only to the 
upper surface of the filter but not into the matrigel. They have moved in response to 
chemotactic signals but have not invaded into the matrigel.
2.2.9 Genetic manipulation
2.2.9.1 Summary
Using established PCR and molecular cloning methods each cDNA was amplified 
from its original vector using primers to the 5’ and 3’ sequences of the cDNA which 
were flanked by restriction enzyme sites (Figures 2.3 and 2.4). The PCR products 
were blunt-end ligated into the PGR-Script vector, excised using the appropriate 
restriction enzyme, then ligated into pEGFP-N1, which provides a C-terminal EGFP 
tag. Where co-transfection of cDNAs was intended (as with CamKIVi-sisand 14-3-3P), 
the cDNAs were also myc-tagged in the original PCR step. In this case the 3’ PCR 
primer, was synthesised with the myc-tag sequence preceding the restriction enzyme 
site and the 5’ PCR primer was either the same as that used for cloning into pEGFP- 
N1 or differed only in the restriction site, if the initial enzyme was incompatible with the 
pLPCX2 vector, into which the cDNAs were ultimately cloned (Figures 2.3 and 2.4).
2.2.9.2 Synthesis of oiigonucleotides
Synthetic oligonucleotides, used as PCR or sequencing primers, were synthesised by 
Robert McFarlane or Christine Lang, Technical Services, BICR, on an Applied 
Biosystems RNA/DNA synthesiser model 392 or 394, using phosphoramidite 
chemistry, using the protocol supplied by Applied Biosystems. Lyophilised 
oligonucleotides were resuspended in 1 ml sterile MilliQ H2O. For quantification 10 pi
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PCR primers: RYBP, PCDHGC3 and STAT6
A. Murine RYBP
5 sequence of RYBP
Primer 1: 5 ' act cca gaa ttc gat atg ggc gac aag aag age cog acc agg cca 
Primer 2: 5' taa acc gaa ttc cga aag att cat cat tea ctg ctg aca tgt ccg
3' sequence of RYBP
gcgacatgtcagcagtgaatgatgaatctttcg gaattc ggttta
B. Human PCDHGC3
5' sequence of PCDHGC3 
Primer 1: 5' act cca gaa ttc gat atg gtc cca gag gcc tgg agg age gga ctg 
Primer 2: 5' taa acc gaa ttc cgt gtg cat tgc tgc ctg gga tgt aga cat tct
3' sequence of PCDHGC3
agaatgtctacatcccaggcagcaatgcacacg gaattc ggttta 
303333^ 6^ 363^66633363063333636363 333336 333333
0 . Murine STAT6
5' sequence of STATS
Primer 1: 5' act cca gaa ttc gat atg tct ctg tgg ggc eta att tcc aag atg 
Primer 2: 5' taa acc gaa ttc ccc age tgg ggt tgg tcc tta ggt cca ggt ggg
3' sequence of STATS
cccacctggacctaaggaccaaccccagctggg gaattc ggttta 
666366333366333333663366663363333 333336 333333
KEY
red = restriction enzyme site 
blue = spacer bases 
green = Kozak base 
grey = frame shift base 
black = cDNA sequence
Figure 2.3
PCR primers used for: A. Murine RYBP; B. Human PCDHGC3; 0 . Murine STATS. Colours depict the 
purpose or function or each base: refer to key above. Also shown for each set of primers is the 3’ 
sequence of the cDNA, in relation to the restriction enzyme site etc. Primer 2 is the compliment to this 
strand drawn 5' to 3'.
7S
PCR primers: HDAC4, HDAC4-H803A, HDAC4-D840N, 
CamKIV,.3 , 3  and 14-3-3P
A. HDAC4, HDAC4-H803A, HDAC4-D840N (human) for cloning into pEGFP-N1
primer 1: 5' act cca gaa ttc gat atg age tcc caa age cat cca gat gga ctt 
primer 2: 5' tea acc gaa ttc cca ggg gcg get cct ctt cca tgg get cct cat
B. CamKIV.,.313 (murine)
(i) for cloning into pEGFP-N1
primer 1: 5' act cca ccg ccg age atg etc aaa gtc acg gtg ccc tcc tgt ccc
primer 2: 5' tea acc ccg egg aag ttt ctt ctg age agt gtc cat gtg aac aaa
(ii) for cloning into pLPCXg
primer 1: 5' act cca gcg gcc gca atg etc aaa gtc acg gtg ccc tcc tgt ccc
primer 2: 5' tea aac gcg gcc get cac aga tcc tct tct gag atg agt ttt tgt
tea agt ttc ttc tga gca gtg tcc atg
C. 14-3-Sp (human)
(i) for cloning into pEGFP-N1
primer 1: 5' act cca gaa ttc ata atg gac aaa agt gag ctg gta cag aaa gcc
primer 2: 5' tea acc gaa ttc cgt tct etc cct etc cag cat etc ctt cgt ccc
(ii) for cloning into pLPCXg
primer 1: 5' act cca gaa ttc ata atg gac aaa agt gag ctg gta cag aaa gcc
primer 2 : 5 ' tea acc gaa ttc tea cag ate etc ttc tga gat gag ttt ttg ttc
gtt etc tcc etc tcc age ate tcc ttc
KEY
red = restriction enzyme site 
blue = spacer bases 
green = Kozak base 
grey = frame shift base 
black = cDNA sequence 
purple = stop codon 
orange = myc-tag
Figure 2.4
PCR primers used to amplify and tag: A. Human HDAC4, HDAC4-H803A and HDAC4-D840N, for cloning 
into pEGFP-N1; B. Murine CamKIV^^.,3 , for cloning into (i) pEGFP-N1 or (ii) pLPCX2; 0 . Human 14-3-3P, 
for cloning into (i) pEGFP-N1 or (ii) pLPCX2. Colours depict the purpose or function or each base: refer 
to key above.
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was removed into 490 pi MilliRO H2O and the OD at 260 nm determined by UV 
spectrophotometry. The concentration of DMA was then adjusted to 50 \M.
2.2.9.3 PCR amplification
Each 50 |ii PCR reaction contained; 1X pfu reaction buffer; all 4 dNTPs, each at 100 
|iM; 1.25 U of turbo pfu; 5% glycerol; 10% DMSO; both primers at a final 
concentration of 0.4 |liM ; and, 20 ng of template (plasmid) DMA. The volume of each 
reaction was adjusted to 50 \i\ with sterile MilliQ H2O. Using a PTC-100 
Programmable Thermal Controller, PCR conditions were as follows: Initial 
dénaturation for 2 min at 95°C; then 30 cycles comprising, dénaturation for 30 secs at 
95°C, annealing for 1 min at 63°C, extension for 5 mins at 72°C; and, finally a further 
extension for 5 mins at 72°C.
2.2.9A  Agarose gel electrophoresis
PCR reactions and restriction enzyme digests were separated by agarose gel 
electrophoresis. 10 pi of DMA loading dye (15% ficoll, 0.25% bromophenol blue) was 
added to each 50 pi PCR reaction and the total volume loaded onto an agarose gel. 
The gel was made by melting 3 g of electrophoresis grade agarose in 300 ml 1XTBE 
(90 mM Tris, 90 mM borate, 3 mM EDTA) by heating in a microwave oven. When the 
solution had cooled (but not set), ethidium bromide was added to a final concentration 
of 0.2 pgml'\ and the gel poured. The Bioline Hyperladder I was used as molecular 
size markers. Electrophoresis was carried out in a horizontal electrophoresis tank 
containing 1XTBE, for approximately 1 hr 30 mins at 100 V. The separated DMA was 
visualised by UV-transillumination of the gel.
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2.2.9.5 Purification of DNA from agarose gels
After separation of the PCR reaction product, or restriction enzyme digest, on a 
TBE/agarose gel, the single band of the correct size was excised using a scalpel. The 
DMA was purified from the gel fragment using the Qiagen QIAquick Gel Extraction Kit 
according to the manufacturer's protocol. The fragment was weighed and 3 times the 
volume (assuming weight in pg is equivalent to volume in pi) of QG buffer added 
followed by incubation at 50°C, with occasional agitation, until the gel slice dissolved. 
One gel volume of isopropanol was then added, and following mixing, the solution 
was applied to a QIAquick spin column and centrifuged at 12,000 x g for 1 min. The 
DMA now bound to the column was washed by applying 750 pi PE buffer to the 
column and centrifuging, at 12,000 x g, for 1 min. The flow-through was discarded and 
the column centrifuged again at 12,000 x g for 1 min. The bound DMA was then eluted 
by applying 50 pi of EB buffer (10 mM Tris-HCI, pH 8.5), leaving the column to stand 
for 2 mins and centrifuging at 12,000  x g for 1 min.
2.2.9.6 Cloning PCR products into the PCR-Script vector
The blunt ended PCR products were ligated into the PCR-Script Cam SK+ cloning 
vector using the PCR-Script Cam Cloning Kit with the protocol provided by 
Stratagene. The reaction mix for the blunt end ligation contains: 10 ng of the cloning 
vector, pre-digested with Srf \] IX  PCR-Script reaction buffer; 0.5 mM rATP; PCR 
product, at a concentration which is 100 times the molarity of the PCR-Script vector; 5 
U Srf I; and, 4 U T4 DMA ligase, in a final volume of 10 pi. After mixing, the reaction 
was incubated for 1 hour at room temperature, then the enzymes were inactivated by 
incubation at 65°C for 10 mins. After brief cooling on ice, the reaction mix was ready 
for transformation into Epicurian Coli XL10-Gold Kan ultracompetent cells (provided
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as part of the cloning kit). 40 pi of the ultracompetent cells, in a 15 ml Falcon tube was 
thawed on ice and 1.6 pi p-mercaptoethanol (provided in cloning kit) added. This was 
incubated on ice for 10 mins with occasional gentle agitation. 2 pi of the cloning 
reaction was added, mixed gently and incubated for 30 mins on ice. The bacteria 
were then heat-shocked at 42°C for exactly 30 secs, before being cooled on ice for 2 
mins. 450 pi of L-broth, pre-heated to 42°C, was added and the tubes incubated at 
37°C, shaking at 225 rpm, for 1 hour. The whole reaction was spread onto an L-broth- 
agar petri dish containing chloramphenicol at 30 pgmM, which had previously been 
spread with 100 pi L-broth containing 2% X-gal and 10 mM IPTG to facilitate 
blue/white colour selection. Incubation was for a minimum of 17 hours at 37°C after 
which time, white (and therefore probably insert-positive) colonies were picked, and 
used to inoculate 5 ml L-broth, containing chloramphenicol at 30 pgml'\ and 
incubated overnight, shaking, at 37°C.
2.2.9.7 Preparation of agar piates
10 g Bactoagar was added to a 500 ml bottle of L-broth, and autoclaved. The bottle 
was allowed to cool to 55°C in a water bath, then the required antibiotic was added 
using sterile technique. Ampicillin was added to a final concentration of 100 pgml'\ for 
selection of pLPCX2 carrying bacteria; or kanamycin to 40 pgml'\ for selection of 
pEGFP-N1 carrying bacteria; or chloramphenicol to 30 pgm l'\ for selection of pCR- 
Script carrying bacteria. The L-broth-agar was then poured into 10 cm diameter petri 
dishes, approximately 10 ml per dish, and allowed to cool before the lids were 
replaced. The plates were stored at 4°C.
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2 2 9 .8  ’’Wiggle" PCR
After overnight incubation of the 5 ml L-broth cultures, "wiggle" PCR was used to 
confirm the presence of insert-positive PCR-Script vector. 5 pi of L-broth culture was 
used as the template in a 50 pi PCR reaction which also included: 1X Taq polymerase 
reaction buffer; all 4 dNTPs, each at 100 pM; 1.25 U of Taq polymerase; 1.5 mM 
MgCb; and, both primers at a final concentration of 0.4 pM. The volume of each 
reaction was adjusted to 50 pi with sterile MilliQ H2O. Using a PTC-100 
Programmable Thermal Controller, PCR conditions were as follows: Initial 
dénaturation for 2 mins at 95°C; then 30 cycles comprising, dénaturation for 30 secs 
at 95°C, annealing for 1 min at 55°C, extension for 3 mins 30 secs at 72°C; and, 
finally a further extension for 5 mins at 72°C. PCR products were separated by 
agarose gel electrophoresis, as described (Section 2.2.9.4).
2.2.9.9 Smaii scale "miniprep” plasmid preparation
After wiggle PCR confirmed the presence of insert in the PCR-Script cloning vector, 
small scale plasmid preparations (“minipreps”) were carried out on up to three of the 
insert-positive, 5 ml overnight L-broth cultures (Section 2.2.9.6) using a Qiagen 
plasmid mini-purification kit, as directed by the supplied protocol. From these cultures 
3ml was removed and the bacteria were pelleted by centrifugation for 1 min at 12,000 
X g then resuspended in 250 |il of PI buffer (50 mM Tris-HCI, 10 mM, EDTA, 100 
pgml'^ RNase A), then lysed by the addition of 250 pi of P2 buffer (0.2 M NaOH, 1% 
SDS), and thorough mixing by inversion. Proteins and detergent were precipitated by 
addition of 350 pi of cold P3 buffer (3 M potassium acetate, pH 5.5) and again, 
thorough mixing. A thick white precipitate forms which was pelleted by centrifugation 
at 12,000 X g for 10 mins. The supernate was decanted into a Qiaprep spin column.
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which was then centrifuged at 12,000 x g for 1 min. At this point the plasmid DNA is 
bound to the column, which was then washed with 750 pi PE buffer (1 mM EDTA 
buffered in PBS). After the flow-through was discarded the column was centrifuged for 
a further 1 min to remove remaining traces of PE. The DNA was then eluted from the 
column by addition of 50 pi EB buffer (10 mM Tris-HCI, pH 8.5).
2.2.9.10 Restriction enzyme digestion
Following the purification of insert-positive pCR-Script (Section 2.2.9.9), the cDNA 
insert was removed from pCR-Script by restriction enzyme digestion. Each reaction 
contained 45 pi “miniprep” DNA and other components as detailed (Table 2.1).
cDNA Enzyme 1 
( 2  pl)
Enzyme 2 
( 2  pi)
Ac BSA 
(0 . 6  pi)
Buffer 
(5.5 pi)
HzO
(W)
RYBP EcoRI React 1 0.5
PCDHGC3 EcoRI - - React 1 0.5
STAT6 EcoRI - - React 1 0.5
HDAC4 EcoRI SspI - React 1 0.5
HDAC4 H803 EcoRI SspI - React 1 0.5
HDAC4 D840 EcoRI SspI - React 1 0.5
CamKIVi_3i3 Notl - - React 3 2.5
CamKIVi.3 i3 Sacll - + Sacll buffer 1.9
14-3-33 EcoRI - - React 3 2.5
14-3-33 EcoRI - - React 3 2.5
Table 2.1
Restriction enzyme digestion of oDNAs from PCR-Script.
HDAC4 is approximately the same size as the PCR-Script vector, which means that 
the two could not be distinguished by agarose gel electrophoresis. SspI was added to 
those reactions containing the wt, or deacetylases inactive, HDAC4 cDNAs, to cut 
PCR-Script, making it smaller than HDAC4 and therefore distinguishable from it. 
Digestion was carried out at 37°C for 1 hour, after which, the whole reaction, plus IX  
DNA loading buffer, was run on an agarose gel (Section 2.2.9.4), and the fragments
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of the correct size excised and purified as described (Section 2.2.9.5). The pEGFP-N1 
and pLPCX2 vectors, which were to receive the inserts removed from PCR-Script, 
were also digested with the appropriate restriction enzyme, and, to prevent religation 
of vector in the subsequent ligation reaction, the vectors were also dephosphorylated. 
1 pg of pEGFP-N1 was digested with EcoRI or Sacll and 1pg of pLNCX2 was 
digested with either Notl or EcoRI, in reactions similar to those detailed above but with 
a total volume of 20  pi as the substrate volumes were smaller and including 1 unit of 
calf intestinal alkaline phosphatase (CIAP). The linearised vectors were then 
separated from the other reaction components on the same agarose gel used to 
separate the fragments to be ligated into them. The relevant bands were excised from 
the gel and purified as described (Sections 2.2.9.4 and 2.2.9.5).
2.2.9.11 Ligation o f cDNA into vector
Ligation of genes into vectors was achieved using a Rapid DNA Ligation Kit, following 
the recommended procedure. Vector and insert DNA, in a molar ratio of 1:3 to 1:5, 
were diluted in the DNA dilution buffer supplied, to a volume of 10 pi, then further 
diluted in T4 DNA ligation buffer (supplied) to a volume of 20 pi. After thorough 
mixing, 1 pi of DNA ligase (supplied) was added, and mixed again. Incubation was for 
5 mins at room temperature before immediate transformation of 5 pi of the reaction 
into E.coli DH5a competent cells (Section 2.2.9.12).
2.2.9.12 Transformation of E. coli DH5a competent cells
E.coli DH5a competent cells were thawed on ice and a 100 pi aliquot removed per 
transformation. 5 pi (approximately 100 ng) of plasmid DNA, or 5 pi of ligation reaction 
was added to the aliquot on ice for 30 mins. The bacteria were then heat shocked for
Chapter 2: Materials and Methods 83
45 secs at 42°C and returned to the ice. 400 pi of L-broth was then added and the 
tubes incubated at 37°C in an orbital shaker at 225 rpm for 45 mins. If the 
transformation was simply to amplify a plasmid, 40 pi of bacteria was pipetted onto 
the surface of an L-broth-agar petri dish, containing the appropriate antibiotic (Section 
2.2.9.7), spread and allowed to dry. If the transformation was using the product of a 
ligation reaction then the whole 500 pi was pipetted onto the dish, spread and allowed 
to dry with the lid off. Petri dishes were then incubated, inverted, overnight at 37°C.
2.2.9.13 Selection of cDNA-positive clones
Up to 8 bacterial colonies, which had been transformed with the ligation mix (Section 
2.2.9.11) were picked and used to inoculate 5ml of L-broth containing the appropriate 
antibiotic: ampicillin was added to a final concentration of 100  pgmM, for selection of 
pLPCX2 carrying bacteria; or kanamycin to a final concentration of 40 pgml'\ for 
selection of pEGFP-N1 carrying bacteria. After overnight incubation, shaking, at 37°C, 
the plasmid was purified from 2ml of bacterial culture using a Qiagen plasmid mini­
purification kit as described (Section 2.2.9.9).
Each “miniprep’-purified plasmid was digested separately with two restriction enzymes 
(Table 2.2). The first is the enzyme which initially produced the sticky ends used to 
facilitate the ligation. This cuts out the insert, confirming its presence and size. The 
second enzyme is selected to determine orientation of the inserted gene. It cuts the 
insert at one eccentric site and cuts the vector at one eccentric site, thereby 
generating fragments of sizes specific to the orientation of the gene. Reactions are 
similar to those described (Section 2.2.9.10). The resultant fragments were separated 
by agarose gel electrophoresis (Section 2.2.9.4) and visualised by UV- 
transillumination.
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Plasmid Insert Restriction enzymes
PEGFP-N1 RYBP EcoRI Haell
pEGFP-NI PCDHGC3 EcoRI Apal
pEGFP-NI STAT6 EcoRI Hindlll
pEGFP-NI HDAC4 EcoRI Hindlll
pEGFP-NI HDAG4 H803 EcoRI Hindlll
pEGFP-NI HDAC4 D840 EcoRI Hindlll
pEGFP-NI CamKIVi.3 i3 Sacll EcoRI
pEGFP-NI 14-3-33 EcoRI Hindlll
PLPCX2 CamKIVi_3 i3 Notl EcoRI
pLPCX2 14-3-33 EcoRI Hindlll
Table 2.2
Restriction enzymes used to digest each oDNA-positive vector to establish 
size and orientation are correct.
2.2.9.14 DNA sequencing
Two plasmids were selected, per cDNA, for sequencing. These had been determined, 
by restriction enzyme digestion of "minipreps" DNA, to carry a correctly orientated 
insert of the correct size. The DNA sequence of the insert and insert/vector junctions 
was determined. Sequencing primers (15 bases long) were designed in both the 5' 
and 3' directions every 300 base pairs within the appropriate cDNAs and were 
synthesised as described (Section 2.2.9.2). In addition the sequencing primers 
supplied by the manufacturers of pLPCX2 and pEGFP-N1 were used to sequence 
vector/insert junctions. The method of sequencing was based on the method of 
Sanger (Sanger et al. 1977). 20 ng “miniprep” plasmid DNA, 3.2 pmols sequencing 
primer, and 8 |il of “Dyedeoxy” reaction mix, were combined in a total volume of 20 pi. 
This was subject to “cycle sequencing” in a PTC-100 Programmable Thermal 
Controller for 25 cycles. Each cycle comprised, 15 secs at 96°C to denature DNA, 1 
sec at 50°C to anneal, and 4 mins at 60°C to extend. The product was ethanol 
precipitated, washed in 70% ethanol and dried by centrifugation under vacuum in a 
Jouan RC10.10. “speedivac”, prior to resuspension in loading buffer (95% formamide; 
25 mM EDTA, pH 8.0; 1.5 mgml'^ detran blue). Samples were then denatured at 94°C
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for 5 mins and transferred immediately to ice. Sequencing was then carried out by Mr. 
Robert McFarlane, BICR Technology Services, using a Biosystems ABI 373A 
automated DNA sequencer, according to the manufacturer’s instructions.
2.2.9.15 Large scale "maxiprep" plasmid preparations
The remaining 3 ml of the 5 ml overnight L-broth cultures carrying plasmid with 
correctly orientated insert, was used to inoculate 300 ml L-broth, containing the 
appropriate antibiotic (Section 2.2.9.13), in 1 litre flasks. Cultures were incubated at 
37°C in an orbital shaker at 225 rpm overnight Large scale plasmid preparations, 
“maxipreps”, were performed, to prepare DNA for transfection into mammalian cells 
(Section 2.2.10). This was done using a QIAfilter plasmid maxi-purification kit as 
directed by the protocol supplied by Qiagen. Bacteria were pelleted from the overnight 
culture by centrifugation at 6,000 x g for 15 mins, and the pellet resuspended in 10 ml 
PI buffer (50 mM Tris-HCI, 10 mM EDTA, 100 mgml'^ RNase A). Bacteria were then 
lysed by the addition of 10 ml buffer P2 (0.2 M NaOH, 1% SDS), with thorough mixing. 
Then 10 ml of cold P3 buffer (3 M potassium acetate, pH 5.5) was added, mixed 
thoroughly and decanted immediately into a QIAfilter Cartridge, where it was allowed 
to stand undisturbed at room temperature for 15 mins. A thick white precipitate forms 
in the lysate which is removed when the contents of the cartridge are passed over the 
QIAfilter as they are expelled, using a plunger, into a QIAGEN-tip 500, which had 
previously been equilibrated using 10 ml QBT buffer (750 mM NaCI, 50 mM MOPS pH 
7.0, 15% isopropanol, 0.15% Triton X-100). The cleared lysate drips through the 
QIAGEN Resin at the base of the QIAGEN-tip 500, so that at this point the plasmid 
DNA becomes bound within the resin. The tip was washed twice with 30 ml QC buffer 
(1 mM NaCI, 50 mM MOPS pH 7.0, 15% isopropanol) and the plasmid DNA then 
eluted with 15 ml QF buffer (1.25 M NaCI, 50 mM Tris-HCI pH 8.5, 15% isopropanol).
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The DNA was precipitated by the addition of 10.5 ml isopropanol and immediately 
centrifuged at 15,000 x g for 30 mins. The precipitate was then washed with 70% 
ethanol and the air-dried pellet resuspended in sterile MilliQ H2O.
2.2.10 Transfection I nucleofection
2.2.10.1 Transfection of celis using "FuGeneG"
Following the protocol supplied with FuGene transfection reagent, cells were grown to 
70% confluence in 6 well plates (3.6 cm diameter wells). For each well, 3 |il of 
FuGene transfection reagent was added to 97 |il of serum free DMEM and incubated 
at room temperature for 5 mins. This mixture was then added dropwise to 1|ag of 
plasmid maxiprep DNA carrying the gene to be transfected. This was then further 
incubated for 15 mins at room temperature, prior to dropwise addition to the 2 ml 
DMEM, with 10% FCS, already covering the cell monolayer in each well. The 
transfection reagents were left on the cells overnight after which time the cells were 
washed with PBS, fresh DMEM plus 10% FCS was added and the cells were 
incubated for a further 24 hours.
2.2.10.2 Stable expression ofcDNAs from TuGene” transfections 
Transfections using FuGene were carried out to achieve stable expression of HDAC4, 
HDAC4-H803A, HDAC4-D840, CamKIVi.313 and 14-3-3p. Following on from the 
above (Section 2.2.10.1), transfected cells were then trypsinised from the dish 
(Section 2.2.1.1) and four 10 cm dishes were each seeded with 1/40th of the total 
number of cells in DMEM plus 10% FCS. These were incubated for 24 hours before 
the medium was replaced with DMEM plus 10% FCS, this time containing G418 at 
700 pgml'\ Cells were then incubated for 2-3 weeks during which time medium was
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replaced mainly every two days, increasing to daily between approximately 5 to 10 
days, during which time there is a high degree of cell death as the G418 selection 
proceeds. When cells were approaching confluence they were harvested (Section 
2 .2 .1 .1) and selected for green fluorescence by fluorescent activated cell sorting 
(FACS) using a FACS Vantage SE (BD Biosciences, Cowley, Oxfordshire, UK.). In the 
case of HDAC4 cells were sorted into individual wells of a 96 well tissue culture plate, 
at 5 cells per well, and grown as normal. Within a few days, wells which had only one 
colony growing were identified and from these clonal populations of HDAC4- 
expressing cells were obtained. For all other cDNAs, FACS-sorted cells were pooled 
into a single polyclonal population. However, four of these polyclonal populations were 
created for each cDNA.
2.2.10.3 Cos-7 cells
Transfections using FuGene were carried out to introduce expression vectors into 
Cos-7 cells to confirm that the vector expresses a protein of the correct molecular 
weight. In this case the cells transiently express the cDNA. Between 24 and 48 hours 
post-transfection (Section 2.2.10.1), the cells were harvested and prepared for 
western analysis as described (Section 2.2.3).
2.2.10.4 Nucleofection
Nucleofector technology is a more efficient way of introducing expression vectors into 
cells and superseded FuGene transfection during this project. Nucleofection was 
carried out using an Amaxa nucleofector, according to the manufacturers protocol. 
Briefly, 5 x 1 0 ^  FBR cells were resuspended in 100 pi nucleofection solution R, and 
this suspension was then added to 5 pg of plasmid DNA (usually approximately 3 pi). 
The suspension was immediately transferred to a nucleofection cuvette, which
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contains electrodes, and nucleofected using programme T-20. Immediately post- 
nucleofection, 500 pi of RPMI tissue culture medium, at 37°C, was added to the 
contents of the cuvette, and the suspension removed.
2.2.10.5 Stable expression of cDNAs from nucleofection
Nucleofector technology was used to achieve stable expression of RYBP, STAT6 or 
RYBP. Following nucleofection (Section 2.2.10.3) the content of the cuvette was 
removed and 1/10th was added to each of two 10 cm dishes containing DMEM plus 
10% FCS, at 37°C. These were incubated for 24 hours before the medium was 
replaced with DMEM plus 10% FCS, containing G418 at 700 pgm l'\ The procedure 
then follows that used to obtain stable expression after transfection using FuGene 
(Section 2.2.10.2). A small amount of the nucleofected cell suspension was also 
added to coverslips to determine the efficiency of nucleofection, though this was not 
necessary for EGFP-tagged cDNAs which could be viewed directly by fluorescent 
microscopy.
2.2.10.6 Nucleofection prior to invasion assays
Cells were transiently nucleofected, primarily for assessment in the invasion assay. In 
this case, following nucleofection (2.2.10.4), the content of the cuvette was removed 
into 10ml DMEM and centrifuged at 400 x g for 5 mins. The cell pellet was carefully 
resuspended in 250 pi DMEM plus 10% FCS and 100 pi was added to the underside 
of the filter on each of two Transwells. The invasion assay then proceeded as 
described (Section 2.2.7.1). The remaining 50pl of nucleofected cell suspension was 
divided between two coverslips for immunohistochemistry or actin staining, as 
described (Sections 2.2.11 and 2.2.5), to confirm that a high enough proportion of the
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cells are expressing the transgene. Immunohistochemistry and/or actin staining was 
carried out 48 hours post-nucleofection.
2.2.11 Immunohistochemistry
19 mm glass coverslips were sterilised in ethanol, allowed to air dry, placed in 2.1 cm 
tissue culture wells (12 well plates), covered with 1.5 ml DMEM and incubated at 
37°C. Nucleofections were carried out as described (Section 2.2.10.3) and 1/10th of 
the total 100 pi nucleofection reaction was added to each pre-incubated well. After 48 
hours, the medium was removed and fixing and permeabilisation of cells was carried 
out as described (Section 2.2.5). Blocking of non-specific binding was then carried 
out, in 400 pi of blocking buffer (0.5% BSA, 10% FCS in PBS) for 20 mins. Coverslips 
were then transferred to a light-tight container which was lined with parafilm to ease 
handling of coverslips with forceps. Primary antibody, diluted as directed by the 
manufacturers protocol, in 50 pi of blocking buffer, was added to the surface of the 
coverslips and left at room temperature in the dark for 45 mins after which the 
coverslips were washed 3 times with blocking buffer. Then FITC-conjugated 
secondary antibody, diluted as recommended, in 50 pi blocking buffer also containing 
100 ngml'^ TRIC-conjugated phalloidin (to stain actin) was added for 45 mins, after 
which the coverslips were immersed in dH20, 3 times sequentially, drained, and 
placed inverted on a drop of Vectashield on a glass microscope slide. Where nuclear 
staining was required, Vectashield containing DAP I stain was used. Excess 
Vectashield was aspirated and the edge of the coverslip sealed with clear nail varnish. 
In experiments where only phalloidin-staining of actin is required, the protocol 
described in section 2.2.5 was followed. Red/green fluorescent images were captured 
by confocal microscope (Section 2.1.7) using a 63X objective.
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Chapter 3
Studies with histone deacetyiase inhibitors
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3.1 Expression levels of histone deacetylases and associated proteins in Fos- 
transformed fibroblasts relative to non-transformed cells
3.1.1 Introduction
Since we had shown in differential gene expression studies (Johnston et al. 2000) 
(Section 1.3.1.2) that two components of the Sin3 complex, SAP 18 and RbAp46, are 
up-regulated in Fos-transformed cells (Figure 1.6), and because this complex is 
implicated in the silencing of gene transcription by histone deacetylation, we further 
investigated the comparative expression levels of other genes with products known to 
be components of the complex, and of other HDACs. If HDACs are also up-regulated, 
then increased histone deacetylation may be a mechanism by which genes are down- 
regulated in Fos-transformation. This would be consistent with previous work (Bakin 
and Curran 1999; section 1.3.1.3) implicating histone deacetylation in transformation 
by the chimaeric, recombinant Fos^ ®'^ ^^  protein and by sustained expression of c-Fos. 
Thus we investigated the expression of HDACs and HD AC complex components at 
the RNA and protein level in FBR cells, compared to that in 208F cells; and to extend 
this to transformation by other oncogenes we made a similar comparison of Ha-Ras- 
transformed 208F cells. Ras being of particular importance since it is frequently 
mutated in human cancer, and because AP-1, being a target of the Ras/Raf/MEK/ERK 
signal transduction pathway, is a downstream effector of Ras (Section 1.2.3).
3.1.2 Expression levels of HD A Cs and related proteins
Firstly, the up-regulation of RbAp46/48 was confirmed by western analysis (Figure
3.1 A), though this was not done for SAP18, since antibodies were unavailable, 
however, previously northern analysis had validated the differential expression of all 
genes identified by the suppressive subtractive hybridisation study (Johnston et al. 
2000; Section 1.3.1.2).
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Many histone deacetylases and associated proteins are up-regulated in 
Fos-transformants
u_
00 a:
o GO <
CN LL Û1
1.000 10.730 2.233
(0.464) (2.155) (1.189)
(1.233) (0.591) (1.567)
RbAp46/48
loading
control
00
o
CN
1.000
(8.059)
(8.332)
q:
00
0.949
(5.619)
(6.123)
HDAC2
loading
control
B
1.000 7.611 4.378
1.000 1.798 1.724
mSinSA
MeCP2
loading
control
1.000 7.910 3.110
1.000 3.334 2.757
HDACS
HDAC5
loading
control
1.000 15.543 6.721
HDAC1
loading
control
00
o
CN
1.000
a:
GO
9.170
I
HDAC4
5.083
loading
control
1.000 5.675 1.651
HDAC6
loading
control
Figure 3.1
Northern and western analyses, showing expression levels of HDACs and related proteins in Fos- and 
Ras-transformed 208F cells. Loading controls are 7s rRNA for all northern blots and ERK2 for all western 
blots. Printed values are in units of OD X mm^, i.e., optical density of a band x the area it covers; and 
have been normalised to the values obtained for the loading control. Additional figures in brackets are 
acfua/densitometric values prior to normalisation to the loading control shown.
A. Western blot confirming increased expression of RbAp46/48 protein in both FBR and RAS cells.
B. Northern blot demonstrating the up-regulation of SinSA, HDAC1 and MeCP2, in both FBR and RAS 
cells. The experiment shown (excluding quantitation) was performed by Mr. Liam Meagher.
C. Western blot showing that HDAC2 is not up-regulated in FBR cells.
D. Northern blot demonstrating the up-regulation of HDACS and HDACS in both FBR and RAS cells.
E. Western blots demonstrating increased expression of HDAC4 and HDAC6  in both FBR and RAS cells.
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To investigate the relative expression levels of Sin3 complex components and related 
proteins we used northern analysis or western analysis (where antibodies were 
available). SinSA itself was found to be up-regulated 7.6-fold and HDAC1 15.5-fold in 
FBR cells, and in Ha-ras transformed 208F (RAS) cells, these figures were 4.4- and 
6.7-fold respectively (Figure S.IB). In addition the methyl transferase, MeCP2 was 
also up-regulated in FBR and RAS cells (Figure S.IB). At the protein level, HDAC2 
expression was, however, found to be equivalent in 208F and FBR (Figure S. 1C). In 
addition, other HDACs, not known to be part of the core complex, but which can 
associate with known complex components, were also found to be up-regulated 
(Figure S.ID and E). The class I, HDACS RNA is up-regulated 7.9-fold in FBRs and 
S. 1-fold in RAS cells and expression of the class II, HDACs 4, 5 and 6 is also 
increased. By northern analysis HDAC5 mRNA is S.S-times more abundant in FBR 
cells and 2.8-times in RAS cells (Figure S.ID) and by western analysis, the expression 
of HDAC4 is up-regulated 9.2-fold in FBRs and 5.1-fold in RAS cells, and HDAC6 is 
up-regulated 5.7-fold in FBR cells and, to a lesser extent, 1.7-fold in RAS cells (Figure 
S.1E). Thus we have demonstrated that in 208F cells transformed by v-Fos^®^ or by 
Ha-Ras there is increased expression of HDACs and of components of HD AC 
repressor complex components.
3.2 Inhibition of histone deacetylases in Fos-transformed cells
3.2.1 Introduction
Since the expression of all the HDACs investigated, with the exception of HDAC2, was 
found to be up-regulated in FBR cells, we investigated the consequences of inhibiting 
HD AC activity, with regard to the transformed phenotype and its possible reversion, by 
treating FBR cells with the histone deacetyiase inhibitors, trichostatin A (TSA) and 
valproic acid (VPA).
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3.2.2 Effect on proliferation
Firstly, we measured the effect the inhibitors have on the proliferation rate of FBR cells 
to determine the optimal experimental concentrations which ensure growth inhibition is 
not a factor affecting results (Figure 3.2). We found that treatment with up to 12 nM 
TSA does not affect proliferation, however, when grown in 20 nM TSA, there was 
approximately, 75% less cells counted after 4 days growth compared to untreated 
FBR cells. VPA does not affect the rate of proliferation at concentrations of up to 50 
|igm r\ but by 100 jiigmM there were 68% fewer cells counted at 4 days.
3.2.3 Effect on morphology and actin stress-fibres
We then proceeded to treat FBR cells with TSA and VPA, at concentrations below 
those which affect their proliferation rate (12 nM and 50 pgml'^ respectively), for 4 
days. Both inhibitors induced reversion of the bipolar morphology, to a less retractile, 
more flattened, morphology similar to that of the parental 208F cells (Figure 3.3). This 
shape change is accompanied by a structural rearrangement of the actin cytoskeleton 
(Figure 3.4). Bipolar FBR cells have lost the actin stress-fibres which are clearly visible 
in the parental 208F cells. Treatment with either TSA or VPA induces their 
reassembly. This implies that increased HD AC expression in Fos-transformed cells is 
responsible for transformed morphology and loss of actin stress-fibres.
Both these morphological and cytoskeletal rearrangements are reversible; by 4 days 
after the removal of inhibitors, FBR cells have almost completely regained their bipolar 
morphology (Figure 3.3) differing only in that they appear to retain a small number of 
short lateral extensions along the lengths of their pseudopods, giving the cells a 
ragged appearance, and in that a small proportion of the cell bodies retain a slightly 
more flattened appearance; however, if the cells are passaged 2 days after the
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FBR cell proliferation is unaffected by concentrations of HD AC inhibitors 
used in subsequent experiments
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FBR cell growth In the presence of HDAC inhibitors
A. Graph showing how the growth of FBR cells is affected by increasing concentrations of TSA. Cell 
numbers, and therefore, rate of proliferation, is unaffected by concentrations of TSA lower than, or equal 
to, 12 nM. Growth medium plus TSA was replaced every 2 days.
B. Graph showing how the growth of FBR celis is affected by increasing concentrations of VPA. Cell 
numbers, and therefore, rate of proliferation, is unaffected by concentrations of VPA lower than, or equal 
to, 50 pgmM. Growth medium plus VPA was replaced every 2 days.
Results shown are derived from 2 separate experiments with triplicate sample in each.
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Inhibition of HDACs causes morphological reversion of 
v-fos"^^^-transformed 208F cells
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Figure 3.3
Digital photographs of phase microscopy.
208F cells are flat and contact inhibited. FBR cells are more light retractile, bipolar in shape, and not 
contact inhibited. On treatment with the HDAC inhibitors, FBR cell morphology reverts to a more 208F- 
like appearance: flat and contact inhibited. Removal of HDAC inhibitors allows the FBR cells to return 
almost completely to their previous transformed morphology, differing only in that they appear to retain 
small lateral extensions on the pseudopods (indicated by black arrows) and a small number of cell bodies 
have a slightly more flattened appearance (indicated by white arrows). These differences compared to 
FBR cells are lost on passage. In this experiment cells were grown in plastic tissue culture dishes.
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Inhibition of HDACs allows reformation of F-actin
208F cells FBR cells
B
FBR+TSA (12 nM)1 day FBR+VPA (50 figml'^) 1 day
FBR+TSA (12 nM) 4 days FBR+VPA (50 pgm r) 4 days
Figure 3.4
Fluorescent microscopy of cells stained for F-actin with FITC-conjugated phalloidin.
A. Actin stress-fibres are clearly visible in 208F cells, whereas FBR cells have no filamentous actin, 
other than cortical actin.
B. On treatment with TSA or VPA, stress-fibres can be seen in FBR cells within 24 hours.
C. By 4 days, FBRs have a similar amount of F-actin to 208F and have assumed a flat, polygonal 
morphology.
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removal of inhibitors the re-seeded cells become bipolar on attachment to the plastic 
and are indistinguishable from untreated FBR cells (data not shown).
Both inhibitors achieve these results, however we observed VPA to be slightly more 
efficient in effecting reversion in cells grown either on plastic or on glass. VPA (50 
pgmM for 4 days) treated FBR cells are closer than TSA (12 nM for 4 days) treated 
FBR cells, in appearance to 208F cells (Figure 3.3). In quantitation of cells grown on 
plastic, optimally, less than 8% of VPA treated cells (50 pgmM for 4 days) remain 
bipolar, compared to approximately 15% of TSA treated cells (12 nM for 4 days) 
These figures are based on the classification of an average of 28 cells in each of 12 
separate, random fields of view, done on two separate occasions (data not shown). In 
quantitation of cells grown on glass coverslips, 17% of VPA treated cells (50 pgmM for 
4 days) remain bipolar (Figure 3.5A), compared to approximately 22% of TSA treated 
cells (12 nM for 4 days; data not shown), however, after 8 days of treatment, with 
either inhibitor, these figures drop further to 7% of VPA treated cells (Figure 3.5A) and 
15% of TSA treated cells (data not shown). Again, these figures are based on the 
classification of an average of 28 cells in each of 12 separate, random fields of view, 
done on two separate occasions.
In a time-course to track the reappearance of actin stress-fibres in FBR cells, grown 
on glass coverslips, at increasing concentrations of inhibitors, we found that the 
reappearance of stress-fibres precedes morphological reversion, actually re-appearing 
within 24 hours (Figure 3.5B), with little increase, after 24 hrs, in the proportion of cells 
with stress-fibres (Figure 3.5B and C). Surprisingly, this re-appearance of stress-fibres 
even occurs at the lower concentration of 25 pgml'^ VPA (Figure 3.5B), which does 
not induce morphological reversion (Figure 3.5A), in contrast to treatment with 50 
pgmM VPA, which does induce reversion (Figure 3.5A). In addition, there is a
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Reformation of F-aotin, in response to HDAG inhibition, occurs before 
morphological reversion and at a lower concentration of HD AC inhibitor
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A. Histogram showing a time-GOurse of stross-fibre reformation in FB'R oells in response to 25 pgmh  ^VPA 
or 50 pgml'  ^VPA treatment. At both oonoentrations of VPA, stress-fibres reform within 24 hours and there 
is only a small inorease in the number of oWls containing fibres with time.
B. Histogram Showing that there is no significant drop in the number of bipolar cells present in FBR 
cells treated with 25 fL^ gmh'' VPA, in up to 8 days. This is in contrast to FBR cells treated with 50 pgmh  ^
VPA in which there is a 83% drop In number of bipolar cells by 4 days of treatment.
C. Fluorescent microscopy of cells stained for F-actin with FlTC-conjugated phalloidin, showing there are 
stress-fibres present In bipolar FBR cells treated with 25 pgml"^  VPA for 24 hours and 4 days, compared 
to parental cells, and showing stress-fibres present after 4 days in 50 pigmh'' VPA in FBR cells which 
show revertant morphology.
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difference in the structure of stress-fibres in cells treated for 4 days with 25 jugml’  ^
VPA compared to 50 pgmM VPA, we see that at 25 pgmM VPA the fibres align in 
parallel with the long axis of the cell but at 50 pgmM VPA the fibres are less parallel 
and begin more to radiate from the cell centre (Figures 3.5C and 3.4). Thus the 
difference in the morphologically reverted cell is not in the quantity of stress-fibres but 
in their organisation.
These results suggest that 25 pgmM VPA is sufficient to facilitate F-actin formation, 
but that the rearrangement of stress-fibres which accompanies morphological 
reversion occurs only at the higher concentration of VPA (50 pgmM). This 
demonstrates that the formation of stress-fibres per se is not sufficient to facilitate 
morphological reversion.
3.2.4 Effect on motility
To investigate whether increased HD AC expression in FBR cells is a contributory 
factor in their increased motility, we carried out scrape wound assays in inhibitor 
treated FBR cells (Section 2.2.6). Here we measured the rate of closure of a wound, 
of between 0.5 and 0.7 mm, scraped in a cell monolayer. We found that 8 nM TSA 
and 25 pgmM VPA had no effect on rate of wound closure even after pre-treatment of 
the cells with inhibitor for 4 days (Figure 3.6). When we increased these 
concentrations to 12 nM and 50 pgmM respectively, there was a significant drop in the 
rate of closure after 4 day (i.e. 3.5 days pre-treatment) treatments with both inhibitors. 
With TSA treatment this drop in motility is 21% and with VPA treatment the drop is 
39% (Figure 3.7).
As an alternative method of assessing 2-D motility, to substantiate the wound assay 
data, we tracked the movement of HD AC inhibitor treated FBR cells, in low density
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Rate of wound closure, and therefore motility, is unaffected by HD AC 
inhibitors at concentrations and durations used to inhibit invasion
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Motility of FBR cells treated with HD AC inhibitors
A. Phase microscopy of an example wounding assay with photographs taken from a time-lapse series, 
where images were captured concurrently at each time point.
"24 hour" treatment of FBR cells is, more exactly, 14 hours pre-treatment plus treatment for the duration 
of the assay. "4 day" treatment is, more exactly, 3.5 days pre-treatment plus treatment for the duration of 
the assay.
The left-hand column shows the wounds at t=0 and the right-hand column shows the wounds at t=13 hrs. 
The scale bar shows that the initial wounds were on average 0.6mm.
White lines show the positions at which the measurements were taken.
B. Graph showing the rate of wound closure (pm per hour) in each case. Results depicted represent the 
average of 3 separate time-lapse experiments with single samples in each.
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Higher concentrations of HD AC inhibitors inhibit motility of FBR cells
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Figure 3.7
Motility of FBR cells treated with HD AC inhibitors.
A. Phase microscopy of an example wounding assay with photographs taken from a time-lapse series, 
where images were captured concurrently at each time point.
"24 hour" treatment of FBR cells is, more exactly, 14 hours pre-treatment plus treatment for the duration 
of the assay. "4 day" treatment is, more exactly, 3.5 days pre-treatment plus treatment for the duration of 
the assay.
The left-hand column shows the wounds at t=0 and the right-hand column shows the wounds at t=13 hrs. 
The scale bar shows that the initial wounds ranged in width from 0.5 to 0.7mm.
White lines show the positions at which the measurements were taken.
B. Graph showing the rate of wound closure (pm per hour) in each case. Results depicted represent the 
average of 3 separate time-lapse experiments with single samples in each.
culture, to minimise any directional or chemotactic effects that could be present in the 
wound assay experiments. Cells were treated for 1, 2 and 4 days with TSA then their 
motility, over a three hour period, was monitored by time-lapse photography (Figure 
3.8). We found that, when FBR cells are treated with 12 nM TSA, at 24 hrs there was 
no significant effect on cell motility, at 2 days, only cells which had flattened in 
response to TSA had reduced motility (cells with an intermediate morphology had an 
intermediate rate of movement; data not shown), and at 4 days, motility was 
significantly inhibited. At 8 nM TSA for 4 days, where, as we have shown, 
morphological reversion does not occur there is no measured effect on motility. We 
concluded that the cells became less motile only when morphologically reverted in 
response to TSA.
Later in this project, the advent of a more sophisticated technology in timelapse 
imaging (Section 2.2.6.2) and in the analysis and quantitation of motility ("Tracker" 
software by Kinetic Imaging) allowed us to repeat this experiment under more exacting 
conditions and such that the results are more easily quantified and presented. In these 
experiments we treated the FBR cells with VPA, but achieved similar results to those 
obtained earlier for TSA. Windrose diagrams (Figure 3.9) illustrate that there is little 
effect on motility with 25 pgml'^ VPA treatment. This shows, that the concentration of 
inhibitor, at which actin stress-fibres reform, and at which FBR cell invasion is 
inhibited, but at which morphological reversion does not occur, there is no effect on 
motility. When FBR cells are treated with 50 pgml'^ VPA for 4 days, and therefore 
have reverted morphology, motility is significantly inhibited. This shows that motility is 
inhibited at the concentration of inhibitor which causes reversion of FBR cell 
morphology.
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The affect of TSA treatment on FBR cell motility
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Figure 3.8
Digital phase contrast microscope images from timelapse sequences, taken of FBR cells which have been 
treated with TSA at indicated concentrations and durations. Yellow lines mark the starting positions of the 
nucleus, and red lines indicate the starting positions of the extremes of the pseudopods.
These images show that when FBR cells are treated with 12 nM TSA, at 24 hrs there is no significant 
affect on cell motility, at 2 days cells which have flattened in response to TSA have reduced motility and 
at 4 days motility was significantly inhibited. Motility is unaffected when FBR cells are treated with 8 nM 
TSA for 4 days.
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Motility is inhibited at the concentration of VPA which effects 
morphological reversion
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Figure 3.9
Windrose diagrams which show that treatment with 25 pgml’'' VPA for up to 4 days, or with 50 pgmh  ^
for 1 day, does not affect the motility of FBR cells; but that treatment with, 50 pgmM VPA for 4 days, 
significantly inhibits motility. Each diagram shows the tracks of 30 cells overlayed with the same origin. 
Tracks were taken from timelapse sequences, with images (at 64X magnification) captured every 10 
mins for 5 hours.
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3.2.5 Effect on invasion
By in vitro inverse invasion assay, FBR cells are invasive compared with 208F cells 
(Hennigan et al. 1994). To determine whether the up-regulated histone deacetylases 
in FBR cells, contribute to their ability to invade, we performed this invasion assay 
(Section 2.2.7). The FBR cells were treated with HD AC inhibitors to determine 
whether inhibiting histone deacetylases also inhibits invasion. TSA and VPA were 
used at concentrations which, as we had previously determined, do not affect the 
proliferation rate of the cells (Section 3.2.2), and which do not affect the motility of the 
cells within a time period equivalent to the duration of the assay. Our results showed 
that both HDAG inhibitors were able to inhibit invasion of FBR cells at these 
concentrations (Figure 3.10A). The extent of inhibition is dose dependent, and 
inhibition by can be measured even at concentrations of inhibitor lower than that 
required to revert their morphology (Figure 3.1 OB). This provides evidence then, that 
histone deacetylases have a role in effecting invasion.
3.2.6 Effect on chemotaxis
It could, however, be argued that impaired invasive ability may actually be a product of 
impaired chemotaxis, since it was previously shown in this laboratory, that in the 
absence of Matrigel (which provides chemotactic factors), FBR cells do not migrate to 
the upper surface of the filter in an inverse invasion assay (Hennigan et al. 1994). To 
discount this possibility we further quantified the original invasion assays, determining 
the number of cells which had migrated to the upper surface of the filter and 
expressing them as a proportion of those cells remaining on the underside. We found 
that there is no significant difference in migration between untreated FBR cells and 
those treated with TSA or VPA, at the concentrations used (Figure 3.11). Therefore,
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Histone deacetylase inhibitors inhibit invasion in FBR cells
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Figure 3.10A
Invasion assays showing FBR cell invasion is inhibited by histone deacetylase inhibitors. The protocol 
and quantitation of invasion assays is fully described in Section 2.2.7. Briefly, basal sections show those 
cells which have remained on the filter and have, therefore, not invaded. The compound images show all 
cells which have travelled 9 pm or more into the Matrigel and are therefore invasive.
(i) 4 nM TSA inhibits invasion of FBR cells.
(ii) 25 pgmM VPA inhibits invasion of FBR cells.
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Invasion in FBR cells is inhibited by histone deacetylase inhibitors at 
concentrations which do not alter morphology, motility or growth rate
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Figure 3.1 OB
Histograms of quantified results from invasion assays (Figure 3.1 OA).
(i) Invasion of FBR cells is inhibited by 4 nM and 8 nM TSA.
(ii) Invasion of FBR cells is inhibited by 25 pgmh  ^ and 50 pgmh  ^ VPA.
Overall results were determined from at least three separate assays with at least duplicate samples within 
each.
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The chemotaxis of FBR cells is unaffected by HD AC inhibitors 
at concentrations which inhibit invasion
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Figure 3.11
A. Example sections used to quantify chemotaxis. The upper row shows those cells remaining on the 
underside of the filter and the lower row shows those cells which have moved through the filter pores to 
the upper surface of the filter. In quantitation a high background value must be subtracted to avoid bleed- 
through from the basal section, to the filter section, affecting the result; also the chemotactic cells were 
counted by eye to verify and validated the computer quantitation.
B. Histograms showing that the chemotactic response in FBR cells treated with 8nM TSA or 25 pgmh  ^
VPA for 4 days is equivalent to that of untreated cells. Each graph is produced from the combined 
quantitation of three assays with duplicate samples in each.
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HDAC inhibitors, at these concentrations do not affect the chemotactic response of the 
cells.
3.2.7 The effect o f histone deacetylase inhibition on EGF-stimulated invasion of 208F 
cells
In a supplementary experiment we also showed that TSA inhibits EGF-induced 
invasion of 208F cells (Figure 3.12). EGF binding at the cell surface signals through 
the Ras/Raf/MEK/ERK transduction pathway to Fos. Thus EGF treatment of 208F 
cells is an alternative way of up-regulating AP-1. This experiment, therefore, supports 
our proposal that invasion, as a consequence of increased Fos activity, is facilitated by 
histone deacetylases.
3.3 Conclusions
In this chapter we have shown that HDACs are up-regulated in Fos-transformed cells 
and that HDAC activity is required for Fos-transformed morphology, actin structure, 
motility and invasion. We have also seen that the different aspects of the transformed 
phenotype are reverted at different concentrations of HDAC inhibitor. Table 3.1 shows 
that invasion is inhibited and stress-fibres reform at 25 pgmM VPA or 8 nM TSA; 
transformed morphology reverts and motility is inhibited at 50 pgmM VPA or 12 nM 
TSA; and finally, cell proliferation is inhibited at 100 pgml'^ VPA or 20 nM TSA. These 
results suggest that individual aspects of transformation are controlled by specific 
groups of genes.
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Inhibition of histone deacetylases inhibits EGF-induced invasion in non- 
transformed cells
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Figure 3.12
Inhibition of HDACs inhibits EGF-induced invasion of 208F cells. 208F cells can be induced to invade by 
treatment with EGF at 100 ngmM. This invasion is inhibited by 8 nM TSA.
The protocol and quantitation of invasion assays is fully described in Section 2.2.7. Briefly, basal sections 
show those cells which have remained on the filter and have, therefore, not invaded. The compound 
images show all cells which have travelled 9 jum or more into the Matrigel and are therefore invasive. The 
cells were stained using the nuclear stain propidium iodide which accounts for the apparent difference in 
appearance between this and previous assays.
112
proliferation (100 pgml VPA, 20 nM TSA) 
morphology, motility (50 pgml'  ^VPA, 12 nM TSA) 
invasion, stress-fibres (25 pgml'  ^VPA, 8 nM TSA)
inhibitor
concentration
Table 3.1
Summary of the effects of HDAC inhibitor treatment on FBR cells, showing the relationship between 
concentration of inhibitor used and the aspect of the FBR phenotype which is affected.
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Genes down-regulated by histone deacetylation
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4.1 Genes down-regulated in Fos-transformed cells: their expression levels in 
response to inhibition of histone deacetylases
4.1.1 Introduction
HDACs are involved in gene silencing (Section 1.2.2.3). For this reason we asked 
whether the increased HDAC expression we find in FBR cells, relative to 208F cells, 
facilitates silencing of those genes found, previously, to be down-regulated in FBR 
cells (Johnston et al., 2000). Thus, if we inhibit HDAC activity, by treatment with VPA 
or TSA, are these down-regulated genes re-expressed?
4.1.2 Expression levels ofRYBP, PCDHGC3 and STAT6
Northern analyses demonstrated that a proportion of those genes down-regulated (at 
the level of transcription) in Fos-transformation are indeed re-expressed in FBR cells 
when HDAC activity is inhibited by treatment with either VPA or TSA. Of the 11 genes 
investigated, those genes found to be re-expressed are: RYBP; STAT6; PCDHGC3; 
fibronectin; and annexin IVA (Figure 4.1; section 1.5). In fact, in an initial experiment to 
determine optimal TSA concentration and treatment duration, for re-expression of 
STAT6, we also showed that this re-expression is time and dose dependent (Figure
4.1 B). Those genes not found to be re-expressed are: cellular retinol binding protein 1 
(CRBP-1); TSC36; frizzled related protein 4 (Frp4); latent transforming growth factor p 
binding protein (LTBP); caspase II; plus a mRNA identified by a novel cDNA sequence 
(clone PD18) from the initial differential screen (Figure 4.2A and B). In addition, 
western analysis of tuberosclerosis complex 1 (TSC1) expression showed that this 
tumour suppressor protein was also not re-expressed (at the protein level) on 
inhibition of HDACs (Figure 4.2C).
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Inhibition of HDAC activity facilitates re-expression of genes down-
regulated in v-FosFBR-transformed cells
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Figure 4.1
Northern blots showing:
A. The re-expression of RYBP, PCDHGC3, fibronectin and annexin IVA, in FBR cells treated with VPA 
(4 days, 25 pgmh^) or TSA (4 days, 8 nM).
B. The re-expression of STAT6 in response to TSA treatment is time and dose dependent. Values 
represent relative expression, in units of OD x mm^, normalised to the loading control.
All loading controls are 7s rRNA.
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Inhibition of HDAC activity does not facilitate re-expression of all genes
down-regulated in v-Fos^BR-transformed cells
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Figure 4.2
A. Northern blots showing CRBP-1 and TSC36 are not re-expressed in FBR cells when treated with VPA 
(4 days at 25 |igmM) or TSA (4 days at 8 nM). Loading controls are 7S rRNA.
B. Northern blots showing Frp 4, LTBP, caspase II, and the mRNA labelled with the novel cDNA probe, 
PD18, are not re-expressed in FBR cells when treated with 8 nM TSA or 25 pgmh'' VPA for 4 or 8 days. 
Example loading control is 7S rRNA.
C. Western blot showing TSC1 is not re-expressed in FBR cells treated with 8 nM TSA or 25 pgmh  ^
VPA for 4 or 8 days. Loading control is ERK2.
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4.2 Ectopic re-expression of genes down-regulated in Fos-transformed cells
4.2.1 Introduction
We have shown that inhibition of HDACs inhibits the ability of FBR cells to invade and 
that inhibition of HDACs results in re-expression of down-regulated genes. We asked 
then, is invasion inhibited as a consequence of re-expression of these down-regulated 
genes? Is re-expression of these genes incompatible with invasion? To answer our 
question we ectopically re-expressed (individually) genes which are re-expressed as a 
consequence of HDAC inhibition, and asked whether invasion is inhibited.
4.2.2 Sub-cloning ofRYBP, PCDHGC3 and STAT6, verification o f sequence and 
molecular weight, and correct expression in cells
We chose three of the genes which we have shown to be re-expressed on inhibition of 
HDACs and investigated the effect of their individual ectopic re-expression in FBR 
cells. The genes were each cloned into the vector pEGFP-N1, which provides a 3’ 
EGFP-tag, and introduced, individually, into FBR cells by nucleofection; an adaptation 
of the electroporation method, which delivers the vector directly to the nucleus. Having 
optomised the nucleofection protocol to achieve greater than 80% efficiency (data not 
shown) we were able to study transient, as well as, stable expression of these genes 
in FBR cells, which enabled us to discount any error arguably inherent in either 
system. Before expression in FBR cells, we confirmed the accuracy of the sequence 
of the cloned genes and of the gene/vector-junctions by DNA sequencing (carried out 
by BICR technology services) and demonstrated, by western analysis, the expression 
of a protein of the expected molecular weight, in Cos-7 cells (Figure 4.3A). Mouse 
endogenous RYBP is reported to be 32 KD and the untagged mouse cDNA to encode 
a protein of similar size (Garcia et al., 1999). We therefore expected, and were able to
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Western analysis of ectopically expressed genes
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Figure 4.3
Western analysis of total cell lysates (25 pg per lane) using anti-EGFP mAb.
A. Transient expression in Cos-7 cells. Lane 1; un-transfected control. Lane 2: EGFP-only expressing 
control. Lanes 3-5: expression of 3’-EGFP-tagged-, RYBP, PCDHGC3 and STAT6, respectively.
B. Stable expression in FBR cells. Lane 1: EGFP-only expressing control. Lanes 2-4: expression of 
EGFP-tagged-, RYBP, PCDHGC3 and STAT6, respectively.
C. Transient expression in FBR cells. Lane 1: un-transfected control. Lane 2: EGFP-only expressing 
control. Lanes 3-5: expression of EGFP-tagged-, RYBP, PCDHGC3 and STAT6, respectively.
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demonstrate, a protein of 59 KD (including the 27 KD EGFP-tag) transiently expressed 
in the Cos-7 cells. We showed the human, EGFP-tagged, PCDHGC3 cDNA to encode 
a protein of approximately 160 KD, again, allowing for the tag, the encoded protein 
should therefore, be 133 KD. Previously, it has been reported to encode a protein of 
“approximately” 150 KD (Sano et al., 1993) referring to a band between the, 97 and 
200 KD molecular weight markers, which could equally be approximated to 133 KD. 
The murine STAT6 cDNA is reported to encode a major protein of 102 KD and a minor 
protein of 84 KD (Quelle et al., 1995), we would therefore expect a major band of 129 
KD, and a minor band of 111 KD. This is indeed what we see in Cos-7 cells, although 
the minor band accounts for a very small proportion of the total.
The expression vectors were then introduced into FBR cells and the correct, both 
stable and transient, expression products confirmed by the same means (Figure 4.3B 
and C). Sizes were as expected, though the RYBP cDNA appears to encode a doublet 
at 59 KD, in both transients and stables, as well as a further doublet at 49 KD in stably 
expressing cells. One possible explanation is that this represents (at 59 KD) a post- 
translational modification and (at 49 KD) cleavage products of both larger bands, 
where a 10 KD peptide has been removed from the N-terminus of the protein.
4.2.3 Cellular localisation and distribution of re-expressed proteins 
We then examined the spacial distribution and localisation of the ectopically 
expressed proteins in the FBR cells (Figure 4.4). EGFP is uniformly distributed within 
the cell. RYBP-EGFP is expressed only in the nucleus. PCDHGC3-EGFP is 
expressed primarily in the plasma membrane. Confirmation of the correct localisation 
is particularly important in the case of PCDHGC3 since it is a transmembrane protein
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Localisation of ectopically re-expressed genes in v-Fos^BR- 
transformed cells
A. stable nucleofectants B. transient nucleofectants
EGFP
RYBP
s;.an,
transverse section
;,s
transverse section
PCDHGC3
STAT6
Figure 4.4
The localisation of ectopically expressed proteins in FBR cells.
A. Shows stable expression
B. Shows transient expression
Expressed proteins are EGFP-tagged, and therefore, green-fluorescent. F-actin is stained with TRITC- 
conjugated phalloidin and is, therefore, red-fluorescent.
PCDHGC3-expressing FBR cells are also shown in transverse section (F-actin not shown) further 
illustrating the localisation of the protein.
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and its correct localisation may have been hindered by the presence of the EGFP-tag. 
It was for this reason that the tag was added in the 3' position since it is the N- 
terminus of the protein which has to traverse the plasma membrane. We also 
visualised the PCDHGC3-expressing FBRs (FP cells) in transverse section to more 
clearly define the distribution of PCDHGC3 in the membrane (Figure 4.4). STAT6- 
EGFP has an almost similar distribution to EGFP, however, STAT6-EGFP is 
considerably less bright, is excluded from the nucleoli, and can be seen more 
predominantly in the nucleus, consistent with its role as a transcription factor which 
shuttles between cytoplasm and nucleus. In addition, the fact that there is virtually no 
27 KD band in western analysis of whole cell extracts from STAT6-EGFP-expressing 
(FS) cells (Figure 4.3B and C), confirms that the distribution pattern is not created as 
an artefact by cells within the population expressing only EGFP.
For all three proteins, in comparing transient versus stable transfectants there was no 
perceived difference in their distribution and localisation within the FBR cell.
4.2.4 Morphology and actin stress-fibres in FBR cells over-expressing RYBP, 
PCDHGC3 or STAT6
In FBR cells over-expressing RYBP (FR cells), PCDHGC3 or STAT6, we were unable 
to detect any change in morphology or in actin stress-fibre arrangement, as 
determined by TRITC-phalloidin staining (Figure 4.4). This was found to be the case 
for both transient and stable expression of the proteins in FBR cells.
4.2.5 Effect on invasion
We then assessed invasive ability, firstly of the stable transfectants expressing each of 
the transgenes. We found that in a three day inverse invasion assay (Section 2.2.7), 
both the parental FBR cells and FBR cells expressing only EGFP (FE cells) invaded 
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equally, and to the extent expected of FBR cells (Figure 4.5A). In contrast, FR, FP, 
and FS cell lines, showed markedly reduced invasion compared with these controls. 
FR cells in particular showed, on average, a 96% reduction in invasion, FP cells were 
approximately 92% reduced, whilst PS cells were the least inhibited, though still with a 
substantial overall reduction in invasion of 80%.
In similar experiments with FBR cells transiently expressing the cDNAs, cells were 
transferred to the invasion assay immediately following nucleofection and 
simultaneously (on each repetition of the experiment) were seeded, into the 
appropriate culture vessel, for fluorescent analysis by confocal microscopy (to confirm 
that 80% or more of the cells were expressing the protein, and with the expected 
distribution) and for western analysis (to confirm the correct size of expressed protein). 
The results from invasion assays of these transiently transfected cells (Figure 4.5B) 
were similar to those obtained for the equivalent stable cell lines, in that invasion was 
markedly inhibited in each case. The reduction in the transient transfectants was 
reduced to approximately 60%, and was similar for transient FR, FP and FS cells. 
Since the expression of all three proteins (individually) appears to inhibit invasion, the 
question arises as to whether the effect we see is due to the expression of these 
protein perse or rather the non-specific by-product of the inappropriate and high level 
of expression of these proteins. For this reason, we carried out the following control 
experiments to validate our results.
4.2.6 Effect on proliferation
Firstly, we made a comparison of growth rates, which confirmed that exogenous 
expression of RYBP or PCDHGC3 or STAT6 does not affect the proliferation of the 
cells relative to the parental FBR cells or to the empty-vector-expressing control FBR
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Re-expression of RYBP, PCDHGC3 or STAT6, inhibits invasion of v- 
FosBBR-transformed cells
stable expression transient expression
m .
yi S
basal section
è é im
FBR empty 1^  
vector 
control
RYBP
STAT6 \
m
compound image basal section compound image
Figure 4.5
A. Stable expression of RYBP or PCDHGC3 or STAT6, inhibits the ability of FBR cells to invade relative 
to parental FBR cells or to EGFP-expressing FBR cells.
(i) Examples of images used to quantify the assay (Section 2.2.7). Basal sections show those cells 
which have remained on the filter and have, therefore, not invaded. The compound images show all cells 
which have travelled 9 pm or more into the Matrigel and are therefore invasive.
(ii) Histogram showing inhibition of invasion by RYBP or PCDHGC3 or STAT6, produced from the 
integrated quantitation of three separate assays with at least duplicate samples in each.
B. As in A. above, but with transient expression of RYBP or PCDHGC3 or STAT6 .
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cells (Figure 4.6). Their rate of proliferation is, therefore, unaltered by the expression 
of these proteins. Moreover, the results obtained for stable and transient expressors 
are equivalent.
4.2.7 Effect on motility
To determine whether the cells are unable to invade because their motility is inhibited, 
we carried out wounding assays, and followed the rate of migration of the cells by 
time-lapse photography, as they moved to close a wound, this was done 
simultaneously for each cell population. For each assay the final time point was 
defined as that point immediately before cells from one side of the wound came in 
contact with those from the other side. We were able to demonstrate that ectopic 
expression of RYBP or PCDHGC3 or STATS has no effect on the motility of FBR cells 
(Figure 4.7); all cell lines were able to move to close a wound at a rate of 
approximately 32pmhr'\
4.2.8 Effect on chemotaxis
As with the HD AC inhibitor studies (Chapter 3), the possibility that the transfected cells 
are unable to invade due to impaired chemotaxis was investigated by analysis of the 
invasion assays. The migration of cells from the base of the filter, through the filter- 
pores to the upper surface is a measure of chemotaxis since it was previously shown 
in this laboratory that FBR cells will not migrate to the upper surface of the filter in the 
absence of Matrigel or serum (Hennigan et al., 1994; Lamb et al., 1997), i.e., without a 
chemoattractant. We found that the number of FBR cells migrating to the top of the 
filter is unaffected by the expression of RYBP, PCDHGC3 or STAT6 (Fig. 4.8), despite 
the marked effect we observe, on their migration into the Matrigel itself.
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Re-expression of RYBP, PCDHGC3 or STAT6, in v-Fos^BR-transformed 
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Figure 4.6
A. Growth rate of stable transfectants. Cells were seeded at 4 x 10"^  per well, at the same time as they 
were seeded in an invasion assay. Results depicted were derived from 4 separate wells per cell line per 
invasion assay.
There is no significant difference between the control, FBR and FE cells, compared with the experimental, 
FR, FP and FS cells.
B. Growth rate of transient transfectants. Cells were seeded at 2 x 10"^  per well, at the same time as they 
were seeded in an invasion assay. Results depicted were derived from 4 separate wells per cell line per 
invasion assay.
There is no significant difference between the control, FBR and FE cells, compared with the experimental 
FR, FP and FS cells. A lower number were seeded compared to the stable transfectants because cell 
numbers are limited by concentrations required for nucleofection. 126
Motility of FBR cells is unaffected by re-expression of down-regulated
genes
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A. Example wounding assay with photographs taken from a time-lapse series. The left-hand column 
shows the wounds at t®0 and the right-hand column shows the wounds at t=16 hours. The scale bar 
shows that the initial wounds were on average 0.8 mm. White lines show the positions at which the 
measurements were taken. Photographs of each cell line were taken concurrently at each time point. 
Cells used were stable transfectants.
B. Graph showing the rate of wound closure (|tm per hour) of each cell line (stable transfectants). Results 
depicted represent the average Of 3 separate time-lapse experiments, with single samples in each.
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Chemotaxis in FBR cells is unaffected by re-expression of down-regulated
genes
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Figure 4.8
A.(i) Example sections used to quantify chemotaxis in FBR cells stably expressing RYBP or PCDHGC3 
or STAT6 . The left-hand row shows those cells remaining on the underside of the filter and the right- 
hand row shows those cells which have moved through the filter pores to the upper surface of the filter.
In quantitation a high background value must be subtracted to avoid bleed-through from the basal section 
to the filter section, affecting the result; also the chemotactic cells were counted by eye to verify and 
validated the computer quantitation.
(ii) Histograms showing that the chemotactic response in FBR cells stably expressing RYBP or 
PCDHGC3 or STAT6 is equivalent to that of parental FBR cells. Each graph is produced from the 
integrated quantitation of three separate assays with at least duplicate samples in each.
B. As in A. above, but with FBR cells which transiently express RYBP or PCDHGC3 or STAT6 .
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4.3 Conclusions
We have shown that 5 out of 11 genes which are down-regulated in v-Fos^®^- 
expressing cells, are re-expressed as a consequence of HD AC inhibition. When these 
genes are ectopically re-expressed, individually, in FBR cells, either transiently or 
stably, invasion is inhibited without affecting, proliferation, morphology, motility, 
chemotactic response, or filamentous actin arrangement.
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5.1 Introduction
In order to define the role of histone deacetylases in Fos-transformation we sought to 
modulate FID AC activity in both 208F and FBR cells, to determine the effect on their 
normal and transformed phenotypes. Theoretically, one might expect an increase in 
HD AC activity in 208F cells to move them to a more transformed phenotype and 
conversely a reduction in HD AC activity in FBR cells to revert some aspect of the 
transformed phenotype, as we have shown with HD AC inhibitor studies (Chapter 3). In 
addition, an increase in HD AC activity in FBR cells might be expected to reduce their 
response to HD AC inhibitors. This chapter describes the strategies we employed to 
modulate the activity of a single histone deacetylase, which we proposed to have a 
key role in Fos-transformation. Our candidate was HDAC4, primarily because, as we 
had shown, of the HDACs considered, it is the most substantially up-regulated in both 
v-Fos- and v-Ha-Ras-transformed cells (Figure 3.IE). This is significant because AP-1 
is a downstream effector of Ras, and Ras is commonly mutated in human tumours, 
thus increasing the likelihood of the involvement of HDAC4 up-regulation in cancer 
itself. In addition, it was demonstrated that HDAC4 represses differentiation in 
myoblasts (Miska et al. 2001), supporting the idea that it has a role in transformation.
5.1.1 Nuclear levels of HD A C4
Since it is known that the activity of HDAC4 (and other class II HDACs) is controlled 
by active nuclear export (Section 1.3.6) it was necessary to determine the level of 
nuclear HDAC4 in 208F and FBR cells, to confirm that FBR cells do indeed have 
comparatively more enzyme with respect to nuclear levels, since increased total 
cellular HDAC4 need not reflect increased nuclear HDAC4. A western blot of nuclear 
extracts from both cell lines was used to confirm that there is approximately 3.8 times 
more nuclear HDAC4 in FBR cells compared to 208F cells (Figure 5.1).
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FBR cells have an increased level of nuclear HDAC4 relative
to 208F cells
208F FBR
nuclear HDAC4
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Figure 5.1
Western blot of nuclear extracts prepared from cell lysates, showing that the level of nuclear HDAC4 
is approximately 3.8-fold increased in FBR cells compared to 208F cells. Values represent relative 
expression, in units of CD x mm ,^ normalised to loading control.
5.1.2 Levels of HDAC4 in response to histone deacetylase inhibitors 
We also determined the effect inhibitor treatment has on the level of endogenous 
HDAC4 expression, to confirm that FIDAC4 inhibition is not accompanied by a 
compensatory increase in F1DAC4. If this were the case, we could not conclude, 
without further investigation, that FIDAC4 activity is actually inhibited. It was therefore, 
necessary to determine that this is not the case.
Western blots were performed on TSA- and VPA-treated FBR cells (Figure 5.2). It was 
found that treatment with up to 15nM TSA for 4 days has no effect on endogenous 
levels of FIDAC4 (Figure 5.2A), likewise, treatment with up to 50 pgml'^ VPA for 4 days 
does not affect FIDAC4 levels (Figure 5.2B). These results determined that, at the 
concentrations of inhibitor with which we treated FBR cells (12 nM TSA or 50 pgml'^ 
VPA) for 4 days, without affecting growth, their level of endogenous FIDAC4 
expression is unaffected.
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Levels of HDAC4 in FBR cells in response to HD AC inhibitor treatment
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Figure 5.2
Western blots of whole cell lysates showing that:
A. Up to 15 nM TSA for 4 days does not affect the expression of endogenous HDAC4.
B. Up to 50 pgmM for 4 days does not affect the expression of endogenous HDAC4.
Loading controls are ERK2. Bracketed values are actual densitometric values, in units of OD x rnm .^ 
Values which are not in brackets represent relative expression, normalised to loading controls.
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5.2 Over-expression of HDAC4 in both normal, and Fos-transformed, fibroblasts
5.2.1 Sub-cloning of HDAC4, verification of HDAC4 sequence, molecular weight and 
correct expression in celis
The wild type (wt) HDAC4 cDNA was cloned into the expression vector pEGFP-N1 
(Section 2.2.9), which provides a C-terminal EGFP tag. The accuracy of the sequence 
of the cloned gene and of the gene/vector junctions was confirmed by DMA 
sequencing (Section 2.2.9.14). We noted a single base change in our cloned 
sequence compared to the Genbank sequence, which did not alter the predicted 
amino acid sequence, and was confirmed by later work (Section 5.3.2) to have been 
present in the original cDNA sequence. Then, by western analysis, we confirmed the 
expression of a protein of the correct expected molecular weight in Cos-7 cells, using 
both anti-EGFP and anti-FIDAC4 antibodies (Figure 5.3A). FIDAG4 has a predicted 
molecular weight of 109 KDa but runs in SDS-PAGE at 140 KDa, possibly due to post- 
translational modification (T. Kouzarides, personal communication). So, including an 
additional 27 KDa for the EGFP tag, we expected, and demonstrated, a protein with 
an approximate molecular weight of 167 KDa.
The vector, carrying HDAC4 cDNA, was transfected into both 208F and FBR cells, 
and those cells stably expressing the transgene were selected with G418. The 
populations were then FACS-sorted for EGFP-positive cells, as described (Section 
2.2.10.2) to establish clonal 208F- and FBR-derived cell lines, stably expressing 
EGFP-tagged wild type FIDAC4. Cell lines were chosen for further study on the basis 
of their high percentage of EGFP-positive cells, as determined by fluorescence 
microscopy, and the ease of detection of the ectopically expressed protein, by western 
analysis (Figure 5.3B).
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Western analysis of ectopically expressed HDAC4-EGFP
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Figure 5.3
Western analyses of total cell lysates (25 |ig per lane). Protein was detected using anti-EGFP or anti- 
HDAC4 antibodies, as indicated.
A. Transient expression in Cos-7 cells, confirming expression of a protein of the correct molecular weight.
B. Stable expression in selected FBR-cell-derived clones. Arrow (a) indicates EGFP-tagged HDAC4 and 
arrow (b) indicates endogenous HDAC4.
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5.2.2 Cellular localisation and distribution of over-expressed HD A 04 
Over-expressed HDAC4 was found mainly in the cytoplasm in both 208F and FBR 
cells, though a low level of the protein was also detectable in the nucleus (Figures 5.4 
and 5.5). This was as expected, as studies have shown that the level of FIDAC4 in the 
nucleus is controlled by an active transport mechanism by which the protein is 
exported from the nucleus (Section 1.3.6). In addition, to confirm that correct 
localisation had not been disrupted by the presence of the EGFP tag, we transiently 
transfected FBR cells with the myc-tagged FIDAC4 (Miska et al. 2001) from which we 
had derived our EGFP-tagged F1DAC4 expression construct. We found no difference 
in FIDAC4 localisation with either tag (Figure 5.4A), which was as previously reported 
in a comparison of myc-tagged, and N-terminal GFP-tagged, HDAC4 (Miska et al. 
2001). In addition, later experiments in which a mutated F1DAC4 is expressed, also 
serve to demonstrate the normal localisation of wtFIDAC4 (Figure 5.1 IB  and section 
5.4). The mutated FIDAC4-EGFP cannot be phosphorylated and therefore cannot 
undergo nuclear export, however, the fact that it does locate to the nucleus 
demonstrates that the EGFP tag does not hinder nuclear localisation.
5.2.3 Over-expression of HD A 04 in 208F cells
As can be seen from the confocal microscope images (Figure 5.5), 208F cells that 
over-express FIDAC4, have a mixed morphology: some are identical to parental 208F 
cells, whilst other cells have assumed a bipolar morphology. The majority of the cells, 
though, range in shape between these two extremes. It should be noted however, that 
we do not find cells which, like FBR cells, are without stress-fibres, although the 
stress-fibres seen in the bipolar cells run parallel with the long axis of the cell, which is 
what we find in FBRs treated with FID AC inhibitors, which remain bipolar, e.g., after 24
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Localisation of ectopically expressed wtHDAC4 in FBR cells
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Figure 5.4
A. Confocal images showing a comparison of the distribution of ectopically expressed myc-tagged 
HDAC4 and ectopically expressed EGFP-tagged HDAC4, in FBR cells. Myc-tagged HDAC4 is visualised 
using mouse anti-myc antibodies hybridised to FITC-labelled anti-mouse antibodies, and is therefore 
green-fluorescent. EGFP is green fluorescent. In both cases, cells were counter-stained with TRITC- 
conjugated-phalloidin for F-actin which is red-fluorescent. HDAC4-myc is transiently expressed and 
HDAC4-EGFP is stably expressed. The distribution is the same in both myc- and EGFP-tagged proteins.
B. Confocal images showing the distribution of HDAC4-EGFP, stably expressed in FBR cells. Cells were 
counter-stained with TRITC-phalloidin for F-actin. Results were similar for all clones.
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Distribution of ectopically expressed HDAC4 in 208F cells
HDAC4-EGFP F-actin merged HDAC4-EGFP F-actin
4
Figure 5.5
Confocal microscope images showing the distibution of HDAC4-EGFP (green fluorescence) in clones 
of 208F cells ectopically expressing HDAC4-EGFP. Cells were counter-stained with TRITC-phalloidin 
for F-actin (red fluorescence). The merged images are those shown in colour. Results were similar for 
all clones.
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hrs VPA treatment at 25 pgmM (Figure 3.5). In quantitation of morphologies we used 
eight phase contrast images per clone; counting and classifying approximately 30 cells 
per image (Figure 5.6). It was not possible to sub-classify those cells with intermediate 
morphology without subjectivity; however, we determined that 26% of 208F cells over­
expressing FIDAC4 assume a bipolar morphology (Figure 5.6), whilst less than 2% 
remain similar to the parental phenotype. Consequently, the remaining 72% of cells 
showed a range of intermediate morphologies.
When the FIDAC4-over-expressing 208F cells were assayed for invasion, however, 
none could be detected in any of the clones (data not shown), despite the move 
towards a more bipolar morphology. This is in keeping with our FID AC inhibitor studies 
(Chapter 3), where we have shown that morphology and ability to invade are 
separable characteristics in terms of FIDAC activity.
5.2.4 Over-expression of HD A 04 in FBR cells
The morphology of FBR cells is unaffected by F1DAC4 over-expression, nor is there 
any quantifiable effect on actin stress-fibres (Figure 5.4). In in vitro invasion assays we 
found that the FIDAC4-expresssing FBR cells were not significantly more invasive than 
the EGFP-expressing control FBR cells (data not shown), however, what we did find 
in in vitro invasion assays was that although these cells are not more invasive than the 
control FBR cells, a higher concentration of TSA is required to achieve inhibition of 
their invasion (Figure 5.7), suggesting that the additional FIDAC4 in these cells allows 
them to overcome the effects of the inhibitors. Inhibition of HDACs by inhibitors can be 
compensated for by HDAC4, suggesting that specifically HDAC4 is able to mediate 
invasion and therefore implying that the invasion of FBR cells is indeed, at least in 
part, a consequence of increased HDAC4 expression.
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208F cells expressing HDAC4 have a more spindle-shaped morphology
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Figure 5.6
The morphology of 208F cells over-expressing wild type HDAC4 compared to that of the parental 208F 
cells and to FBR cells. 208F cells become more spindle-shaped when they over-express HDAC4. In 
quantitation, 26% of HDAC4-expressing cells were bipolar (indicated by arrows), 2% of cells resembled 
the parental 208F cells and the remaining 72% have an intermediate morphology. Each photograph is 
representative of the population as a whole.
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FBR cells, over-expressing wild type HDAC4, are less sensitive to 
TSA-induced inhibition of invasion
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Figure 5.7
A. Example invasion assay showing that invasion of FBR cells is inhibited by 8 nM TSA, but that 8 nM 
TSA does not inhibit invasion in FBR cells over-expressing HDAC4. The upper assay shows the effect of 
8 nM TSA on FBR cell invasion and the lower assay shows the effect of 8 nM TSA on invasion in FBR 
cells which have stable ectopic expression of HDAC4.
B. Histogram showing the combined quantitation of three invasion assays with duplicate samples, 
identical to that shown in A. TSA treatment is at 8 nM.
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5.3 Expression of deacetylase-inactive forms (H803A and D840N) of HDAC4 in 
Fos-transformed cells
5.3.1 Introduction
With the intention of reducing the level of active HDAC4 in the cell we introduced, 
individually, by transfection, two deacetylase-inactive forms of HDAC4 (Miska et al. 
1999). These genes each have a single point mutation in their catalytic site that has 
been shown to greatly reduce their deacetylase activity (Miska et al. 1999); they are 
termed HDAC4-H803A and HDAC4-D840N (Section 2.1.5.1). It was reported, in 
deacetylase assays of immunoprecipitated enzyme, that HDAC4-H803A had 
approximately 80% less activity than HDAC4 and HDAC4-D840N had approximately 
70% less activity than HDAC4 (Miska et al. 1999). It was not known whether the 
inactive HDAC4 enzymes would act in a dominant-negative manner in vivo, however if 
this were the case we would hope to be able to demonstrate some indication of 
reversion of the transformed phenotype when they are expressed in FBR cells, such 
as re-appearance of actin stress-fibres or deceased invasion. Another possibility is 
that we would see an increased sensitivity to HD AC inhibitors, e.g., morphology would 
revert more quickly or at a lower concentration of inhibitor.
5.3.2 Sub-cloning of H803A and D840N, verification of sequence and molecular 
weight, and expression in FBR cells
The two point-mutated HDAC4 cDNAs; H803A and D840N (Miska et al. 1999), were 
each sub-cloned into the expression vector pEGFP-N1 (Section 2.2.9), again in the 
same manner as for the cloning of the wild-type gene. The accuracy of the sequence 
of the cloned genes and of the gene/vector junctions was confirmed by DMA 
sequencing (Section 2.2.9.14). Apart from the silent base change we had seen in the 
wild-type HDAC4 (Section 5.2.1), the only changes to the Genbank sequence resulted
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from the engineered base substitutions, in each case. In H803A, the codon CAT for 
histidine, has been replaced with GCC for alanine; and in D840N, the codon GAC for 
aspartic acid, has been replaced with AAC for asparagine.
Western analysis confirmed the expression of a protein of the correct expected 
molecular weight in Cos-7 cells, using both anti-EGFP and anti-HDAC4 antibodies 
(Figure 5.8A). As previously discussed (Section 5.2.1) we would expect, and were 
able to demonstrate, a protein with a molecular weight of 167 KD. There are also three 
smaller molecular weight bands, which could perhaps represent less phosphorylated 
forms of the protein, and reflect the banding pattern we see for ectopically expressed 
wt HDAC4. We then transfected the vectors, carrying the cDNAs, into FBR cells. After 
G418 selection and FACS sorting, four stable populations were produced for each 
cDNA, that were distinct, in that they arose from four separate transfections, but 
(unlike the wtHDAC4-over-expressing populations) were not clonal (Section 2.2.10.2). 
We chose to move from clonal selection at this point to avoid the possibility that the 
response of a clone is not representative of the population as a whole. We had seen in 
previous experiments that clones sometimes differed slightly in morphology and in 
invasive ability, in addition a non-clonal population can be used in experiments more 
quickly (without the requirement to amplify cell numbers) after stable expression is 
established and we had seen previously that stable populations lose expression of the 
transgene with increasing time in culture.
Western analysis confirmed the expression of a protein of the correct molecular weight 
in FBR cells (Figure 5.8B). Using both anti-EGFP and anti-HDAC4 antibodies, we 
detected, as expected, a protein of approximately 167 KD. The anti-HDAC4-probed 
membrane also showed a protein band at 140 KD, representing the endogenous 
protein, also present in control FBR cells. Also detected in extracts from FBR cells
Chapter 5; Results 143
Expression of HDAC4-H803A and HDAC4-D840N proteins
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Figure 5.8
A. Western analysis of Cos-7 ceiis expressing deacetylase-inactive forms (H803A and D840N) 
of the HDAC4 gene.
B. Western analysis of FBR celis expressing deacetylase-inactive forms (H803A and D840N) 
of the HDAC4 gene. Popuiations 1-4 represent distinct, but non-cional, popuiations of celis.
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expressing deacetylase-inactive HDAC4-EGFP, were a number of extra lower bands, 
which are most likely products of degredation of the fusion protein, also detected by 
HDAC4 antibodies, since the immunogen for this antibody was the extreme C- 
terminus of HDAG4.
5.3.3 Localisation of H803A and D840N in FBR cells
Both deacetylase-inactive HDAC4 proteins localised, in FBR cells, in the same 
manner as their wild-type counter-part. The majority of the protein was in the 
cytoplasm, with a small, but clearly detectable proportion in the nucleus (Figure 5.9). 
We also counted 1.2% of cells which had either a uniform distribution over the whole 
cell, or an almost uniform distribution, but with a slight emphasis on the nucleus. This 
is in keeping with published studies, stating that in a small proportion of cells, HDAC4 
does locate to the nucleus (Miska et al. 1999; Grozinger and Schreiber 2000; Wang et 
al. 2000), however, this distribution is similar to that we have observed for EGFP 
expressed alone, and is just as easily accounted for by the small protein (slightly 
larger than EGFP) seen by western analysis (Figure 5.8B) using both anti-EGFP and 
anti-HDAC4 antibodies, which could localise in a similar manner to EGFP.
5.3.4 Effect on morphology and actin stress fibres
We could not find any difference in the morphology of FBR cells over-expressing 
deacetylase-inactive HDAC4 compared to FBR cells, nor was there any increase in 
actin stress-fibres (Figure 5.9). Neither did we find an increased sensitivity to HD AC 
inhibitors, with regard to morphological reversion or re-appearance of stress-fibres 
(data not shown).
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FBR cells with stable expression of HDAC4-H803A or HDAC4-D840N
H803A-EGFP F-actin
I
D840N-EGFP F-actin
A
Figure 5.9
Examples of FBR cells with stable expression of either HDAC4-H803A or HDAC4-D840N. In each of the 
six double images, the left-hand panel shows the EGFP-tagged transgene (green fluorescent) and the 
right-hand panel shows F-actin which is stained with TRITC-phalloidin (red fluorescent). The third image 
in each column shows an example of the 1.2% of cells which had either a uniform distribution over the 
whole cell, or an almost uniform distribution but with a slight emphasis on the nucleus, as described in the 
text.
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5.3.5 Effect on invasion
In in vitro invasion assays, the deacetylase inactive cells are, as anticipated, less 
invasive than FBR cells (Figure 5.10A, untreated cells, and 5.1 OB), which suggests a 
dominant-negative effect from the ectopically expressed gene and shows that HDAC4 
is indeed required for the ability of the FBR cells to invade.
On treatment of the H803A- and D840N-expressing FBR cells with VPA, however, we 
found that the deacetylase inactive cells require a higher concentration of VPA to 
achieve a percentage inhibition of invasion equivalent to FBR cells (Figure 5.10). This 
is best seen in the 20pgmr^ VPA treatment (Figure 5.10A), where there are more 
invasive cells in FBR-HDAC4-D840N and in FBR-HDAC4-H803A, compared to FBR 
cells. This apparent resistance to inhibitor is probably best explained by binding of the 
inhibitor to the inactive enzyme, which, being in such excess, reduces the amount of 
inhibitor available for inhibition of endogenous HDACs. This could also be considered 
to be an explanation as to why wtHDAC4 over-expressing FBR cells are resistant to 
inhibition of invasion by HD AC inhibitors. In the case of wtHDAC4, however, the 
resistance to inhibitor is far more dramatic, which can be seen in a comparison of 
Figures 5.7A and 5.10A. It is therefore unlikely that this explanation would be 
sufficient. The fact that there is more active HDAC4 in these cells makes a significant 
difference to the level of resistance to inhibitors.
5.4 Over-expression of TMHDAC4, in both normal, and Fos-transformed 
fibroblasts
5.4.1 Introduction
It is known that the level of HDAC4 (and the other class II HDACs) in the nucleus is 
controlled by its export into the cytoplasm (Section 1.3.6). Since we found our over-
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FBR
Invasion assay showing invasion of HDAC4-H803A and 
HDAC4-D840N expressing FBR cells
untreated 10 pgmM VPA 20 pgmM VPA 40 pgml'^ VPA
FBR-H803A
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r . V . ^  si -----------------     .
FBR-D840N
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Figure 5.1 OA
Invasion assay showing that FBR cells expressing either HDAC4-H803A or HDAC4-D840N are less 
invasive than parental FBR cells. The assay also shows that FBR cells expressing deacetylase-inactive- 
HDAC4 are more resistant to the inhibition of invasion by VPA.
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Invasion of HDAC4-H803A and HDAC4-D840N expressing FBR cells
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Figure 5.1 OB
Histogram showing the combined results of three invasion assays showing that FBR cells expressing 
either HDAC4-H803A or HDAC4-D840N are less invasive than parental FBR cells.
The assays also show that FBR cells expressing deacetylase-inactive-HDAC4 are more resistant to the 
inhibition of invasion by VPA.
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expressed HDAC4 locates mainly to the cytoplasm of both 208F and FBR cells, we 
considered that this may be because the exogenous protein is being exported, so that 
although the cell over-expresses the protein, the level, active, in the nucleus is little 
affected. To address this possibility, we ectopically expressed a mutated form of 
HDAC4, that we have termed TMHDAC4, which has three serine residues replaced by 
alanines, and which, therefore, cannot be phosphorylated (Wang et al. 2000). The 
mechanism by which HDAC4 is exported requires its phosphorylation at these three 
serine residues. In this phosphorylated state 14-3-3(3 (and possibly s) can bind to it, 
facilitating its nuclear export by complexing with the nuclear export receptor, CRM1 / 
exportinl
5.4.2 Sub-cloning of TMHDAC4, verification of TMHDAC4 sequence and molecular 
weight, and its expression in ceils
The sub-cloning of TMHDAC4 and the verification of its sequence was carried out 
exactly as described for wtHDAC4 (Sections 5.3.2 and 2.2.9) and TMHDAC4 was 
confirmed to have three point mutations relative to wild-type FIDAC4. Sequencing 
showed these to be: T to G mutations at positions 736, 1399, and 1894, which change 
the codons from TCU, TCG and TCC, to GCU, GCG, and GCC respectively. 
Therefore our sub-cloned sequence differs from wild-type only in the three expected 
(Wang et al. 2000) serine-alanine substitutions.
Transfection into Cos-7 cells showed transient expression of a 167 KDa protein by 
western analysis (Figure 5.11 A). In addition to this, we transiently expressed, in Cos-7 
cells, TMHDAC4 which carries an N-terminal flag epitope, using the original vector 
(Wang et al. 2000) from which we had sub-cloned the TMHDAC4 gene, and 
demonstrated that a protein of approximately 140 KDa is expressed (Figure 5.11A).
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Analysis of TMHDAC4 expression
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Figure 5.11
A. Western analysis of whole cell lysates of Cos-7 cells transiently expressing EGFP-tagged and myc- 
tagged TMHDAC4, detected using mouse anti-EGFP and mouse anti-flag antibodies respectively, 
hybridised to HRP-tagged anti-mouse antibodies in both cases.
B. Confocal microscope images of Cos-7, 208F or FBR cells, showing the localisation of transiently 
expressed TMHDAC4-EGFP to the nucleus. DAPI staining indicates the nucleus (blue fluorescence) and 
the EGFP tag shows the location of TMHDAC4 (green-fluorescence).
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The difference between these expressed proteins is accounted for by the size of the 
EGFP-tag. Fluorescence microscopy of the transiently expressed TMHDAC4-EGFP 
showed the protein locates exclusively to the nucleus in 72% of cells (based on the 
classification of, an average of 25 cells, in each of 20 separate, random fields of view) 
a further 28% showed the protein in both nucleus and cytoplasm. The pattern of 
localisation in the nucleus is quite distinctive (Figure 5.11B) with a uniform distribution 
in discrete round dots. This pattern of localisation is now well documented, not only for 
HDACs (Miska et al. 1999; Wang et al. 2000) but also for other HDAC complex 
component proteins (Wu et al. 2001).
After confirmation of nuclear localisation, we attempted to create stable cell lines of 
FBR cells expressing either our TMFIDAC4-EGFP or flag-TMHDAC4. Following 
transfection and G418 selection, TMHDAC4-EGFP-expressing cells were further 
selected, by FACS, for green fluorescence and pooled; and individual clones of G418- 
resistant, flag-TIVIFIDAC4-expressing FBR cells were amplified. Unfortunately, the only 
cell populations derived, either did not express full-length protein, or in the one flag- 
TMHDAC4 clone which apparently did, expression was not in the nucleus. This 
suggests that TMHDAC4, is toxic to the cells. That is, when the cells are unable to 
control the nuclear HDAC4 levels by nuclear export, they are unable to reduce it to a 
level that can be tolerated. In the case of the clone which did express full length 
protein it is possible that this protein had acquired a mutation which allowed its nuclear 
export or prevented its nuclear import. Consequently, we did not proceed further with 
this approach.
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5.5 Expression of CamKIVi.313 and 14-3-3p in Fos-transformed cells
5.5.1 Introduction
As discussed previously (Section 1.3.6) it is thought that levels of nuclear HDAC4 and 
HDAC5 are controlled by the active transport of phosphorylated histone deacetylase 
across the nuclear membrane into the cytoplasm, thus reducing the level of HDAC4 
and HDACS involved in transcriptional control. In myoblasts it was shown that the 
kinase which phosphorylates HDAC4 and HDACS, is CamKIV and that it is, the 
transport protein, 14-3-3p which binds the phosphorylated deacetylase allowing it to 
be transported from the nucleus by CRM1 / exportini (Adachi and Yanagida 1989; 
Stade et al. 1997).
Based on this model we devised a strategy to reduce the nuclear HDAC4 levels in 
FBR cells, which would allow us to investigate the consequences of reduced 
transcriptional silencing by HDAC4, on the transformed phenotype. It was our intention 
then, to facilitate some form of reversion in the FBR cells, in particular to reduce their 
ability to invade, by expressing constitutively active CamKIV and over-expressing 14- 
3-3p (Tanji et al. 1994; Li et al. 1995) either independently, or simultaneously.
5.5.2 Sub-cloning of CamKiV 1 . 3 1 3  and 14-3-3/3, verification of sequence and 
molecular weight, and expression in FBR cells
We acquired the cDNA of a constitutively active form of mouse CamKIV which is 
truncated at the C-terminus, and comprises only amino acids 1 to 313, therefore 
lacking its 3' regulatory region, termed CamKIVi-313 (Sun et al. 1994). This cDNA was 
cloned into the expression vector, pEGFP-N1, which provides a C-terminal EGFP tag 
and confers G418 resistance. In addition CamKIVi.313 was alternatively 3’ myc-tagged 
using a PCR approach (Section 2.2.9) and cloned into the vector pLPCX2 which
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confers puromycin resistance. The wild type 14-3-3p cDNA was cloned similarly, so 
that potentially we could create stable cell lines over-expressing either or both of these 
genes by puromycin and/or G418 selection plus FACS for green fluorescence. The 
accuracy of the sequence of the cloned genes and of the gene/vector junctions was 
confirmed by DNA sequencing (Section 2.2.9.14).
By western analysis, we confirmed the expression of proteins, with the correct 
expected molecular weight in Cos-7 cells, using both anti-EGFP and either anti- 
CamKIV or anti-14-3-3p antibodies (Figure 5.12A and B). This was done only with 
respect to the expression of those genes carried by the pEGFP-N1 vector, as only this 
vector carries the SV40 origin of replication necessary for amplification within Cos-7 
cells. We confirmed the expression of a 59 KDa protein in the case of CamKIV and a 
protein of 56 KDa representing 14-3-3p. In the CamKIV blot the anti-EGFP antibody 
binds to a doublet at 30 KDa, which may be a degradation product of the full sized 
protein. In the 14-3-3p blots the lower band visualised by anti-EGFP is most likely a 
product of degradation of the fusion protein and the lower band visualised by anti-14- 
3-3p is endogenous 14-3-3P, present also in the control.
Using the pEGFP-N1 constructs, which we had confirmed correctly express CamKIVi. 
313 and 14-3-3P, we attempted to create FBR cell lines with stable expression of these 
genes. We tried initially, to do this using a transfection method and latterly using 
nucleofection (Sections 2.2.10.2 and 2.2.10.5).
We were unable to create a population of FBR cells stably expressing constitutively 
active CamKIV. Cell death was particularly high in transfections, with dying cells 
showing extensive surface blebbing, characteristic of apoptosis. The populations we 
selected by G418 followed by FACS, expressed only two EGFP-tagged proteins of
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Western analysis of CamKIV.,.3.,3 and 14-3-Sp expression
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Figure 5.12
Western analysis of transfected cells.
A. Cos-7 cells transiently expressing CamKIV^_3 3^ -EGFP, visualised using anti-EGFP (left) and anti- 
CamKIV (right) antibodies. EGFP-tagged CamKIV is, as expected, 59 KDa.
B. Cos-7 cells transiently expressing 14-3-3p, visualised using anti-EGFP (left) and anti-14-3-3(3 (right) 
antibodies; both showing expression of a protein of 56 KDa, as expected.
C. FBR cells which were expected to have stable expression of CamKIV.,.3 .,3 -EGFP. Only a doublet band 
at 30 KDa is seen.
D. Four distinct, but non-clonal populations of FBR cells which have stable expression of 14-3-3P, 
visualised using anti-EGFP (left) and anti-14-3-3P (right) antibodies; all showing expression of a protein 
of 56 KDa, as expected. The anti-14-3-3P blot (right) also shows a lower 29 KDa band, corresponding to 
the endogenous protein.
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approximately 30 KDa, as shown by western analysis (Figure 5.12C); and by 
fluorescence microscopy, the distribution of the ectopically expressed protein was 
consistent with that of EGFP (data not shown). The populations transfected with the 
pLPCX2 vector carrying myc-tagged CamKIVi.313 gave no bands on western blot and 
no staining by immunofluorescence, with either anti-myc or anti-CamKIV antibodies 
(data not shown). We concluded that FBR cells are unable to tolerate constitutively 
active CamKIV, and that the enzyme is effectively toxic to them.
In contrast, our experiments showed that FBR cells easily accommodate over­
expressed 14-3-3P-EGFP. In transfections there was negligible cell death as a 
consequence of its expression (data not shown), and western analysis showed the 
expression of a protein of 56 KDa, with either anti-EGFP or anti-14-3-3p antibodies, in 
each of four distinct, but non-clonal, populations (Figure 5.12D). Three of the four 
populations showed no bands other than the 56 KDa protein, using anti-EGFP 
antibody, and the only other band in the anti-14-3-3p-probed western blot corresponds 
to endogenous 14-3-3p. The cellular localisation of the expressed protein was 
consistent with a protein which shuttles between nucleus and cytoplasm and which 
remains bound to exported proteins in the cytoplasm preventing their re-entry into the 
nucleus. Expression is throughout the cell (though it is not consistently found in the 
ends of pseudopods) with less in the nucleus compared to the cytoplasm (Figure
5.13).
5.5.3 FBR cells stably over-expressing 14-3-3/3: effect on morphology, actin stress- 
fibres and invasion, and response to TSA
As can be seen from the confocal images of 14-3-3P localisation in FBR cells (Figure
5.13), there is no apparent effect on the morphology or stress-fibre arrangement in 14-
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FBR cells stably expressing 14-3-3)3
14-3-3P F-actin 14-3-3P F-actin
A #
Figure 5.13
Confocal microscope images showing the distribution of ectopically expressed 14-3-3|3-EGFP in FBR 
cells. In each of the four double images, the left-hand panel shows 14-3-3P-EGFP (green fluorescent) 
and the right-hand panel shows F-actin which is stained with TRITC-phalloidin (red fluorescent).
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3-3P-EGFP over-expressing FBR cells (F14 cells). In in vitro invasion assays we could 
not detect any measured effect on the invasive ability of the cells (Figure 5.14A and 
B). We did find that there was slight variation between populations (though the 
variation was always within the error bars), however, when we pooled these, the 
resultant population was indistinguishable from FBR cells expressing EGFP. When 
treated with TSA, the F14 cells did not differ from FBR cells in their morphological 
response with respect to cell flattening and actin stress-fibre rearrangement (data not 
shown) either temporally or qualitatively. In invasion assays of TSA-treated cells, 
neither did we see any significant difference in inhibition of invasion, between the F14 
populations and the two control populations of FBR or FBR expressing EGFP (Figure 
5.14C).
5.5.4 Invasion assays with FBR cells co-expressing exogenous CamKIVi.313, 
and 14-3-3p
We thought it is possible that there is no effect of expressing exogenous 14-3-3P 
because 14-3-3P can only export HDAC4, if HDAC4 is phosphorylated. It may 
therefore be necessary to express both 14-3-3p and CamKIVi.313 simultaneously to 
facilitate nuclear export of HDAC4. Since we were unable to create stable CamKIVi.313 
expressing FBR cells, we transiently expressed CamKIVi.3i 3-myc in our F14 cells and 
used these in invasion assays, 24 hours post-nucleofection (Figure 5.15). In addition, 
we included in these assays FBR cells which were co-nucleofected with CamKIVi.313- 
EGFP and 14-3-3p-myc. We found that transient CamKIVi.3i3-EGFP or transient 
CamKIVi.3i3-EGFP plus transient 14-3-3p-myc inhibited invasion of FBR cells by 
100% and that CamKIVi.3i3-myc expressed transiently in F I4 cells inhibits invasion by 
96% (Figure 5.15B).
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Invasion in FBR cells expressing 14-3-3P
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Figure 5.14
A. Histogram of the quantified results of two invasion assays, showing invasion in four distinct, but non- 
clonal, populations of 14-3-3p-expressing FBR cells.
B. Histogram of the quantified results of two invasion assays, showing the invasion in 14-3-3p-expressing 
FBR cells. In this case the separate populations, shown in A, have been pooled.
0. Invasion assay showing effect of TSA on four distinct, but non-clonal, populations of 14-3-3P- 
expressing FBR cells.
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FBR cells expressing CamKIV.,.3.,3, or CamKIV^_3^3and 14-3-Sp, 
are not invasive
FBR cells: Un-transfected pEGFP-N1 CamKIV1-313
CamKIV., .3.,3-EGFP 
-EGFP 14-3-3p-myc
F14 cells: Un-transfected pLPCX2 CamKIV., .3., 3-myc
B
FBR F14
Figure 5.15
A. Invasion assay showing that:
(i) Invasion is inhibited in FBR cells transiently expressing CamKIV.,,3 , 3 , or transiently co-expressing 
CamKIV,_3.,3 and 14-3-3p, compared to FBR cells or to FBR cells which transiently express EGFP.
(ii) Invasion is inhibited in F14 cells transiently expressing CamKIV,.3 , 3 , compared to F14 cells and to F14 
cells transfected with the pLPCX2 vector.
B. Histogram depicting the quantified results of the invasion assay shown in A.
This experiment was performed only once as it was superseded by a larger experiment (Figure 5.16), 
Therefore, the error bars are small since they indicate only the error internal to the experiment, i.e., 
between samples rather than between experiments. 160
5.5.5 Invasion assays with FBR ceils co-expressing exogenous CamKiV 1.313,
14-3-3p  and/or TMHDAC4
If it is the case that invasion is inhibited by CamKIVi.313 and 14-3-3p, or by CamKIVi. 
313, because HDAC4 has been exported from the nucleus, then we thought it may be 
possible to rescue the non-invasive phenotype by expressing TMHDAC4 in these 
cells, since this protein cannot be phosphorylated to facilitate its export. Consequently 
we designed an invasion assay where FBR and F14 cells were co-nucleofected with 
various combinations of CamKIVi.313, 14-3-3P and TMHDAC4 (Figure 5.16A and B). 
These experiments differed from those in the previous section, in that cells were 
transferred to the invasion assay immediately post-nucleofection.
We found that in FBR cells, when CamKIVi.313 or TMFIDAC4 are expressed 
individually (Figures 5.17 and 5.11 show confocal microscope images, demonstrating 
correct, expected localisation of CamKIVi.3i3-EGFP or TMHDAC4-EGFP) they inhibit 
invasion by 83% and 91% respectively, however, when they are co-expressed, 
inhibition of invasion drops to 45%, thus the non-invasive phenotype of either protein 
is rescued by the expression of the other. Similarly, though more dramatically, we see 
this in F14 cells, where CamKIVi.313 or TMFIDAC4 inhibit invasion by 63% and 81% 
respectively, but when co-exp ressed there is no inhibition of invasion, indeed there 
appears to be an increase of 15% compared to F I4 cells, though this differential is 
within error bars and is probably not be significant. Interestingly, when all three 
proteins are co-exp ressed in FBR cells invasion is inhibited by 73% yet when 
CamKIVi.3i3 and TMHDAC4 are co-exp ressed in F14 cells (i.e., all three proteins are 
expressed, but in this case expression of 14-3-3(3 is stable) there is no inhibition of 
invasion.
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FBR cells co-expressing TMHDAC4 and C a m K I V . , a r e  invasive
controls:
FBR + pEGFP-NI- Tî't' . V*" ' ■ * 1
FBR cells expressing:
CamKIV-EGFP
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Figure 5.16A
Invasion assay showing that:
(I) FBR cells which transiently co-express CamKIV , ^ , 3  and TMHDAC4 are invasive, in contrast to FBR 
cells which transiently express CamKIV , ^ , 3  or which transiently express TMHDAC4, which are non- 
invasive.
(ii) F14 cells which transiently co-express CamKIV,^,3 and TMHDAC4 are invasive, in contrast to F14 
cells which transiently express CamKIV , ^ , 3  or which transiently express TMHDAC4, which are non- 
invasive.
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Figure 5.16B
Histogram depicting the quantified results of the invasion assays shown and described in A  (Figure 5.16A ). 
Quantification was of three identical assays, with duplicate samples in each.
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FBR cells transiently expressing CamKIV.,.3.,3
CamKIVi.3i3
-EGFP
TRITC
-phalloidin
Figure 5.17
Confocal microscope images of nucleofected FBR cells used in invasion assays (Figure 5 .16), showing 
the distribution of transiently expressed CamKIV,^,3 -EGFP in FBR cells. In each of the three double 
images, the left-hand panel shows CamKIV,^,3 -EGFP (green fluorescent) and the right hand panel shows 
F-actin is stained with TRITC-phalloidin (red fluorescent). Images were captured 24 hours post- 
nucleofection. It is reported that wtCamKIV has a more uniform cellular distribution, but locates to the 
nucleus when activated (Lemrow et al. 2004). Constitutively active CamKIV,^,3 , however, has been 
shown to locate to the nucleus (Lemrow et al. 2004).
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5.6 Conclusions
In this chapter, we showed firstly, that over-expression of HDAC4 in FBR cells confers 
resistance to inhibition of invasion by FID AC inhibitors; and that over-expression of 
FIDAG4 in 208F cells results in a morphological change, with cells becoming more 
bipolar in appearance. Secondly, we demonstrated that expression of deacetylase- 
inactive FIDAC4 inhibits invasion in FBR cells. Finally, we showed that when 
individually expressed, CamKIVi.313 and TMFIDAC4, inhibit invasion in FBR cells, but 
when co-expressed, the non-invasive phenotype is rescued.
Many of the results described in this chapter, whilst interesting, remain preliminary. 
Although approaches taken were valid, we did not obtain results which, if further 
investigated, promised to yield data which would be easily interpreted and/or 
confirmed, and thus translated into publishable data. This being the necessary aim in 
today’s scientific climate, we chose to leave these lines of research in order to 
concentrate on the more promising data described in chapters 3 and 4, which did 
ultimately prove fruitful (McGarry et al. 2004).
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Chapter 6
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6.1 General Introduction
Work in this laboratory in recent years has been largely concerned with investigating 
the hypothesis that AP-1 regulates a multigenic invasion programme. This advocates 
that genes which are up-regulated by AP-1 are effectors of invasion and that genes 
which are down-regulated by AP-1 are suppressors of invasion. Generally, our 
strategy has been to decrease expression or function of genes which are up- 
regulated, by AP-1, in Fos-transformed cells; and conversely, to increase expression 
of genes which are down-regulated, by AP-1, in Fos-transformed cells, and, in both 
cases, to examine the consequences with respect to reversion of the transformed 
phenotype.
In the current study, we have shown that HDACs are up-regulated genes in v-Fos™- 
transformed cells, and therefore, are proposed to be effectors of invasion. HDACs, 
however, function to down-regulate genes, so the consequence of their increased 
expression, is increased down-regulation of genes. Down-regulated genes are, by our 
hypothesis, invasion suppressors, thus their re-expression would suppress invasion. 
Consequently, we proposed that inhibition of HDACs (effectors of invasion) would 
result in the increased expression of down-regulated genes and in the inhibition of 
invasion. To establish a link between re-expression of down-regulated genes and 
inhibition of invasion, we re-expressed these HDAC-sensitive genes individually in 
FBR cells and assessed whether invasion is inhibited.
6.2 Studies with histone deacetylase inhibitors
6.2.1 Introduction
Initially we demonstrated that several histone deacetylases and functionally 
associated proteins are up-regulated in Fos-transformed fibroblasts relative to the 
parental non-transformed cells, leading us to consider the role of HDACs in the Fos-
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transformed phenotype; thus, we investigated the consequences of their inhibition. 
The HDAC inhibitors we have used are both currently in clinical trials as anticancer 
agents. They are structurally distinct (Figures 1.8 and 1.9), which strengthens the 
validity of our results, making it is less likely that the phenotypic changes we see 
(similar for both inhibitors) are by mechanisms other than through the relief of HDAC- 
mediated transcriptional repression. The results from these studies of the effects of 
inhibitors on the Fos-transformed phenotype are summarised in Table 6.1 (below).
Reverted
morphology
Re-appearance 
of stress-fibres
Inhibition of;
motility invasion growth chemotaxis
TSA
(nM)
4 - ND - + 80% - -
8 - + - + 90% - -
1 2 + + + + - ND
2 0 + + + + + ND
VPA
(pgmr'')
25 - + - + 90% - _
50 + + + + 95% - ND
1 0 0 + + + + + ND
Table 6.1
Summary of the effects of HDAC inhibitors on the Fos-transformed phenotype after treatment for 4 
days. ND = not done.
6 .2.2 Characteristics of Fos transformation are mediated by up-regulation of HD A Os 
Our results demonstrate that morphological transformation, lack of actin stress-fibres, 
increased motility, and ability to invade, as orchestrated by v-Fos'^®^, are mediated by 
the up-regulated expression of histone deacetylases, which are known to facilitate 
transcriptional repression of genes. We should perhaps bear in mind though, that 
transcriptional repression of a transcriptional repressor would result in the up- 
regulation of genes; or that the transcriptional repression of, say, a phosphatase could 
result in a higher proportion of phosphorylated, and therefore, active protein. So,
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although we think of histone deacetylation in terms of gene silencing, the 
consequences of their increased expression may be more of a change in the balance 
of genes expressed; a shift in the steady-state.
6.2.3 Invasion can be inhibited without affecting morphology, motility, chemotaxis or 
proliferation
We have shown that proliferation of FBR cells is unaffected by < 50 pgml'^ VPA or < 
12 nM TSA. The ability of Fos-transformed cells to invade is inhibited at 
concentrations of > 25 pgml'^ VPA, or > 4nM TSA, therefore, within the ranges, 25 to 
50 pgmM VPA, and 4 to 12 nM TSA, we can inhibit invasion without affecting growth 
(Table 6.1). Moreover, at lower concentrations within these ranges invasion is 
inhibited without affecting transformed morphology or motility; nor is the chemotactic 
response diminished. This separates morphology, motility and chemotaxis from 
invasion, in terms of gene expression. Since HDAC inhibitors relieve the suppression 
of gene expression mediated by HDACs, it would suggest that very little re-expression 
of genes is required to inhibit invasion, in comparison with morphology / motility / 
chemotaxis, and therefore, that invasion is a very precisely orchestrated function, such 
that re-expression of down-regulated genes (or any slight disruption to the tightly 
defined balance of genes expressed) is incompatible with the phenotype. This has 
indeed proved to be the case, in our studies with the re-expression of genes down- 
regulated by Fos (Chapter 4; section 6.3).
6.2.4 HDAC inhibitor-induced morphological reversion is reversible
The phenotypic reversion we see in response to HDAC inhibition is reversible. By 4 
days after the removal of inhibitor morphology has almost completely returned to 
bipolar. If the cells are passaged this happens more quickly. A plausible explanation
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for this can be found using our data on the re-expression of genes in response to 
HDAC inhibition. One such re-expressed gene is fibronectin, which is secreted by the 
cell as part of the extracellular matrix. When HDAC inhibitor is removed from the 
culture, the fibronectin in the extracellular matrix will still be present. This could explain 
why, although the cells regain their bipolar morphology they retain what appear to be 
lateral points of attachment to the extracellular matrix along the pseudopod. These are 
most probably retraction fibres, where integrins in focal adhesions have not 
disengaged from their extracellular contacts. If the cells are passaged subsequent to 
removal of inhibitor the re-seeded cells do not have these “retraction fibres”, probably 
because there is no fibronectin in the new vessel.
6.2.5 Inhibition of invasion correlates with formation of actin stress-fibres 
From our data (Table 6.1), it appears that reversion of morphology correlates with 
inhibition of motility with respect to concentration of inhibitor required and therefore to 
a related gene-expression profile; whilst invasion correlates with a loss of actin stress- 
fibres. Reformation of F-actin, on inhibition of HDACs, shows that HDACs have a role 
in inhibition of F-actin formation, perhaps by the silencing of genes involved in its 
polymerisation. Surprisingly, we discovered that there is significant stress-fibre 
reformation within 24 hours of treatment with 25 pgml'^ VPA, which could provide an 
explanation as to why no preincubation with inhibitor is required to inhibit invasion in in 
vitro assay. This, however, assumes that stress-fibre reformation is required for 
inhibition of invasion, but when we have re-expressed genes down-regulated in FBR 
cells, we have shown that invasion is inhibited in the absence of stress-fibres 
(Sections 4.2.4 and 4.2.5), therefore this cannot be the case.
Stress-fibres reform in the absence of morphological reversion, this shows that the 
formation of stress-fibres is not sufficient to facilitate morphological reversion. It may
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be that rearrangement of stress-fibres is required. In bipolar cells with stress-fibres the 
fibres run parallel to the long axis of the cell, however, on reversion of morphology the 
fibres tend to radiate from the centre of the cell (Figure 3.4). This differs from 208F 
cells in that their stress-fibres tend to have a more cross-wise appearance with 
bundles of fibres angled relative to one another. There is no further increase in the 
proportion of cells with stress-fibres when inhibitor concentration is increased, thus we 
have achieved the maximal quantitative effect at 25 pgmM. These results suggest 
that, like inhibition of invasion, little re-expression of genes is required to permit 
polymerisation, however, further re-expression is required to permit the re­
arrangement of the polymerised actin. Thus, it is most probable that reversion of 
morphology correlates with the re-arrangement of stress-fibres rather than their 
formation.
It is perhaps also worthy of note here, that the reappearance of stress-fibres within 24 
hours of inhibitor treatment, hints at the possibility of a cytoplasmic role for FIDACs in 
this respect; perhaps inhibiting stress-fibre reformation by the direct deacetylation of a 
cytoplasmic protein, say for example, deacetylation of G-actin retains it in its 
monomeric state. Further experiments to determine exactly when, within the 24 hours, 
the stress-fibres reappear and whether this can occur in the absence of mRNA and 
protein synthesis, would determine whether a direct cytoplasmic role is likely.
6.2.6 EGF-stimulated invasion in non-transformed cells is inhibited by HDAC inhibition 
Finally, in a supplementary experiment we also showed that TSA inhibits EGF-induced 
invasion of 208F cells. This is important in that it demonstrates that when AP-1 is up- 
regulated by a commonly occurring in vivo mechanism, inhibition of invasion is 
facilitated by FID AC inhibition. It answers the criticism that mutated Fos is not 
commonly found in tumours, and therefore that it cannot relate to the in vivo situation.
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It is also for this reason that we included Ras-transformed cells in our survey of HDAC 
and related protein expression levels, in normal versus Fos-transformed cells, and 
why up-regulation of HDAC4 in Ras-transformation was a factor in its choice for 
further study (Section 5.2).
6.2.7 Conclusions
We conclude that, epigenetic repression of gene expression by up-regulated histone 
deacetylases plays a key role in the transformation of fibroblasts by v-Fos^®^. When 
we inhibit the up-regulated histone deacetylases we inhibit invasion of the v-Fos- 
transformed cells, stress-fibres reform, transformed morphology reverts and motility is 
inhibited. At lower concentrations of HDAC inhibitors we inhibit invasion, and bring 
about reformation of actin stress-fibres, without affecting morphology, motility, or 
chemotaxis, separating these characteristics from invasion and stress-fibre 
reformation in terms of gene expression and suggesting that invasion is, in 
comparison, controlled by a very finely orchestrated programme of gene expression.
6.3 Genes down-regulated by histone deacetylation
6.3.1 Introduction
Previous work in this laboratory identified genes that are up- and down-regulated as a 
consequence of v-Fos^®^ expression (Johnston et al. 2000; Ozanne et al. 2000). 
Using HDAC inhibitors, we have demonstrated that HDAC activity is responsible for 
the down-regulation of several of these genes in Fos-transformed cells. In addition we 
have shown that not all genes down-regulated in FBR cells can be re-expressed as a 
consequence of HDAC inhibition. This shows that other factors are also required in the 
down-regulation of genes in FBR cells; probably primarily DNA méthylation, as 
indicated by our finding that HDAC1, SinS, SAP18, RbAp46 and MeCP2 are up-
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regulated in FBR cells. These are all components of large protein complexes with 
deacetylase activity, which are recruited to DNA through methylated DNA binding 
proteins, thus méthylation is required for targeting.
6.3.2 Histone deacetylases mediate suppression of genes down-regulated by v-Fos 
Investigating the response to inhibition of histone deacetylases in terms of gene re­
expression, we treated FBR cells with both TSA and VPA, which resulted in the 
increased expression of five out of eleven genes, to the levels observed in 
untransformed 208F cells; that is, the silencing of these genes by histone 
deacetylation (whether directly or indirectly) is relieved on treatment of FBR cells with 
histone deacetylase inhibitors. Three of the genes, STAT6 , RYBP and PCDHGC3, 
when expressed individually in FBR cells, are potent inhibitors of invasion without any 
effect on cellular morphology, actin stress-fibres, motility, chemotaxis, or proliferation. 
This shows that it is not solely the re-expression of these genes, in response to HDAC 
inhibitors, which is responsible for reversion of transformed morphology, formation of 
stress-fibres or inhibition of motility; but that expression of any of one of these genes is 
incompatible only with invasion. Each gene then, is demonstrated to be a member of 
the, previously proposed, AP-1 regulated multigenic invasion programme (Johnston et 
al. 2000; Ozanne et al. 2000). By definition, each component of a programme (a single 
gene product) functions to achieve the aim of the programme. For down-regulated 
genes, their expression is inconsistent with invasion as we have demonstrated by their 
over-expression in FBR cells. The finding that HDAC inhibitors severely restrict 
invasion demonstrates that HDAC activity is a positive regulator of the multigenic 
invasion programme.
The inhibition of invasion that we have demonstrated when each of our genes is re­
expressed, occurs both in FBR cells which transiently express the genes, and in FBR
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cells, which stably express the genes. In transiently expressing cells, there is a 
sudden, high level of expression of the protein and the cell has little time to make 
adjustments; in stably expressing cells, the level of expression is lower and the cell 
has had several generations to re-establish the steady state of its expression profile, 
thus accommodating the gene. We have shown, therefore, that the inhibition of 
invasion cannot due to a long-term accommodation of the cell to expression of the 
repressed genes; nor can it be due to the cells reaction to a sudden high level of 
expression of the protein. Interestingly, invasion is more strongly inhibited when the 
genes are stably expressed, suggesting that when the cell has altered its steady-state 
of gene expression, as a consequence of the new protein, the impact on invasion is 
greater. It could be argued that this is closer to the in vivo situation as expression of 
any gene may have consequences in terms of gene-expression, particularly when the 
gene is a transcription factor like STAT6 or a transcription cofactor like RYBP. In the 
case of the transmembrane receptor, PCDHGC3, there could be, for example, 
intracellular signalling as a consequence of extracellular binding to the protocadherin, 
which results in gene expression changes.
6.3.3 Proteins, ectopically re-expressed in FBR cells
The mechanisms by which these genes inhibit invasion are not known, but it is 
probable that RYBP and STAT6 as transcription factors/cofactors inhibit invasion by 
altering gene expression. The targets of these genes in this context remain to be 
identified, but suggest that the v-Fos regulated multigenic invasion programme 
consists of a transcriptional cascade or network that controls the effectors and 
inhibitors of invasion.
RYBP, a transcription co-factor (Garcia et al. 1999), interacts with the transcription 
factors, YY1, E2F2, E2F3, E2F6 and the polycomb complex proteins, Ringl and M33
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(Garcia et al. 1999; Trimarchi et al. 2001; Schlisio et al. 2002), but does not bind DNA 
directly. Depending on the transcription factor to which it is bound, RYBP could 
function as a transcriptional repressor or activator. In the context of Fos-transformation 
its role awaits further investigation; however, it would seem less likely to be through 
interaction with E2F2 and E2F3, which stimulate expression of the cell cycle regulator 
Cdc6 (Schlisio et al. 2002), as the rate of cell cycle progression does not appear to be 
altered upon re-expression of RYBP, either by HD AC inhibitor treatment or by 
transgene. It may be that RYBP functions through interaction with the polycomb group 
proteins suppressing gene expression, however, since the role of E2F6 is not clearly 
defined, it could be a co-factor for E2F6, that is itself a component of the mammalian 
Bmil-containing polycomb complex that functions to suppress gene expression 
(Trimarchi et al. 2001). There is of course the possibility that there are yet 
undiscovered transcription factors that RYBP interacts with.
STAT6 , an interleukin (IL) -4 and IL-13-regulated transcription factor, is also down- 
regulated in FBR cells relative to 208F cells and its expression is returned to 208F 
levels following HD AC inhibition. The role of STAT6 in Fos-transformation may be 
related to role in activating transcription of tissue inhibitor of matrix metalloproteinase 
(TIMP) genes (Gatsios et al. 1996; Bugno et al. 1995) or in altering expression of 
extracellular matrix components such as type I collagen (McGaha et al. 2003; Buttner 
et al. 2004).
Re-expression of the cell-cell adhesion / recognition protein PCDHGC3 (formerly 
protocadherin-43 or PCDH2) may affect the way the cells interact. They may be able 
to make cell contacts where previously they could not, or it may be more difficult for 
them to break cell-cell contacts. If this is how inhibition of invasion occurs, one might 
also expect motility to be inhibited, which is not the case; though of course we could 
not predict how these cell-cell contacts will behave in a motility assay compared to an
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invasion assay. Interestingly, mammalian E-cadherin has been shown to be a 
suppressor of cell migration and tumour invasion (Behrens et al. 1991; Chen and 
Obrink 1991; Frixen et al. 1991; Schipper et al. 1991; Fahraeus et al. 1992) and 
Drosophila fat, a cadherin-related protein, functions as tumour suppressor (Mahoney 
et al. 1991). The human homologue of fat has been shown to be expressed in 
fibroblasts (Matsuyoshi and Imamura 1997).
The finding that three HDAO-repressed genes all affect invasion without affecting 
proliferation or motility, strongly suggests that the invasion programme is precisely 
controlled to permit invasion and that genes are down-regulated as a consequence of 
activation of the invasion programme. In this context it is significant perhaps that the 
Fos-transformed cells have never been selected for invasiveness; rather it seems to 
be the consequence of a sustained increase in AP-1 activity that establishes the AP-1- 
regulated multigenic invasion programme.
6.3.4 Conclusions
From these experiments then we can conclude that, histone deacetylation alone, is 
sufficient to facilitate the silencing of at least a proportion of those genes, shown to be, 
down-regulated in Fos-transformation, and inhibition of histone deacetylase activity 
can relieve the silencing of such genes. The ectopic re-expression of some (RYBP, 
PCDHGC3, STAT6 ), if not all, of these silenced genes inhibits invasion; the 
inappropriate expression of any one of them then, is incompatible with the invasive 
phenotype. Although these cells have inhibited invasion they are unaffected in 
morphology, motility, chemotactic response, or rate of proliferation. That is, histone 
deacetylases are responsible for down-regulation of genes, the expression of which 
would be incompatible with invasion but not with transformed morphology, motility, 
chemotactic response, or rate of proliferation.
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6.4 Strategies to modulate levels of HDAC4 in Fos-transformed cells
6.4.1 Introduction
To determine whether specifically, HDAC4 has a role in mediating transformation by v- 
Fos^® ,^ we employed several strategies. To increase HDAC4 in both FBR and 208F 
cells we ectopically expressed wtHDAC4 (Section 5.2) or TMHDAC4 (Sections 5.4 
and 5.5.5), and to decrease HDAC4 we ectopically expressed CamKIVi.313, 14-3-3p 
(Section 5.5), or two forms of deacetylase-inactive HDAC4 (Section 5.3). One might 
expect an increase in HDAC4, in 208F cells, to confer some aspect of transformation; 
and in FBR cells, to provide resistance to the effects of HD AC inhibitors. Conversely, 
decreased HDAC4 in FBR cells may result in reversion of some aspect of the 
transformed phenotype.
6.4.2 Over-expression of wtHDAC4 in Fos-transformed fibroblasts
Our results showed that over-expression of HDAC4 in FBR cells has no effect on their 
ability to invade, though, significantly, they did become resistant to inhibition of 
invasion by HD AC inhibitors.
There are three main plausible explanations as to why an increase in HDAC4 does not 
increase invasion. Firstly, the level of HDAC4 may already be optimal for invasion. An 
increase in HDAC4 would result in increased transcriptional repression, and as 
previously discussed (Section 6.2.2), this would result in both decreases and 
increases, in genes expressed, and in activities of proteins. It would seem unlikely, 
since we are advocating that invasion is a very precisely controlled process, that this 
apparent disruption would favour increased invasion. Secondly, it is possible that, 
despite an increase in cellular HDAC4, the level in the nucleus remains unaffected 
due to a compensatory increase in nuclear export. Thirdly, it is equally possible that 
increased nuclear HDAC4 is ineffectual without a concomitant increase in proteins
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which together form the HDAC4 transcriptional repression complex. These 
explanations are not mutually exclusive; in fact the true explanation could equally be a 
combination of all three.
We also showed that HDAC4-over-expressing FBR cells are resistant to inhibition of 
invasion by HD AC inhibitors; that a higher concentration of HD AC inhibitor is required 
in these cells, to achieve the equivalent percentage inhibition of invasion found in FBR 
cells. In terms of explanation, it may simply be that the increased HDAC4 binds 
inhibitor and effectively sequesters it, such that the level of HD AC inhibition is reduced 
in a general sense. It could also be the case that increased HDAC4 is able to 
compensate mechanistically for other HDACs which are inhibited; that there is 
redundancy in the HDACs in this situation. This would mean that HDAC4 is able to 
suppress gene expression such that invasion can occur. A more attractive scenario is 
that increased HDAC4 compensates, specifically for the HDAC4 which is inhibited. 
Here the conclusion would be that, in Fos-transformed cells, HDAC4 is a positive 
regulator of invasion, and our previous results suggest that it does this by down- 
regulating genes, the expression of which is incompatible with invasion.
6.4.3 Expression of wtHDAC4 in normal fibroblasts
208F cells have 9-fold less HDAC4 than FBR cells, and are non-invasive. One might 
expect that on ectopic expression of HDAC4, they would become invasive, but this is 
not the case. In chapter 5 we have shown that re-expression, in FBR cells, of any 
individual gene, normally down-regulated in FBR cells, inhibits their invasion (of those 
we tested). In addition, it was shown previously in this laboratory, that another gene 
that is down-regulated in FBR cells, TSC36, also inhibits invasion when re-expressed 
(Johnston et al. 2000; Ozanne et al. 2000). Thus unless increased HDAC4 in 208F 
cells is able to mediate the down-regulation of every gene which is down-regulated in
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FBR cells, we would be unlikely to see an increase in invasion. In addition we also 
showed that not all genes down-regulated in FBR cells can be re-expressed as a 
consequence of HD AC inhibition. This shows that other events, such as DNA 
méthylation, may also be required for the down-regulation of these genes, or that 
down-regulation also occurs by deacetylase-independent mechanism. Consequently, 
we could not expect an increase in HD AC expression to facilitate down-regulation of 
all genes, required to be down-regulated for invasion to occur. Of course, we should 
also consider that, as well as the requirement for down-regulation of invasion 
suppressors to facilitate invasion, there may also be the requirement for the up- 
regulation of genes which are effectors of invasion. Finally, an alternative possibility 
may be that other components, which are required to complex with HDAC4, are still 
lacking in HDAC4-over-expressing 208F cells, such that although HDAC4 is abundant, 
it is not sufficient to facilitate increased transcriptional repression required to permit 
invasion. Consequently, it is not surprising that HDAC4-over-expressing 208F cells 
are not invasive.
When we expressed wtHDAC4 in 208F cells, we partially transformed their 
morphology. As we have shown (Chapter 3 and 4) morphology and ability to invade 
are distinct in terms of gene profile (though they are clearly closely related). Again we 
can provide evidence to support this, in that populations of 208F cells over-expressing 
HDAC4 have a high proportion of bipolar cells, or of cells which have moved towards 
the bipolar phenotype, despite being non-invasive. Possibly HDAC4 has a role in the 
cytoplasm; a role which is relevant to the morphology of the cell but not to its ability to 
invade. This is not unprecedented since HDAC6 has been shown to have a 
cytoplasmic role, binding the dynein motors of tubulin, reportedly involved in regulating 
microtubule stability and function through deacetylation (Hubbert et al. 2002; 
Matsuyama et al. 2002; Zhang et al. 2003) and in the clearance of misfolded proteins
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from the cytoplasm by dynein motors (Kawaguchi et al. 2003). In addition the NAD+- 
dependent, Sir2 class III deacetylase, has been shown to be a tubulin deacetylase 
(North et al. 2003).
6.4.4 Expression of deacetylase-inactive forms (H803A and D840N) o f HDAC4 in 
Fos-transformed cells
Expression of deacetylase-inactive HDAC4 in FBR cells rendered them, up to 50% 
less invasive than control, EGFP-expressing, FBR cells, and perhaps surprisingly, 
conferred a slight resistance to inhibition of invasion by HD AC inhibitors.
To decrease invasion in FBR cells, deacetylase-inactive HDAC4 may be acting in a 
dominant-negative manner. There are three possible explanations as to how this may 
occur. Perhaps HDAC4-containing-complex formation cannot occur due to the change 
in stoichiometry. That is: a single complex which is normally A-HDAC4-B, becomes 
two incomplete complexes, A-H803A and H803A-B, thus suppression cannot occur. 
Were this the case however, it would seem unlikely that it would not also occur with 
wtHDAC4 over-expressed in FBR cells, which it does not. Another possibility is that, 
rather than disrupting the HDAC4 containing complex the deacetylase-inactive 
HDAC4 becomes part of the complex in the same way as would wtHDAC4, thus 
effectively sequestering it. Lastly, the mechanism by which the cell exports HDAC4 
from the nucleus, may not distinguish between active and inactive enzyme, thus in 
maintaining the same nuclear level of HDAC4, it actually reduces HDAC4 nuclear 
activity, since a proportion of the remaining nuclear HDAC4 will be of the deacetylase- 
inactive form.
The data we generated in this experiment, was unusually variable between repetitions, 
which is reflected in the error bars generated. The variability in the data we collected 
could be a product of unstable dynamics of HDAC4 nuclear export in the deacetylase-
V
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inactive HDAC4-expressing FBR cells, such that they are unable to achieve a 
comfortable equilibrium and constantly strive for maximal possible HDAC4 export. 
This may be less of a difficulty in wtHDAC4 over-expressing FBR cells if the high 
enzymatic activity plays a role in the mediation of increased nuclear export. 
Deacetylase-inactive HDAC4-expressing FBR cells were slightly resistant to inhibition 
of invasion by HD AC inhibitors. The most likely explanation for this observation is 
simply that the deacetylase-inactive HDAC4 competes with endogenous HDACs for 
binding to the inhibitor, therefore, effectively sequestering it, and reducing inhibitor 
activity. One may think then, that this explanation could also be applied to the 
resistance to HD AC inhibitor observed in wtHDAC4 over-expressing FBR cells, 
however, there is a significant difference. The resistance to inhibition of invasion is 
slight in deacetylase-inactive HDAC4-expressing cells (Figure 5.10A), whereas, in 
wtHDAC4-expressing cells the resistance is greater than 90% on treatment with 8 nM 
TSA.
We considered the results from this section to be inconclusive in terms of explanation, 
and although many answerable questions arose, pursuing them was unlikely to yield 
worthwhile informative results in the timescale available.
6.4.5 Expression of TMHDAC4 in both normal, and Fos-transformed fibroblasts 
By fluorescent microscopy we saw that HDAC4-EGFP and HDAC4-myc locate to the 
cytoplasm with low nuclear expression. Consequently, in further experiments we 
addressed the possibility that wtHDAC4 does not increase invasion simply because 
the cell exports all over-expressed HDAC4 from the nucleus. As previously described 
(Section 5.4.1), TMHDAC4 cannot be phosphorylated at sites required to facilitate its 
nuclear export. We were able to show that TMHDAC4-EGFP does indeed locate to 
the nucleus in cells transiently expressing the protein, however we were unable to
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create stable cell lines of 208F or FBR expressing TMHDAC4-EGFP or TMHDAC4- 
flag and concluded that the protein is toxic to the cells, which agrees with the 
possibility that over-expressed HDAC4 is exported from the nucleus reducing nuclear 
activity to tolerated levels.
In studies with 208F and FBR cells transiently expressing TMHDAC4 we did not find 
these cells differed from parental cells, morphologically or in terms of actin stress-fibre 
arrangement. In invasion assays, FBR cells expressing TMHDAC4 were not invasive. 
If, as we believe, the level of HDAC4 in FBR cells is optimal for invasion, it is entirely 
expected that TMHDAC4-expressing FBR cells are non-invasive. In this case 
transcriptional repression by HDAC4 would be too high to mediate an invasion 
permissive gene profile. Of course alternatively, this could simply have been due to 
the toxicity of the protein, however, in invasion assays, discussed below (Section 
6.4.7), where TMHDAC4 was transiently co-expressed with CamKIVi.313 (which is able 
to phosphorylate endogenous HDAC4, thereby facilitating its nuclear export) we found 
that TMHDAC4 was able to rescue the non-invasive phenotype of CamKIVi.313 
expressing FBR cells.
6.4.6 Expression of CamKIVi. 3 1 3  or 14-3-3P in Fos-transformed cells 
The purpose of expressing constitutively active CamKIV or 14-3-3p in FBR cells was, 
by facilitating HDAC4s nuclear export, to reduce the level of HDAC4 involved in 
transcriptional repression and, if HDAC4 has a role in transformation, particularly in 
invasion, we would expect reversion in some aspect of the transformed phenotype, 
specifically, in the ability to invade.
14-3-3P is a ubiquitous protein, and western analysis showed FBR cells have a high 
level of endogenous protein. Our experiments showed that FBR cells easily 
accommodate over-expressed 14-3-3P-EGFP. In transfections there was negligible
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cell death as a consequence of its expression (data not shown). Its cellular localisation 
was as expected, however, there was no detectable effect on the proliferation (data 
not shown), morphology, actin stress-fibres or invasion, of FBR cells stably expressing 
the protein. In contrast, we were unable to create a population of FBR cells stably 
expressing constitutively active CamKIV. Cell death was particularly high in 
transfections, with cells showing extensive surface blebbing, characteristic of 
apoptosis (data not shown). Possible explanations are that 14-3-3p has almost no 
effect because it is already in excess; or that export of HDAC4 is not increased 
relative to that in FBR cells because HDAC4 is not more phosphorylated than it is in 
FBR cells, or perhaps an increase in other factors is also required to facilitate nuclear 
export. Constitutively active CamKIV, on the other hand, is most probably toxic to the 
cells; a likely scenario, since it is known to have multiple substrates unrelated to our 
study, the phosphorylation of which will have any number of unforeseen effects 
(Soderling 1999; Agell et al. 2002). This toxicity, however, rather than being general, 
may be specific to the export of HDAC4, in that the changes in gene expression as a 
consequence of decreased HDAC4 nuclear activity, are toxic. Alternatively, 
expression of CamKIVi.313 may reduce the level of HDAC4 in the nucleus to the extent 
that the resultant changes in gene expression are incompatible with invasion, 
suggesting that HDAC4 is indeed required for the ability of FBR cells to invade.
6.4.7 Invasion assays with FBR cells co-expressing exogenous CamKIVi.313,
14-3-3p, and/or TMHDAC4
FBR cells co-expressing CamKIVi.313 and 14-3-3p are poorly invasive, as are FBR 
cells expressing TMHDAC4, however co-expressing CamKIVi.313 with TMHDAC4 in 
FBR or F I4 cells restores their ability to invade; in FBR cells to 55% of control cells 
and, dramatically, in F14 to >100% of control cells. We conclude that, although
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CamKIVi.3i 3 mediates the nuclear export of HDAC4, it is unable to facilitate export of 
TMHDAC4 such that TMHDAC4 functionally replaces the exported wtHDAC4 in the 
nucleus, thus rescuing the invasive phenotype. In the case of non-invasive 
TMHDAC4-expressing cells, the level of HDAC4 (endogenous plus TMHDAC4) in the 
nucleus may be too high for invasion (or viability) to occur. Co-expression of CamKIVi_ 
313 and 14-3-Sp along with TMHDAC4, however, decreases the level of nuclear 
HDAC4, by exporting the endogenous protein, thus invasion can occur. Why would 
the return to invasiveness be more dramatic in F14 cells? These cells stably express 
14-3-3P and so have had several generations to make alterations in gene expression, 
to accommodate increased 14-3-3p expression. One might expect these changes to 
account for the difference in invasion we observe.
These results suggest that HDAC4 does have a role in the epigenetic silencing of 
genes incompatible with the invasive phenotype. Even if it is simply that expression of 
either CamKIVi-313 or TMHDAC4 individually is toxic to the cells, the fact that one is no 
longer toxic in the presence of the other shows that this in itself is a specific response 
involving HDAC4, since the expression of one of these proteins is apparently 
incompatible with the normal functioning of the cell in the context of the gene 
expression profile of invasive cells.
6.4.8 Conclusions
The experiments carried out in this chapter were conceptually sound as evidenced by 
published studies. The TMHDAC4 approach has been used by several groups to force 
localisation of the transgene to the nucleus (Wang et al. 2000). Constitutively active 
CamKIVi.3i3 was used to force nuclear localisation of wtHDAC4 (Miska et al. 2001) 
These studies, however, in looking at morphology and invasion with reference to Fos- 
transformation, yielded nothing concrete in terms of publishable results.
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The main conclusions to this section, with regard to proving or disproving our 
hypothesis, that specifically, HDAC4 has a role in transformation by v-Fos, and in 
particular, is required for the ability of FBR cells to invade, are as follows. Firstly, we 
demonstrated that expression of HDAC4 in normal fibroblasts partially transforms their 
morphology. This tells us that probably, HDAC4 activity is necessary, but not sufficient 
to transform morphology. Secondly, we showed that expression of HDAC4 in v-Fos- 
transformed cells confers resistance to the inhibition of invasion by HDAC inhibitors, 
and thirdly, that expression of deacetylase-inactive HDAC4 in v-Fos-transformed cells 
inhibits invasion. From these we can conclude that probably, HDAC4 activity is 
necessary, but not sufficient to mediate invasion. These conclusions however, require 
confirmation, which would be best achieved using siRNA to HDAC4.
6.5 Summary of conclusions
Overall the work in this thesis demonstrates that:
1. HDACs are up-regulated in Fos-transformed cells.
2. HDAC activity is required for Fos-transformation, specifically invasion.
3. Individual aspects of transformation (bipolar morphology, increased motility, 
absence of stress-fibres) are controlled by specific groups of genes.
4. HDAC activity mediates down-regulation of genes in Fos-transformed cells.
5. Re-expression of down-regulated genes inhibits invasion in Fos-transformed cells.
In addition it is probable that:
6. HDAC4 activity is necessary but not sufficient for transformed morphology in 
fibroblasts.
7. HDAC4 activity is necessary but not sufficient to facilitate invasion in fibroblasts.
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7.1 Introduction
Possible future work can be divided into two sections. There are the longer term aims 
which would further develop the project and are indeed new projects in themselves. 
Also, there are short term experiments designed to answer questions arising from the 
work presented in the preceding chapters. For the longer term, there are two, possibly 
three, main avenues of exploration which arise. Firstly, there is the question as to what 
are the mechanisms by which the genes, down-regulated in FBR cells (STAT6, RYBP 
and PCDHGC3), inhibit invasion when they are re-expressed? Secondly, we could 
ask, what are the larger scale changes in gene expression in response to HDAC 
inhibition? Thirdly, there is the question of a possible cytoplasmic role for HDACs in 
the mediation of cytoskeletal re-arrangement.
7.2 Short-term aims
For the short term, there are many experiments which could be done to substantiate 
our results and further develop our understanding of HDACs and HDAC-controlled 
gene expression in Fos-transformation. Perhaps the most obvious approach would be 
the use of small interfering RNA (siRNA) technology, to investigate the role of HDAC4 
(or indeed other HDACs) in mediation of the transformed phenotype. We would be 
able to examine the consequences of decreasing the level of HDAC4 in FBR cells, 
with regard to reversion of their transformed characteristics, specifically invasion.
With regard to the role of HDAC4, perhaps an important question to ask may be: what 
is the level of expression of RYBP, PCDHGC3 and STAT6 in 208F cell lines which 
stably express HDAC4. This could be done by northern analysis of our stable cell lines 
of 208F cells expressing the HDAC4 transgene. It would help to determine whether 
the increased expression of HDAC4 in FBR cells is responsible for the down- 
regulation of these genes. In the complimentary experiment to this we could ask: given
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that RYBP, STAT6 and PCDHGC3 are re-expressed in FBR cells, on treatment with 
VPA or TSA, does this re-expression still occur in our FBR cells which stably express 
HDAC4, upon inhibitor treatment. It is possible, since, as we have shown, these cells 
are resistant to inhibition of invasion by HDAC inhibitors, that they also do not re­
express the genes that we have shown to be incompatible with invasion. This would 
further substantiate our conclusion that RYBP, STAT6 and PCDHGC3 are 
incompatible with invasion and that HDAC4 is capable of their suppression.
Of course, the direct interaction of HDAC4 with the promoter regions of the down- 
regulated genes (in FBR cells) could be determined by chromatin immunoprécipitation 
(ChIP) assay, though this would perhaps be a longer term aim.
7.3 Long-term aims
7.3.1 The role of STAT6, RYBP and PCDHGC3 in the inhibition of invasion 
Perhaps the next step in this project would be to determine the mechanisms by which 
STAT6, RYBP and PCDHGC3 inhibit invasion. For the transcription factor STAT6, and 
the transcription co-factor RYBP, initial studies could use microarray technology to 
determine the gene changes which occur as a consequence of their ectopic 
expression in FBR cells. As already mentioned, ChIP assays could be used to 
determine the direct interaction of these transcriptional regulators with target genes. 
Those genes identified by these techniques would determine the future direction of the 
project. Studies with the cell-cell adhesion / recognition protein, PCDHGC3 would 
consider the role this protein has on cell interaction. We could reduce levels in 208F 
cells, or in HDAC inhibitor-treated FBR cells, and determine whether the cells become 
invasive. This could be done using siRNA to decrease expression of the protein in 
208F cells. Alternatively we could add blocking antibody, which recognises the 
extracellular portion of the protein, to 208F cells in culture, to block cell-cell interaction;
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or treat the cells with the extracellular portion of the protein itself, which may either 
block interaction, or if binding of this portion is required for intracellular signalling from 
the receptor, may result in the increased activity of the receptor.
7.3.2 Gene expression changes in response to HDAC inhibitors
The primary subject of this work is Fos. Since Fos is a transcription factor, our main 
concern must be gene expression changes as a result of increased AP-1 activity, and 
in this study as a consequence of, v-Fos-mediated, increased HDAC expression. To 
expand our limited study of genes re-expressed as a consequence of HDAC inhibition, 
we could use microarray technology. This was not done originally in our study 
because, at that time, rat microarrays were not as comprehensive as they are now. 
With microarrays we could determine which gene changes were common to VPA and 
TSA treatment, and of particular interest, we could determine which changes occurred 
at the different concentrations we have used to effect changes in the transformed 
phenotype. For example, as we have shown in FBR cells, treatment with 8nM TSA 
inhibits invasion but does not bring about morphological reversion, whereas treatment 
with 12nM TSA inhibits invasion and causes morphological reversion. A comparison of 
the gene changes occurring in each of these cases would yield genes which are 
specific to invasion. In addition we could carry out a time-course of gene expression 
changes, since as we have seen, for example, morphological reversion occurs over 
several days.
7.3.3 A cytoplasmic role for HDACs
Finally, it would be interesting to determine, whether HDACs have a cytoplasmic role 
in the re-formation of stress-fibres. As we have shown, in a time-course to track the re­
appearance of stress-fibres in inhibitor treated FBR cells (Section 3.2.3), the stress-
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fibres have reformed within 24 hours. If we were able to demonstrate that this re­
appearance actually occurs quickly, say within 6 hours, and that it occurs in the 
absence of RNA or protein synthesis, then we would have evidence that a direct 
cytoplasmic role is likely. We could then investigate the possibility that HDACs 
deacetylate cytoskeletal proteins and inhibit the ability to form stress-fibres, or 
conversely, that acétylation of cytoskeletal proteins is required for stress-fibres 
formation.
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